B-Type Natriuretic Peptide and  Novel Cardiac Ultrasound  in Very Preterm Neonates: Potential Markers for the Detection of Pulmonary Hypertension and for Risk Stratification by Harris, Sarah Louise
ii 
   
B-Type Natriuretic Peptide and  
Novel Cardiac Ultrasound  
in Very Preterm Neonates: 
Potential Markers for the Detection of Pulmonary 









A thesis submitted for the degree of 
Doctor of Philosophy  






   
Abstract 
 
Very premature birth causes an interruption of cardiorespiratory development. Successful 
pulmonary adaptation requires synchronous development of alveoli and pulmonary capillary 
networks. Very premature birth threatens this process. Exposure to excess oxygen, combined 
with the modifying effects of growth and inflammation, can cause bronchopulmonary dysplasia 
characterised by maldevelopment of alveoli and pulmonary vasculature. This may be 
complicated by pulmonary hypertension causing right heart dysfunction which may persist to 
adulthood.  
As pulmonary hypertension develops insidiously, and is associated with significant morbidity 
and mortality, screening is recommended. However, there are no consensus diagnostic criteria 
and a paucity of validated heart ultrasound parameters in the very preterm population. N-
Terminal proB-type Natriuretic Peptide (NTproBNP), a cardiac hormone, is a promising 
biomarker as it is a sensitive marker of ventricular wall pressure and volume stress and predicts 
pulmonary hypertension in other settings. There is limited data in very preterm infants. 
Premature infants have unstable oxygen saturations due to multifactorial causes which may be 
exacerbated by pulmonary hypertension. Oxygen saturation targeting attempts to reduce 
hypoxia and hyperoxia. Modern oximeters allow detailed analysis of oxygen saturation patterns 
but optimal measures of instability have not been established. 
We investigated temporal changes in NTproBNP and factors influencing levels, in a cohort of 
very preterm infants. We evaluated NTproBNP as a biomarker for pulmonary hypertension by 
pairing NTproBNP with heart ultrasound and pulse oximetry data in the neonatal period and 
report clinical and neurodevelopmental outcomes at two years. Quantitative measures of right 
heart function and compliance with oxygen saturation alarm limits in our unit were evaluated. 
Current screening recommendations were reviewed. 
We demonstrated high NTproBNP on days 3 and 10 then decreasing NTproBNP beyond the 
period of cardiac transition. NTproBNP was a highly sensitive and specific marker of 
haemodynamically significant patent ductus arteriosus and a modest predictor of severe 
bronchopulmonary dysplasia. None of our cohort had evidence of pulmonary hypertension at 
36 weeks post menstrual age by predefined conventional heart ultrasound criteria. However, 
we demonstrated it is feasible for more advanced quantitative measures of right heart function 
to be incorporated into clinician performed heart ultrasound that may be of value to screening 
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programmes. We showed changes in these parameters over time, reviewed their reliability, and 
investigated differences in infants with and without bronchopulmonary dysplasia. Oxygen 
saturation instability increased in our cohort over time peaking at day 28 and was greater in 
infants with bronchopulmonary dysplasia. We identified oxygen saturation coefficient of 
variation and percentage time less than 88% as useful measures of instability. Compliance with 
oxygen saturation alarm limits in our unit was low despite high levels of nursing experience 
potentially exposing extremely premature infants to iatrogenic hyperoxia which may contribute 
to pulmonary hypertension.  
In summary, we found a lower than expected rate pulmonary hypertension in our very preterm 
cohort. There is insufficient evidence for NTproBNP as a standalone biomarker for pulmonary 
hypertension but it may be useful as an adjunct to comprehensive heart ultrasound evaluation. 
To reduce pulmonary hypertension, surveillance of at risk infants and oxygen saturation 
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The Impact of Premature Birth on Cardiopulmonary 
Development 
 
Importance of premature birth  
Globally one in ten babies are born prematurely.2 Premature birth is defined by the World 
Health Organisation as birth before 37 completed weeks gestation.3 , 4 Rates of premature birth 
are rising and there is considerable geographic variation (Fig.1).2, 3 Common causes of preterm 
birth are maternal preeclampsia (a hypertensive disorder of pregnancy), chorioamnionitis 
(uterine infection), uteroplacental haemorrhage, premature rupture of membranes and 
spontaneous preterm labour of unclear aetiology.5   
 
Figure 1: Estimated preterm birth rates by country for the year of 2010 
 
Reproduced with permission from: Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. 
National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for 




   
In New Zealand 7.4% of live-born infants are born prematurely and 1.3% are born at < 32 weeks 
gestation.6 When intensive care is available survival rates are high. The Australia and New 
Zealand Neonatal Network (ANZNN), has prospectively collected data on all high risk infants, 
admitted to the 27 regional neonatal intensive care units (NICU) since 1995 including New 
Zealand level 2 units from 1999. ANZNN survival rates for infants admitted to a neonatal unit in 
2013 rose from 66% for babies born at 24 weeks to 98% for those born at 29 weeks gestation.7   
Several major advancements have contributed to the rise in survival rates. In 1972 New 
Zealanders Sir Graham Liggins and Dr Ross Howie made the serendipitous discovery that 
antenatal corticosteroids accelerate fetal lung maturity. This intervention reduced mortality 
from premature lung disease to one third of that in the untreated group.8 Subsequent 
advances, such as lung surfactant replacement therapy which prevents collapse of alveolar lung 
units and improves ventilation and the shift away from invasive ventilation to gentler modes of 
non-invasive ventilation have contributed to the now very high survival rates seen in the 
developed world.9 10 There remains, however, significant global inequity in healthcare provision 
and premature birth remains the number one cause of newborn deaths globally and the 
second leading cause of death in children under five.3  It is estimated that >75% of deaths 
secondary to premature birth are preventable without intensive care.3  
As survival has increased, long term sequelae of premature birth have become apparent. 
Premature-born children at risk of poor neurodevelopmental and learning outcomes, poor 
respiratory health and impaired growth.11, 12 There is also significant evidence for the 
developmental origins of health and disease (DOHAD) in which the in-utero and early life 
environment influence the risk of disease in adulthood.13 Three of the most significant non-
communicable disease challenges facing society, heart disease, diabetes and obesity, are 
thought to have their origin in the in-utero and perinatal milieu of experiences.13 The fetus has 
the capacity to adapt to a sub-optimal intrauterine environment to ensure survival.  However, 
when there is a mismatch of in-utero and post-natal conditions, such as a period of growth 
restriction followed by liberal nutrition, this adaptive programming can predispose an individual 
to obesity, cardiovascular disease, dyslipidaemia and diabetes.14 15, 16 Premature infants are at 
particularly high risk of this developmental plasticity having long term health consequences.17-21 
The societal cost of preterm birth is considerable.22 In 2005 the United States annual minimum 
cost of preterm birth was estimated to be $26.2 billion, while in the United Kingdom costs to 
the public sector were estimated to be £2.946 billion.23 24 These are underestimates as these 
studies only focus on the immediate costs of neonatal care and the long term costs of major 
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childhood morbidities. They do not include the cost to caregivers or the late effects on adult 
health.  
Thus prematurity is common, is a significant contributor to global child mortality, has lasting 
health effects and consumes a large portion of health budgets. However, tremendous 
improvements have been made in outcomes after prematurity through high quality research 
and evidenced based practice. Preventing premature birth or the complications of premature 
birth is of great importance as it can have far reaching  effects on individuals, families and 
society. 
 
Figure 2: Premature baby in incubator 
 
Permission to use image for educational and teaching purposes granted by family. 
The impact of premature birth on lung development 
Lung development remains the single greatest challenge for infants born too early, contributing 
to long hospital stays, respiratory morbidity in early childhood and late deaths beyond neonatal 
discharge.25, 26 Effective respiration requires complex synchrony between the neural drive of 
the respiratory control centre in the brain, the mechanics of airway, diaphragm and intercostal 
musculature and gas exchange at the level of alveoli and pulmonary vasculature.27 Premature 
birth disrupts the normal embryological development of this system.  
Animal and human studies have demonstrated that the detrimental effects of premature birth 
on lung architecture are influenced by antenatal factors, such as placental insufficiency, 
chorioamnionitis, antenatal steroids and postnatal factors including surfactant deficiency, 
oxygen exposure, mechanical ventilation and sepsis (Fig. 3).28   
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Figure 3: The impact of premature birth on lung development 
 
Reproduced with permission from Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 
2007(357):1946-55, Copyright Massachusetts Medical Society. 
An infant born at < 28 weeks gestation has lungs that are transitioning between the canalicular 
and saccular stages of development. At this stage air sacs and the vascular network surrounding 
them are primitive with reduced surface area for gas exchange (Fig. 4). The interstitial gap is 
wide, reducing efficiency of gas exchange. Surfactant-producing cells are only just beginning to 
be differentiated and the resultant surfactant deficiency threatens the stability of end-
expiratory lung volumes and significantly decreases lung compliance. This results in a risk of 
acute respiratory distress syndrome (RDS) and subsequent bronchopulmonary dysplasia (BPD), 
a form of chronic lung disease. The risk of BPD is inversely proportional to gestational age with 
rates of 50% at 24-25 weeks, 26% at 26-27 weeks and 12% at 28-29 weeks.29
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Figure 4: Appearance and growth of the lung in the canalicular, saccular and alveolar stages  
 
Note large surface area achieved by branching and septation and thin alveolar/vascular interface increasing 
efficiency of gas exchange.  TB=terminal bronchiolus; sac=saccule; arrows=capillaries. AD=alveolar duct; a=alveolus.  
Reproduced with permission from: Journal of Anatomy. Volume 201, Issue 4, pages 325-334, 14 OCT 2002 DOI: 
10.1046/j.1469-7580.2002.00097.x http://onlinelibrary.wiley.com/doi/10.1046/j.1469-7580.2002.00097.x/full#f1 
Copyright John Wiley& Sons 
Canalicular and Saccular Stages 
 Respiratory airways develop 
accompanied by arteries and veins 
 Thinning of epithelium by underlying 
capillaries allows gas exchange 
 Surfactant first detectable at 24-25 
weeks gestation 
 Mesenchyme decreases 
 Alveoli start to appear from 29 
weeks 
Alveolar Stage 
 Cup shaped alveoli with double 
capillary loops at 34 weeks 
 Alveoli multiple and increase in size 
until 2-3 years  
 Capillary bed increases in area 




   
The original description of BPD was based on the pathological changes seen in moderately 
preterm infants exposed to high concentrations of oxygen and aggressive mechanical 
ventilation.30 With the introduction of antenatal corticosteroids, surfactant, non-invasive 
respiratory support and oxygen saturation monitoring, the pathology of BPD has changed. 
Historically BPD was characterised by severe inflammation, fibrosis and airway damage. “New 
BPD” occurs in extremely premature infants and is characterised primarily by arrested or 
impaired pulmonary development with alveolar hypoplasia and malformed pulmonary 
vasculature (Fig. 5). Animal BPD models can be induced by exposure to hyperoxia.(Fig.5) 
Intrauterine programming is likely to play a role in the development of BPD as intrauterine 
growth restriction and placental insufficiency, chorioamnionitis, maternal smoking and lack of 
antenatal steroids prior to preterm birth all influence risk of subsequent BPD.31-33 The 
combination of inflammation and oxidative stress is central to the arrest of normal pulmonary 
development. 34, 35 
 
Figure 5: Histological presentation of new BPD 
 
(A,B) Histology of a patient with fatal new BPD, demonstrating increased distal airspaces with decreased septation 
and reduced alveolarization (A); as well as pulmonary vascular wall thickness is present in small arteries (arrow in 
(B)), suggestive of pulmonary hypertension.  
(C,D) Confocal images of postnatal day 7 mouse lungs exposed to either room air (C) or 85% O2 hyperoxia (D) from 
birth onward. Note that the hyperoxic lung exhibits reduced alveolarization, exemplifying the alterations in distal 
airspace that mimics new BPD. Nuclei are stained with DAPI (blue) and green signal is extracellular matrix 
autofluorescence. 
Reproduced with permission from: Abman SH, Conway SJ. Developmental determinants and changing patterns of 
respiratory outcomes after preterm birth. Birth Defects Res A Clin Mol Teratol. 2014;100(3):127-33. Copyright John 




   
The impact of prematurity on the immature heart  
Heart and lung function are intimately related. Premature birth disrupts normal 
cardiopulmonary development. The underdeveloped heart, lungs and pulmonary vasculature of 
the prematurely born infant have to adapt and function in a way that is entirely different to 
that of the foetus.  
The heart of an infant born very prematurely has an immature cellular structure that is less 
adapted to the physiological stressors of post-natal life. Myocytes are smaller, often with a 
single nucleus compared to the multinucleated myocytes of the term infant, there are fewer 
sarcomeres, immature contractile proteins and fewer mitochondria.36, 37 38 During foetal life 
cardiac size is increased by cardiomyocyte hyperplasia (increasing cell numbers), however, 
postnatally hypertrophy (increase in cell size) predominates.39  The preterm heart is less 
compliant and contractile than that of a term born baby.40  
During foetal life the right ventricle (RV) predominates with a thicker ventricular wall and 
greater cardiac output than the left ventricle (LV).41  The pulmonary vasculature is a low flow, 
high resistance circuit. In contrast the LV encounters relatively low systemic pressure in foetal 
life with the placenta acting as a high flow, low resistance circuit. After birth the loss of the 
placenta leads to an immediate increase in systemic pressure and LV afterload. The inflation of 
the lungs and exposure to relative hyperoxia leads to a fall in pulmonary vascular resistance and 
decreased RV afterload. With premature birth a heart that is still developing encounters a 
sudden increase in systemic pressures and a decrease in pulmonary pressures dramatically 
altering the relationship between the left and right ventricle before the heart has fully matured.  
Postnatal persistence of the ductus arteriosus (PDA),a foetal conduit between the main 
pulmonary artery (MPA) and aorta, increases with decreasing gestational age and may further 
complicate cardiac transition to postnatal life causing left to right shunting, higher flow through 
pulmonary vasculature, reduced pulmonary compliance, increased LV output and vascular steal 
phenomena reducing blood flow to vital organs.42 43 Premature birth also has long term effects 
on the cardiovascular system predisposing preterm-born adults to an increased risk of 
hypertension, coronary artery disease, dyslipidaemia and diabetes.44-46  
Embryological development of the heart is coordinated by a foetal cardiac gene programme 
which leads to fundamental differences in the heart of the foetus compared to that of the 
neonate. The foetal heart’s primary energy source is carbohydrate in the form of glucose or 
lactate.47 48 This provides a highly efficient source of energy and is maintained by the constant 
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supply of glucose via the placenta. This enables energy to be rapidly mobilised during times of 
stress. One third of the foetal cardiomyocyte volume is glycogen.47, 48 The foetal cardiomyoctye 
sarcomere has a higher ratio of myosin heavy chain (MHC) β to MHCα which renders it stiffer 
and less contractile.47, 48 Levels of B-type natriuretic peptide (BNP), a cardiac hormone, are high 
and thought to play a role in promoting foetal cardiac development with animal studies 
demonstrating that natriuretic peptide receptor knockout results in marked cardiac 
hypertrophy and fibrosis.49-51 
After birth this foetal cardiac gene programme undergoes a rapid switch, to the so-called 
“adult” cardiac gene programme, thought to be primarily mediated by exposure to higher 
oxygen concentrations, perinatal hormones and an abrupt discontinuation of glucose supply. 
This programme is characterised by a predominance of fatty acid oxidation for energy 
metabolism with only 2% of the cardiomyocyte volume being glycogen.47 The MHCβ:MHCα 
ratio decreases decreasing stiffness and increasing contractility.48 BNP levels, after an initial rise 
during transitional circulation, subsequently fall.52, 53 This switch is however, potentially 
reversible. At subsequent times of cardiac stress the heart may revert to this foetal cardiac 
gene programme which, in the short term, has a cardioprotective effect.48, 54 The interaction 
between foetal gene programmes and modification by the in-utero and post-natal 
environments is currently an area of active research.  
Pulmonary vascular disease after preterm birth 
In addition to the disruption of the normal pattern of cardiopulmonary development, 
premature birth also puts infants at risk of pulmonary vascular maldevelopment. Indeed 
alveolar development appears to be dependent on pulmonary vascular development in what 
has been termed “the vascular hypothesis”.55, 56 In an example of synchronised development, 
respiratory epithelial cells secrete vascular growth factors that act on endothelial cell receptors 
to drive pulmonary vascular development (Fig.6).56 The development of the pulmonary capillary 
network in turn drives alveolarization. 
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Figure 6: Schematic of proposed interactions between vascular growth factors and their receptors during 
alveolarization  
 
Vascular growth factors are secreted by the respiratory epithelium and signal to their receptors located on the 
vascular endothelium to promote angiogenesis and drive alveolarization. (AEC2 = alveolar epithelial type 2 cell, VEGF 
= vascular endothelial growth factor).  
Reprinted with permission of the American Thoracic Society. Copyright © 2018 American Thoracic Society. Thebaud 
B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in 
chronic lung disease. Am J Respir Crit Care Med. 2007;175(10):978-85.The American Journal of Respiratory and 
Critical Care Medicine is an official journal of the American Thoracic Society 
 
Pulmonary vascular disease, in premature infants, is characterised by a paucity of pulmonary 
vessels which are dysmorphic and dysfunctional. Histology of the lung shows pulmonary vessels 
that are reduced in number, maldistributed and dysmorphic with medial hypertrophy and distal 
muscularisation.56 Functionally they are also abnormal with a tendency to vasoreactivity that 
compromises gas exchange.57  These abnormal pulmonary vessels sit alongside alveoli that are 
larger but fewer in number.58 Intrapulmonary arteriovenous anastamotic vessels (IAAV) have 
also been found in the lungs of infants who have died of BPD.59 These connecting vessels are 
present in foetal life but should disappear postnatally. They shunt deoxygenated blood into the 
pulmonary venous network bypassing the gas-exchange interface.  Inflammation and immune 
regulatory cells also appear to modify lung angiogenesis which may explain the relationship 
between chorioamnionitis and BPD. 60 In combination these features result in poorer gas 
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exchange and a propensity for precipitous drops in oxygen saturation necessitating respiratory 
support. 
In foetal life the placenta is the major organ of gas exchange.  Placental underperfusion, such as 
that seen with preeclampsia and other hypertensive disorders of pregnancy, is associated with 
a subsequent increased risk of BPD and particularly associated with an increased risk of BPD-
associated pulmonary hypertension.61 This suggests foetal programming may be important in 
the subsequent development of the pulmonary vascular disease associated with premature 
birth.  
The most severe end of the pulmonary vascular disease spectrum is pulmonary hypertension 
which may cause right heart failure.  BPD-associated pulmonary hypertension may also be 
complicated by left ventricular dysfunction, systemic to pulmonary collaterals and pulmonary 
vein stenosis. 62, 63 Prospective studies have suggested 18% of infants with a birthweight of 
<1000g will develop pulmonary hypertension with a significantly higher rate in those who 
develop BPD.64 
Infants with pulmonary vascular disease and in particular pulmonary hypertension are at 
increased risk of recurrent episodes of hypoxemia, prolonged hospitalisation and need for 
respiratory support including home oxygen therapy, increased risk of readmission with 
respiratory illness in the first few years of life, increased risk of death, neurodevelopmental 
impairment and potentially  long term cardiorespiratory effects in adulthood.65, 66 62, 67-71 This 
condition has significant short and long term financial implications for families, the health 
system and society. Further research is needed to understand the pathophysiology of BPD-
associated pulmonary hypertension, to develop better diagnostic tools and ultimately to 
develop preventative strategies of care.  
Impact of oxygen on pulmonary vascular development 
Hypoxia is a potent pulmonary vasoconstrictor. During foetal life the developing lung is exposed 
to a low oxygen tension. Hypoxia stimulates the release of vascular endothelial growth factor 
(VEGF) and consequently the development of lung vasculature and acts as a cofactor in the 
growth of pneumocytes.72  
Premature birth exposes an underdeveloped lung and respiratory network to relative hyperoxia 
compared to the in-utero environment. Hyperoxia (a supply of oxygen that is in excess of 
cellular requirements) is known to have deleterious effects on the immature lung with 
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prolonged exposure to high concentrations causing inflammation, cell death and consequent 
pulmonary oedema.73, 74 Exposure to excess oxygen and oxidative stress may be a potentially 
preventable cause of pulmonary hypertension in preterm infants due to the suppressive effects 
on vascular endothelial growth factors, activation of inflammatory pathways and cellular 
toxicity. The mechanisms by which this damage is triggered are complex (Fig.7). Hyperoxia 
reduces the transcription of VEGF which is vital for pulmonary vascular development.75, 76  
Excess oxygen also generates reactive oxygen species and activates an inflammatory response. 
This triggers a cascade that ultimately damages mitochondria, the cellular power unit, leading 
to cell death.73 The result of exposure of the developing lung to hyperoxia is a pulmonary 
vascular bed that has reduced numbers of small pulmonary arteries that are maldistributed and 
with increased distal smooth muscle leading to heightened vasoreactivity. In turn, as normal 
pulmonary vascular development is needed for the development of alveoli, inhibition of VEGF 
results in alveoli that are both simple in structure and decreased in number.55, 56 Exposure to 
other inflammatory events such as chorioamnionitis or post-natal sepsis will further aggravate 
this damage.35 
 
Figure 7: A proposed model of hyperoxia-derived lung damage in neonates delineating some of the pathways 
 
Hyperoxia exposure leads to release of certain mediators [eg. VEGF and angiopoietin 2] that disrupt the alveolar-
capillary membrane leading to pulmonary oedema which contributes to lung injury. Other cytokines [eg. interleukin 
(IL)-1, IL-6, IL-8, transforming growth factor (TGF) b, tumour necrosis factor (TNF) a, VEGF] are also released from 
lung cells that attract inflammatory cells to the lung. These inflammatory cells as well as hyperoxia per se release 
reactive oxygen species, which can initiate the mitochondrial-dependent cell death pathway. The cytokines and cell 
death mediators contribute to pulmonary injury resulting in hyperoxia-derived lung damage. (PKC=protein kinase C). 
 
Reproduced with permission from: Bhandari V. Hyperoxia-derived lung damage in preterm infants. Semin Fetal 
Neonatal Med. 2010;15(4):223-9.Copyright Elsevier  
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Infants born prematurely are also at risk of chronic intermittent hypoxemia  (where the supply 
of oxygen is inadequate to meet cellular requirements) due to intrinsic and extrinsic factors. 
This  is known to increase the production of free radicals.77 In premature infants recurrent 
hypoxemia is often accompanied by a subsequent period of hyperoxemia. Intermittent hypoxia-
hyperoxia exposure in preterm animal models is associated with the down-regulation of 
hypoxic-inducible factor (HIF) and angiogenic gene expression and alveolar simplification.78 It is 
likely to be a significant contributing pathway to the development of BPD and pulmonary 
vascular disease. Chronic intermittent hypoxemia may also have lasting effects on respiratory 
control causing a subsequent decreased response to acute hypoxia.27, 79 An understanding of 
the impact of hypoxia and hyperoxia is critical in order to support optimal lung development 
and reduce risk of pulmonary hypertension. The effects of too little and too much oxygen on 
the developing lung are complex and sometimes contradictory (Fig.8,9). Identifying just the 
right amount of oxygen for the very preterm infant has proved to be the holy grail of neonatal 
research. 
 
Figure 8: Effects of hypoxia and hyperoxia on the developing lung 
 
Reproduced with permission from: Vogel E.R, Britt R.D, Trinidad M.C, Faksh A, Martin R.J, MacFarlane P.M, et al. 
Perinatal oxygen in the developing lung. Can J Physiol Pharmacol. 2015;93(2):119-27. Copyright Canadian Science 








Figure 9: Potential mechanisms by which hypoxia and hyperoxia affect lung development 
 
 Hypoxia activates the HIF-VEGF pathway of vascular development. Hyperoxia can cause oxidative damage to alveolar 
epithelium. Hypoxia and hyperoxia can induce proinflammatory and profibrotic mediators. 
Reproduced with permission from: Vogel E.R, Britt R.D, Trinidad M.C, Faksh A, Martin R.J, MacFarlane P.M, et al. 
Perinatal oxygen in the developing lung. Can J Physiol Pharmacol. 2015;93(2):119-27. Copyright Canadian Science 
Publishing or its licensors 
Epidemiology of late pulmonary hypertension in preterm infants  
There are limited published data regarding the epidemiology of pulmonary hypertension 
associated with premature birth and even less regarding the spectrum of pulmonary vascular 
disease. It is estimated that the incidence of pulmonary hypertension in infants born 
prematurely ranges from 17-37%.64 80-82 Prospective studies suggest up to 14% of extremely 
premature infants with no or mild BPD but up to 29% of those with moderate to severe BPD 
have signs of  pulmonary hypertension at 36 weeks corrected post-menstrual age (PMA).83, 84 
However, there are wide variations in the population studied, the diagnostic tools and criteria 
used and the timing of assessment. Infants with BPD and pulmonary hypertension have 
significantly greater morbidity and health care utilisation than those with BPD alone.85 Mortality 
has been estimated at 38% of infants diagnosed with bronchopulmonary dysplasia-associated 
pulmonary hypertension with a probability of survival 3 years after diagnosis of 52%.62  
One of the problems for the neonatologist with published clinical data is that the series tend to 
be from highly selected patients referred to centres specialising in pulmonary hypertension. It 
is difficult to know what the incidence is of pulmonary hypertension in a general population of 
premature infants as there are no large multicentre, prospective studies or standardised 
screening procedures although screening is recommended.86-88  
ATI, ATII = alveolar type I and II cells 
HIF = hypoxia-inducible factor 
VEGF = vascular endothelial growth factor 
TGFβ= a profibrotic transforming growth 
factor 
 IL-6 and IL-8 are proinflammatory 
interleukins 
ROS = reactive oxygen species 
ECM = extracellular matrix 
nrf2 = a transcription factor that protects 
against oxidative injury. 
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Factors associated with an increased risk of pulmonary vascular disease include extreme 
prematurity, poor placental perfusion such as that seen with preeclampsia, chorioamnionitis, 
intrauterine growth restriction (IUGR), exposure to excessive oxygen, BPD, mechanical 
ventilation, pulmonary vein stenosis, aorto-pulmonary collaterals and large persistent patent 
ductus arteriosus.60-62, 67, 82, 89-92 
Further research is needed to establish the incidence of pulmonary hypertension in very 
premature infants. We also need to establish which risk factors should prompt screening 
investigations and to identify establish optimal timing of such screening in the hope that early 
treatment may improve outcomes. There is, however, a paucity of evidence regarding the 
treatment of late pulmonary hypertension in very premature infants. 
Management of late pulmonary hypertension in preterm infants 
The approach to managing pulmonary hypertension in premature infants is complex and 
requires a multi-faceted approach. There are a lack of randomised controlled trials of 
treatment in this population and recommendations are mostly based upon expert opinion.93-96 
On the basis of this expert opinion: Lung disease should be evaluated and every attempt made 
to optimise lung function and enhance gas exchange. Hypoxia, which can precipitate a 
pulmonary hypertensive crisis, should be avoided. Equally, iatrogenic hyperoxia must be 
minimised to avoid further impairment of pulmonary vascular development. Structural airways 
anomalies such as vocal cord paralysis, sub-glottic stenosis, tonsillar/adenoidal hypertrophy 
and tracheomalacia should be excluded. Nutrition should be optimised. Gastroesophageal 
reflux or microaspiration may also contribute to pulmonary hypertension and should be 
managed. 
Inhaled nitric oxide is a pulmonary vasodilator that mediates production of cyclic guanosine 
monophosphate (cGMP) which induces smooth muscle relaxation. Nitric oxide needs to be 
administered continuously due to the short half-life and is expensive and labour intensive. It is 
a very effective treatment for acute persistent foetal circulation with high pulmonary vascular 
tone in term infants.97 Results for late pulmonary hypertension in very premature infants may 
be more mixed due to the fixed structural component of the disease. No long term benefit has 
been demonstrated in this population.98, 99 
Cardiac catheterisation is recommended prior to commencing chronic vasodilator therapies. 
Sildenafil is a phosphodiesterase-5 inhibitor that induces pulmonary vasodilation mediated 
through cGMP. It can be administered orally, has a longer half-life and is considerably cheaper 
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that nitric oxide. It can also be safely administered in a community setting. Sildenafil may be a 
safe and effective treatment for late pulmonary hypertension in very premature infants 
although not all studies have shown consistent improvements in oxygenation, it does not 
appear to prevent BPD and there are no data on long term outcomes.100-104   
Prostacyclin analogues are second line therapy options for resistant pulmonary hypertension. 
These agents activate adenylate cyclase which increases cyclic adenosine monophosphate 
which results in smooth muscle relaxation. There is very limited data on safety and efficacy for 
their use in the preterm population and they are associated with significant side effects 
rendering them unsuitable for the outpatient setting.95 
Conditions of hypoxia cause the release of endothelin-1, a potent endothelial vasoconstrictor. 
Endothelin-1 receptor antagonists act to counter this. These agents can be given orally, 
however there are very little data on their use in the preterm population and side effects limit 
their use. 
Animal studies suggest that treatment with bone marrow sourced mesenchymal stem cells or 
even just mesenchymal stem cell conditioned media, may protect against oxygen-induced lung 
injury and pulmonary vascular maldevelopment.105 Although promising, this therapy is at the 
experimental stage only. 
Treatment of pulmonary hypertension in premature infants is complex, challenging, expensive 
and potentially harmful. Therefore it is vital that there are clear diagnostic criteria and reliable 
diagnostic tests before embarking upon treatment. 
Diagnosis of late pulmonary hypertension in preterm infants 
The Pulmonary Vascular Research Institute Task Force has published a consensus classification 
for paediatric pulmonary hypertensive vascular disease which recognises BPD-associated 
disease as a separate subgroup. 106 Pulmonary hypertensive vascular disease can be defined as 
a mean pulmonary artery pressure at rest and at sea level of >25 mmHg and a pulmonary 
vascular resistance index >3.0 Wood units.m2 for biventricular circulations.87, 107 However, this 
definition relies on cardiac catheterisation and is generally applied in children above the age of 
three months. In younger infants who are still completing the transition from foetal to neonatal 
circulation a systolic pulmonary artery pressure of > 36mmHg is generally considered 
elevated.108, 109 Cardiac catheterisation is the current gold standard test for evaluating the 
structure of the pulmonary vascular bed and measuring pulmonary vascular pressure. However, 
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this is an invasive procedure that is available only at specialist centres and the transport of 
fragile premature infant for this procedure carries a significant morbidity and mortality risk.  
Echocardiography utilising ultrasound offers a non-invasive assessment of cardiac structure and 
function and an indirect assessment of pulmonary pressures. However, it still involves some 
handling of infants and accuracy is dependent on the skill of the scanner. Furthermore there is 
limited validated data on echocardiographic measures of late pulmonary hypertension in the 
preterm population and debate persists regarding an echocardiographic definition of 
pulmonary hypertension in this setting.64, 80, 81, 110-113 Because of the structural and functional 
differences between the premature heart and the mature heart more data needs to be 
collected to establish baseline reference echocardiographic indices in the preterm population. 
Only then can we validate optimal echocardiographic measures of late pulmonary 
hypertension. A simple, reliable and affordable screening test for at risk infants that would 
enable clinicians to triage which infants warrant echocardiographic assessment and referral for 
cardiac catheterisation would also be of great value. 
Screening for late pulmonary hypertension  
The development of late pulmonary hypertension is ominous for a preterm infant heralding a 
significant risk of death.62, 80, 81, 114, 115 As it develops insidiously the disease is usually well 
established by the time it is clinically apparent and irreversible structural changes have taken 
place in the pulmonary vasculature. Management strategies, primarily oxygen and pulmonary 
vasodilators, are at best designed to support the infant, acting on any reversible 
vasoconstriction while waiting for lung growth and maturation to ameliorate the structural 
component of the disease. Prolonged respiratory support or oxygen is often required. 
Moreover, after apparent clinical improvement, pulmonary hypertensive crises may occur 
when an infant is challenged by a respiratory infection or general anaesthetic.98, 116 Even with 
time and growth abnormal pulmonary artery pressures and subclinical ventricular dysfunction 
can persist throughout childhood and adolescence, affecting exercise tolerance, while in 
adulthood structural and functional abnormalities of the right ventricle become apparent and 
are associated with an increased risk of heart failure and cardiovascular death.71, 117 45, 98 These 
challenges and concerns have led to recommendations to screen preterm infants for late 
pulmonary hypertension in the hope that detecting the disease at an earlier stage of its 
evolution will facilitate earlier treatment and decrease mortality and morbidity.  
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To successfully screen for a disease it is necessary to: 
1. Understand the pathophysiology such that a population at risk can be screened while those 
not at risk are not subjected to screening 
2. Have a screening test that is low risk, not excessively invasive, cost effective and that exhibits 
an acceptable level of sensitivity / specificity 
3. Have a treatment available that will improve outcomes 
4. Time screening at a point that most cases will be detected and detection at this point will 
improve outcomes  
A consensus statement has recently been released on the evaluation of BPD-associated 
pulmonary hypertension by the Paediatric Pulmonary Hypertension Network, a 
multidisciplinary group of North American pulmonary hypertension experts.86  Other screening 
algorithms have also been proposed by the American Heart Association, the American Thoracic 
Society, the European Paediatric Pulmonary Vascular Disease Network and pulmonary 
hypertension research groups.62, 87, 88, 111-113, 118-120 However, a recent survey of American 
Academy of Pediatrics neonatology members revealed only 38% currently have an institutional 
screening protocol.121   
There are currently no national screening recommendations for late pulmonary hypertension in 
preterm born infants in New Zealand. There is currently no international consensus on 
screening for late pulmonary hypertension in premature infants. Several groups have recently 
published screening recommendations. These are compared in Appendix A. These 
recommendations are American Heart Association class of recommendation level 1 and level of 
evidence B or C meaning the benefit of screening is considered greater than the risk but the 
recommendation is based upon evidence from a single randomised controlled trial or non-
randomised studies or consensus expert opinion.87 
Who to screen 
Current recommendations tend to adopt a broad, risk factor based approach or an approach 
that is more targeted to symptoms of pulmonary hypertension or a combination of the two. 
Where screening is based upon established risk factors it is recommended to screen infants 
born at extremely low gestational age, and/or extremely low birthweight and/or those with a 
diagnosis of BPD. The more symptom-based approach recommends screening infants with 
significant and persistent oxygen or respiratory support needs or unexplained poor growth. 
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When to screen 
Most groups recommend initial screening at 36 weeks PMA which ties in with the time point at 
which infants are classified as having BPD or not. However, most groups also argue that 
screening could occur at any time in infants who were exhibiting signs and symptoms 
suggestive of pulmonary hypertension.  
Mehler et al demonstrated that 41% of infants with pulmonary hypertension do not develop 
signs of pulmonary hypertension until after discharge from NICU demonstrating the need for 
follow-up of at-risk infants.112 Whether to screen again and the timing of subsequent screening 
was variable in the studies reviewed. Timing ranged anywhere from 6 weeks after initial scan to 
at 1 year of age depending on whether pulmonary hypertension had been diagnosed on initial 
screen or not and the degree of ongoing respiratory support. 
How to screen 
There is currently no consensus criteria for the diagnosis of late pulmonary hypertension in 
premature infants although all reviewed screening algorithms agree that echocardiography 
should be the initial test. Only three studies offered definitive ultrasound criteria for diagnosis. 
The remainder suggested a range of parameters that could be used to evaluate for evidence of 
raised pulmonary pressures and right heart dysfunction. Common to all studies was 
interrogation of the TR jet if present and an evaluation for septal flattening. Most studies also 
included RV hypertrophy or dilatation and measures of RV dysfunction. Cardiac catheterisation 
was generally only recommended for severe disease or prior to the commencement of long-
term vasodilator therapy. 
The cardiac stress hormone BNP, or the terminal fragment (NTproBNP) were not 
recommended as a screening test in isolation due to lack of data but some proposed their use 
to monitor effects of treatment.86-88, 113  
Resource implications  
The broader the chosen screening criteria the greater the likely cost of the programme and the 
higher the risk of exposing infants to unnecessary testing. However, restrictive criteria may 
decrease costs but increase the risk of missing infants with pulmonary hypertension.  
The primary test costs associated with screening relate to echocardiography. Ideally screening 
echocardiograms should be performed by specialist cardiac sonographers. This is a limited 
human resource often with a significant test cost and may also have potential safety 
implications if it requires an unstable infant to be transported out of the NICU. Neonatologists 
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are increasingly acquiring heart ultrasound skills which, if certified and maintained, may allow 
cot side screening on the neonatal unit at reduced cost. However, by 36 weeks PMA some 
infants who may qualify for screening may have been transferred to regional centres without 
neonatal echocardiography services. The frequency of follow-up scans would also significantly 
add to the cost of any programme.  
If BNP or NTproBNP blood testing is incorporated into screening protocols there will be a 
laboratory cost attached to this. This may be significant if the sample requires transportation to 
another centre as this test is not universally available. There are also potential ethical 
implications if blood testing was not otherwise indicated at this time.  None of the reviewed 
studies performed a cost-benefit analysis. It is clear that more data is needed on both the role 
of BNP in detecting pulmonary hypertension in preterm infants and which heart ultrasound 
parameters offer the best predictive value. 
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Biomarkers have been defined by the National Institutes of Health Biomarkers Definitions 
Working Group as “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention”.122 A useful biomarker is one that is inexpensive, easy to measure 
with minimal patient discomfort and consistently adds diagnostic or prognostic information to 
guide management. Examples of biomarkers currently in use include haemoglobin A1c (HbA1c), 
troponin T (TnT) and C-reactive protein (CRP).  The level of HbA1c (haemoglobin that is 
irreversibly bound to glucose over the lifespan of a red blood cell) is used to monitor long term 
glycemic control in adults and children with diabetes, to guide therapy and thereby lower the 
risk of long term complications.123, 124 Plasma cardiac TnT, a protein release by damaged heart 
muscle, is widely used to rule out myocardial infarction in patients presenting to the emergency 
department with chest pain and also helps clinicians prognosticate the risk of poor 
outcomes.125, 126 Plasma CRP  is a non-specific inflammatory marker that is used in neonates to 
support or refute a diagnosis of sepsis.127 Biomarkers should demonstrate high sensitivity and 
specificity in order to reduce the likelihood of false positive or false negatives. A biomarker is 
currently lacking for neonatal pulmonary vascular disease but B-type Natriuretic Peptide (BNP) 
has been proposed. 
BNP is a hormone rapidly released predominantly by ventricular cardiac myocytes in response 
to the stretch induced by pressure and volume loading.128, 129  Smaller quantities are also 
released from cardiac atria and the brain where it was originally discovered. Hypoxia and 
ischaemia have also been shown to stimulate the release of BNP and other hormones and 
cytokines may influence levels.130, 131  
There is a minimal amount of stored BNP and it is essentially “made to order” with the gene, 
located on the short arm of chromosome 1, being transcribed in less than an hour in response 
to stimuli. BNP is initially released as preproBNP then cleaved into signal peptide and a 108 
amino acid (aa) prohormone (proBNP) (Fig.10). This is subsequently cleaved into the 32-aa 
active BNP hormone and the biologically inert 76-aa N-terminal proBNP fragment (NTproBNP) 
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by the actions of corin, a transmembrane cardiac protease, or furin, a convertase concentrated 
in the Golgi apparatus and expressed in a wide range of tissues.  
 
Figure 10: Synthesis and processing of BNP 
 
Reproduced by permission from Springer Nature License: Springer. Heart Fail Rev. Originally published in: Cantinotti 
M, Law Y, Vittorini S, Crocetti M, Marco M, Murzi B, et al. The potential and limitations of plasma BNP measurement 
in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an 
update. Heart Fail Rev. 2014;19(6):727-42 
BNP mediates its biological actions by binding to natriuretic peptide receptor A (NPR-A) and 
activating cyclic GMP. BNP acts on the kidney to increase glomerular filtration and inhibit 
sodium reabsorption producing a consequent natriuresis and diuresis.129 BNP also has 
cardiovascular effects, reducing blood pressure and pre-load by inducing arterial and venous 
vasodilatation as well as having a direct effect on myocardial relaxation and inhibitory effects 
on the sympathetic nervous system.129, 132 In combination these effects are cardioprotective 
acting to reduce pressure and volume loading on the heart and reduce pathological 
remodelling. BNP also appears to play an anti-inflammatory role decreasing the production of 
oxygen free radicals by activated macrophages.133 
BNP is progressively broken down primarily by renal clearance pathways by the actions of 
natriuretic peptide clearance receptor C located in the vasculature and by the actions of neutral 
endopeptidases (Fig.11). Endopeptidases are expressed on renal tubules, vascular endothelium, 
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heart and lungs. In disease states, in addition to the bioactive 32-aa BNP, cleavage at other sites 
of the prohormone occurs and some of the BNP detected by immunoassays are these 
biologically inert fragments. Atrial natriuretic peptide, a related cardiac hormone, and BNP 
compete for the same receptors and so can effectively inhibit one another in terms of 
clearance and bioactivity. The actions of BNP are also antagonised by the actions of the renin-
angiotensin-aldosterone system which encourages sodium and water retention and 
vasoconstriction.  
NTproBNP has no known biological activity but is more stable than BNP with a longer half-life of 
120 minutes compared to 20 minutes for BNP. The clearance of NTproBNP is less well 
understood but attributed to renal clearance.134 
 
 
Figure 11: Release and degradation of B type natriuretic peptide 
 
Reproduced from Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. 
Heart. 2006;92(6):843-9, with permission from BMJ Publishing Group Ltd. 
 
As BNP and particularly NTproBNP are renally cleared they will be elevated in renal 
impairment.135 BNP and NTproBNP have also been reported to be elevated in septic shock.136-




BNP is  part of the foetal cardiac gene programme that is switched off after birth but can be 
reactivated in times of cardiac stress later in life.47 This allows a switch back to carbohydrates 
for cellular energy which is conducive in the short term to cellular survival, particularly in the 
context of an hypoxic environment.48  Under these circumstances a rise in BNP acts as a 
cardioprotective agent to prevent pathological remodelling in a heart under stress.54, 142 
However, if the stress persists ultimately these short term adaptive mechanisms will fail.  
BNP in adult medicine 
Plasma levels of BNP and NTproBNP have been evaluated in a number of settings using 
validated assays. In adults, increasing age is associated with increasing BNP levels with smaller 
differences seen due to ethnicity, gender and body mass.143, 144 BNP and NTproBNP have now 
been widely adopted in adult medicine where they are used to diagnose, prognosticate and 
monitor response to treatment for heart failure.145-147 The American Heart Association and 
European Society of Cardiology clinical practice guidelines endorse the use of BNP and 
NTproBNP in the evaluation of the patient with heart failure.148, 149  BNP and NTproBNP also 
have value in predicting poor outcomes in pulmonary hypertension and acute coronary 
syndrome.150-152 An NTproBNP cut-off level of 35 pmol/L has high negative predictive value for 
heart failure in patients presenting to emergency department with acute breathlessness with 
heart failure being very likely if level is > 53 pmol/L.129 High NTproBNP levels are also an 
independent predictor of short term cardiac risk in adults with acute coronary syndrome.152, 153. 
In adults with heart disease, natriuretic peptides play a role in reducing pathological cardiac 
remodelling.142 This led to recombinant BNP (nesiritide) being approved as a treatment for 
heart failure although it is no longer widely used  despite its favourable haemodynamic effects 
as it offers no reduction of mortality or readmission rates.154, 155 Elevated BNP and NTproBNP 
levels in adults with pulmonary hypertension are associated with poorer prognosis and serial 
monitoring demonstrates a fall in levels with successful treatment.151, 156-158 
BNP in childhood disease 
BNP and NTproBNP have proven to be useful adjunct to clinical assessment for the diagnosis, 
risk stratification and monitoring of children with congenital heart disease, heart failure, 
cardiomyopathy and pulmonary hypertension.159-161 162-164 A recent systematic review has 
highlighted the wide variation in levels of BNP/NTproBNP in children with pulmonary 
hypertension and the difficulties in using these markers to guide clinical practice.165 
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BNP in neonates 
BNP is expressed in the human placenta and may have a role in maintaining blood supply to the 
foetus by acting as a vasodilator.166 Corin deficient pregnant animal models show 
characteristics of preeclampsia and markedly impaired trophoblast invasion with uterine spiral 
artery remodelling.167 BNP also suppresses cardiac fibroblast growth and may have a role in 
cardiac organogenesis.166 Animal models where natriuretic peptide actions are knocked out 
exhibit hypertension, cardiac hypertrophy and fibrosis.50, 51 Studies of circulating NTproBNP 
levels in the foetus have found levels 4-10 fold higher in foetuses where there is anaemia, 
cardiac or urinary tract malformations or intrauterine growth restriction.168 169, 170 
BNP and NTproBNP do not cross the placenta, but can be measured in cord blood and reflect 
foetal levels.171, 172 There are no differences in BNP or NTproBNP levels taken in arterial 
compared to venous cord blood. NTproBNP levels correlate highly with plasma BNP levels in 
plasma and umbilical cord blood. 173 174 175 Although levels in adults show sex differences and 
also increase with advancing age, levels  are not affected by gender in the neonatal or 
childhood period although some differences have been shown in levels at puberty.171, 172, 176 
BNP is purported to play a role in neonatal transitional circulation, rising immediately after birth 
to peak on day 1-2 before declining to steady state levels. 53 177 It is likely this surge in BNP is 
stimulated by the sudden increased pressure on the left ventricle caused by cord clamping and 
loss of the low resistance placental circuit. BNP has been shown to be elevated in infants with 
persistent foetal circulation, also known as persistent pulmonary hypertension of the newborn 
(PPHN).178 This condition has different pathophysiology, clinical course, response to therapy 
and outcome compared to late pulmonary hypertension in very premature infants. Persistence 
of a haemodynamically significant patent ductus arteriosus (HsPDA) will cause elevation of BNP 
levels as will any other condition causing pressure or volume loading of the heart.179, 180 181 52, 173 
BNP and NTproBNP have proved to be a useful biomarker for the identification of HsPDA and 
monitoring response to treatment.180  
NTproBNP and late pulmonary hypertension in preterm infants 
Despite improvements in the survival of preterm infants, BPD rates remain static and 
contribute to poor short term and long-term outcomes.182-184 Undetected BPD-associated 
pulmonary hypertension may contribute to respiratory morbidity, intensive care readmission 
and late deaths. Identifying infants who have pulmonary vascular disease may allow targeted 
monitoring and therapy for this high risk group. NTproBNP, a sensitive marker of cardiac stress, 
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offers theoretical promise as a low cost initial screening tool for the detection of early cardiac 
dysfunction secondary to rising pulmonary vascular pressure.  
Two small studies have found higher levels of NTproBNP on day 3 and 28 in infants who go on 
to develop BPD even after adjusting for gestational age and PDA status.185, 186 The few studies of 
late pulmonary hypertension in preterm infants have used a range of assay kits and have varied 
significantly in terms of patient selection, timing of testing and diagnostic criteria used for 










Diagnostic criteria for 
PH 
Testing  Results 
Cuna 2013187 
Retrospective study 
comparing BNP levels 
in those with and 
without PH 
Preterm infants with 
BPD undergoing 
screening echo for PH 
(25, 16 with PH, 9 
without) 
At least one of: 
1.Tricuspid regurgitant 
jet velocity increased 
2.Interventricular 
septum flattening 
3. Right ventricular 
hypertrophy 
4. Right to left shunting 
Variable timing for 
echocardiographic 
diagnosis of PH  
  
BNP measured +- 10 
days of scan 
BNP assay not 
identified 
Median BNP higher in 
those with PH higher 
(413 vs 55 pg/ml) 
p<0.001 
BNP≥117pg/ml had 
93.8% sensitivity and 




and BNP in infants with 
BPD and PH 
Preterm infants with 
BPD and PH  
(36) 
At least one of: 
1.Tricuspid regurgitant 
jet velocity increased 
2.Interventricular 
septum flattening 
3. Right ventricular 
hypertrophy 
4. Right to left shunting 
Initial echocardiogram 
and BNP between 4-6 
weeks then monthly. 
ADVIA Centaur BNP 
assay (Siemens USA) 
Peak BNP levels lower 
amongst survivors (128 
vs 997 pg/ml) p <0.004 
Peak BNP≥220 pg/ml 
had 90% sensitivity and 







NTproBNP levels in 
preterm infants with 
and without PH  
< 27 weeks and or 
<=750g with BPD at 36 
weeks PMA 
(20, 5 with PH, 15 
without) 
1. Left ventricle systolic 
eccentricity index 
>=1.5 or  
2. Flat interventricular 
septum in systole 
Echo at 36 weeks PMA 
and NTproBNP testing 
within 1 week of echo  
Assay not identified 
NTproBNP level 
significantly higher in 
PH vs no PH 
(1650 vs 520pg/ml) 
p=0.001 
NTproBNP >1000pg/ml 
predicted PH with 








Diagnostic criteria for 
PH 




NTproBNP levels in 
preterm infants with 
and without PH 
<30 weeks GA and 
<1500g birthweight 
(52 infants, 8 with PH) 
1. PA pressure 
>25mmHg estimated 
by tricuspid regurgitant 
jet velocity and 
2. right ventricular 
hypertrophy and/or 
3.flattening of the 
inter-ventricular 
septum 
On all scans at 28, 32, 
36 weeks PMA 
VITROS NTproBNP 
assay 
28 weeks PMA cut-
point of 2329 pg/ml for 
detection of PH 
 
Reference values and testing 
Before NTproBNP or BNP can be considered as a possible biomarker for pulmonary 
hypertension normal values in healthy preterm infants over time must be established. There 
are a number of commercial assays available for both BNP and NTproBNP including point of 
care testing. Whole blood levels are stable at room temperature when collected in ethylene 
diamine tetra acetic acid (EDTA) additive tubes for at least 24 hours for BNP and at least 72 
hours for NTproBNP. The levels also remain stable during the freezing and thaw process 
allowing batch processing. 
Caution should be exercised in comparing BNP studies and interpreting “reference values” as 
there is known to be some variability depending on the assay type and the age at blood 
sampling.171, 172, 176, 191, 192 Roche Diagnostics (Basel, Switzerland) assays are the most widely 
used and have minimal variability.193 Although there is a one to one ratio of active hormone to 
N-terminal fragment, NTproBNP levels are approximately six times higher in the blood due to 
the longer half-life. BNP and NTproBNP levels are reported in pg/ml or pmol/L. For NTproBNP 
there is an eight-fold difference with 1 pmol/L = 8.457pg/ml.194   Differences in glycosylation 
may also affect levels as it may block the actions of corin and furin and also interfere with the 
ability of some assays to detect BNP or NTproBNP by competing for the binding site.195  
Reference values for amniotic NTproBNP levels for foetal life from 10-34 weeks have been 
reported showing a steady decline in NTproBNP from 10 weeks to a steady state by about 26 
weeks.168 Mean cord blood levels of NTproBNP in healthy neonates have been reported to be 
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578-670 pg/ml (71-79pmol/L) using a Roche testing kit.171, 172, 176 Neonatal reference levels in 
healthy term infants from four pooled studies using the Roche testing kit suggest a 
median(range) on day 0-2 of 3183 pg/ml (260-13224) or  374 pmol/L (31-1555) and a day 3-11 
median(range) of 2210 pg/ml (28-7250) or 260 pmol/L (3.3-853).192 A further study reporting 
NTproBNP levels in healthy term neonates in the first few days of life reported a mean(SD) of 
3042(1783)pg/ml  or 360 pmol/L (210)172. The wide variation in the first few days of life reflects 
the dynamic variation in transitional circulation and variable age at testing and numbers of 
infants tested in most studies have been small.138  
Biological markers have inherent variability, exhibiting variability on serial testing even in 
conditions of apparent clinical stability. NTproBNP is no exception. A small component is due to 
analytic variation, but the remaining “biological” variability reflects a multitude of physiologic 
factors that influence secretion and clearance of these peptides.  Understanding the degree of 
normal variability of any given biomarker within a stable physiological state is important to 
interpret serial levels. The biological variability (or relative change value) of NTproBNP is 
currently accepted to be 25% in adults with stable heart failure, meaning that a 25% change in 
NTproBNP levels is likely to represent a clinically significant change (either deterioration or 
improvement) in the patient’s physiological state.196 The accepted relative change value for 
healthy adults is higher at approximately 50% reflecting lower levels and a greater percentage 






NTproBNP is a sensitive marker of cardiac wall stress that is widely used in the adult setting for 
diagnosis and prognosis. It can be easily tested in preterm infants and holds potential as a 
biomarker for rising pulmonary artery pressure causing heart strain. Serial testing of high risk 
infants may allow clinicians to identify those infants in need of further investigation by 
echocardiography and cardiac catheterisation, to identify infants who may benefit from 
medications that lower pulmonary pressures and to monitor the response to this therapy. 
 
Gaps in current knowledge 
There are, however, significant gaps in our current understanding. Further research is needed 
to establish the normal pattern of NTproBNP levels over time and the factors that influence 
NTproBNP in preterm infants, particularly factors that are prevalent such as patent ductus 
arteriosus and BPD. It is also important to establish whether there may be glycosylation or post-
translational processing differences that may affect assay interpretation. If it is to be 
investigated as a marker to support the detection of late pulmonary hypertension in premature 
infants it will need to be paired with heart ultrasound ideally with objective, quantitative and 




Heart Ultrasound in the Detection of Late Pulmonary 
Hypertension in Preterm Infants 
 
Introduction 
Cardiac catheterisation is the gold standard test for measuring pulmonary pressures. The 
procedure involves accessing the vascular system, usually via the femoral vein, and feeding a 
catheter up into the heart and great vessels. It enables the direct measurement of pressures in 
the main pulmonary artery and right ventricle. The injection of contrast medium allows a 
pulmonary angiogram to provide detailed anatomical information. However, it is invasive and 
only available at specialist units necessitating the potentially hazardous transport of a fragile 
neonate to access this service. This makes cardiac catheterisation unethical and unacceptable 
as a screening tool. It is reserved for the most severe cases or when additional cardiac 
pathology is suspected.  
 Heart ultrasound is now widely available in neonatal intensive care units with many 
neonatologists now trained in clinician performed heart ultrasound (Fig.12). It is safe, non-
invasive and well tolerated by the infant. It is used for assessing cardiac structure and function 
as well as monitoring disease progression and response to treatment. Heart ultrasound has 
been used to estimate pulmonary pressures and offers reasonable accuracy in the early period 
post-delivery.197, 198 There is less certainty about the use of heart ultrasound for the estimation 




Figure 12: Photo of premature baby having a heart ultrasound. Permission to use photo for educational and teaching 
purposes granted by family 
It would be valuable to have established and validated heart ultrasound parameters that could 
be used to detect evolving pulmonary hypertension in the context of BPD. Unfortunately there 
are no large, prospective trials comparing heart ultrasound against cardiac catheterisation for 
the diagnosis of late pulmonary hypertension in infants born prematurely. What we currently 
know is derived and inferred from adult studies and small, mostly retrospective, paediatric and 
neonatal studies using different ultrasound criteria at different time points.  
There are no direct heart ultrasound measures of pulmonary artery systolic pressure.  
Measures that have been used conventionally to assess for pulmonary hypertension have 
included tricuspid regurgitation (TR) jet peak velocity, ductal shunt pattern, shortened main 
pulmonary artery (MPA) acceleration time, interventricular septal flattening and the presence 
of  right ventricular (RV) hypertrophy or dilatation. However, these traditional ultrasound 
techniques do not reliably predict pulmonary hypertension when compared directly to cardiac 
catheterisation.199  Newer techniques including tissue Doppler imaging (TDI) and speckle 
tracking hold promise.200, 201  However, whatever the technique used it is important to 
understand what the parameter is measuring and potential pitfalls. Some measures, such as TR 
jet peak velocity and ductal shunt pattern estimate RV systolic pressure. Other measures such 
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as tricuspid valve inflow E/A wave ratio and right index of myocardial performance (RIMP) 
assess RV dysfunction while some demonstrate the effects of prolonged raised pulmonary artery 
pressures (RV hypertrophy/enlargement). Unfortunately not all measures are obtainable 
consistently in neonates where assessment is often hindered by high heart rates and rapid 
ventilation. The measurements also have a degree of intraobserver and interobserver 
variability and some are completely subjective rather than quantitative measures. Most do not 
have reference ranges established for the neonatal still less the preterm population nor 
account for the developmental changes in these parameters over time.202, 203 It is also 
important to be aware that pulmonary hypertension is also relative to left sided cardiac 
pressures. In the absence of a central arterial catheter, the measures of left ventricular (LV) 
pressure are also imprecise.  LV systolic and diastolic dysfunction may also contribute to 
pulmonary hypertension. Hence clinicians must assess the heart using a broad range of 
ultrasound techniques in order to accumulate evidence to support or refute a diagnosis of 
pulmonary hypertension. In addition, preterm pulmonary vascular disease is a spectrum of 
disease which develops gradually over time. There is no defined time point at which at risk 
infants develop pulmonary hypertension. Serial assessments are therefore likely to be 
important to identify infants on a pulmonary hypertension trajectory. 
Conventional heart ultrasound parameters to assess for pulmonary 
hypertension 
A number of different heart ultrasound measures and assessments can be used for the 









Table 2: Echocardiographic measures commonly used in the evaluation of late pulmonary hypertension (PH) 
Echo Parameter Information derived Qualitative or 
quantitative 
Reference ranges available or 
diagnostic cut off suggested? 
Drawbacks 
TR jet Doppler 
interrogation 
Estimate of pulmonary 
artery pressure  
Quantitative > 2.7m/s consistent with elevated 
pulmonary pressure 
Use of Bernoulli equation to estimate 
PA pressure: ≥35mmHg and > ½ 
systemic considered significant  
Not always present even with PH, 
very angle dependent, variable 
sensitivity and specificity 
Interventricular septum 
position at end systole 
Estimate of pulmonary 
artery pressure 
Qualitative Flat – approximately half systemic 
pressure 
Flat-posterior systolic right to left 
bowing –systemic pressure 
Severe post-systolic bowing – 
suprasystemic pressure  
Interobserver variability 
LV eccentricity index Estimate of pulmonary 
artery pressure 
Quantitative Systolic eccentricity index >1.3 205, 206 May also be increased by pure 
volume loading 
Shortening of MPA 
acceleration time 
Estimate of pulmonary 
artery pressure 
Quantitative Corrected  AT/RVET <0.31207, 208 Variability in measurement 
Unable to assess if turbulence 
from PDA 
High pulmonary vascular 
resistance may prolong  AT 
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Echo Parameter  Information derived  Qualitative or 
quantitative  
Reference ranges available or 








No Subjective. Absence of notching 
may occur in pulmonary 
hypertension (suggestive of 
pulmonary venous hypertension) 
RV dilatation RV function Qualitative No Subjective and may be biased by 
experience of reviewer. 
Dependent on duration of PH 
RV hypertrophy RV function Qualitative No Subjective and may be biased by 
experience of reviewer. 
Dependent on duration of PH 
TAPSE RV lateral wall 
longitudinal 
performance 
Quantitative As per gestational age209 
<0.5cm is less -2SD for infants < 30 
weeks 
Reference ranges refer to 
preterm infants who are only 1-2 
days old 
TAPSE may not reflect global RV 
function 
Angle and load dependent 
 
PR jet Doppler 
interrogation 
Estimate of mean and 
diastolic pulmonary 
artery pressure 
Quantitative Early peak  and end diastolic velocity 
used with Bernoulli equation 
(4xV2)+RA pressure210 
≥25mmHg diastolic pulmonary 
pressure consistent with pulmonary 
hypertension 




Echo Parameter Information derived Qualitative or 
quantitative 
Reference ranges available or 
diagnostic cut off suggested? 
Drawbacks 
Shunt gradient  
(PDA, VSD) 
Estimate of pulmonary 
artery pressure 
Quantitative Method to calculate for PDA shunt 
described by Musewe. 211 
With unidirectional shunts difference 
between pulmonary and systemic 
systolic pressures can be calculated 
using 4 x (peak shunt velocity) 2  
Often complex to measure if 
shunts are bidirectional. 
 
RV fractional area 
change 
Estimate of pulmonary 
artery pressure 
Quantitative Levy 2015 Often difficult to define 
endocardium 
Tricuspid E/A by pulsed 
Doppler 
Right heart function Quantitative As per gestational age212 Waves often become fused at 
high heart rates. 
Affected by volume status and the 
use of inotropes. Progressive 
diastolic dysfunction will cause a 
rise in atrial pressure which can 
cause a “pseudonormal” ratio. 
Tricuspid RIMP(Tei 
index) 
Right heart function Quantitative As per gestational age212 Can be affected by heart rate.  
Angle dependent. 
May be unreliable in the presence 







Echo Parameter Information derived Qualitative or 
quantitative 
Reference ranges available or 
diagnostic cut off suggested? 
Drawbacks 
TV S’ by TDI Right heart function Quantitative By gestational age213, 214 Load dependent and may be 
pseudonormalised under 
conditions of volume loading. 
Angle dependent 
Can be affected by heart rate 
TV E’ by TDI Right heart function Quantitative By gestational age213 Angle dependent 
E’and A’ may fuse at high heart 
rates 
TV A’ by TDI Right heart myocardial 
function 
Quantitative By gestational age213 Angle dependent 
 E’and A’ may fuse at high heart 
rates 
LV dilatation Left ventricular function Qualitative No Intra and Interobserver variability 
LV hypertrophy Left ventricular function Qualitative No Intra and interobserver variability 
Mitral valve RIMP (Tei 
index) 
Left ventricular function Quantitative As per gestational age212 Can be affected by heart rate.  
Angle dependent. 
Can be difficult to acquire. 
Left ventricular 
ejection fraction by 
Simpsons Biplane 
method 
Left ventricular function Quantitative 55-70%215 Inaccurate if imaging planes are 
off-axis or foreshortened or in 




Left ventricular function  Quantitative  28-38%215 Angle dependent 
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Echo Parameter Information derived Qualitative or 
quantitative 
Reference ranges available or 
diagnostic cut off suggested? 
Drawbacks 
Mitral valve E/A by 
pulsed Doppler 
Left ventricular function Quantitative By gestational age212  Waves may be fused at high heart 
rates 
Mitral valve S’ by TDI Left ventricular function Quantitative By gestational age213 Angle dependent. May be 
affected by heart rate. 
Mitral valve E’ by TDI Left ventricular function Quantitative By gestational age213 Angle dependent. Waves may be 
fused at high heart rates.  
Mitral valve A’ by TDI Left ventricular function Quantitative By gestational age213 Angle dependent. Waves may be 
fused at high heart rates 
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Tricuspid regurgitation jet 
In the absence of pulmonary stenosis the peak velocity of a TR jet on conventional 
Doppler correlates with MPA systolic pressure.216-220. Use of the Bernoulli equation   
allows estimation of the RV systolic pressure (RVSP= 4x (peak TR jet velocity2) which, in 
the absence of a gradient across the pulmonary valve, is equivalent to the MPA systolic 
pressure.204 The TR jet must demonstrate a complete, clearly defined envelope and peak 
velocity in order to be used to estimated MPA systolic pressure (Fig. 13, 14). 
Concurrent measurement of the systemic pressure is needed, ideally with invasive blood 
pressure (BP) monitoring. A level of greater than one third of systemic pressure is 
indicative of raised right heart pressures.  However, a significant TR jet may only be 
present in less than a third of preterm infants with a diagnosis of BPD-associated 
pulmonary hypertension.80, 199, 221 
 
 
Figure 13: Mild tricuspid regurgitation on Doppler ultrasound (flow shown below baseline) 
Chapter 1  40 
 
 
Figure 14: Significant tricuspid regurgitation on Doppler ultrasound 
 
Ductal shunting pattern 
Pulmonary pressures can be qualitatively estimated from the pattern of shunting 
through a patent ductus arteriosus using pulse wave Doppler from a high left parasternal 
view (Fig. 15). Low velocity bidirectional shunting can be considered to reflect systemic 
level pulmonary artery pressures whilst exclusive right-to-left shunting is suggestive of 
suprasystemic pulmonary artery pressure.211, 222, 223 As pulmonary pressures rise, the 
duration of right to left shunting will increase with <30% of the cardiac cycle  close to but 
below systemic pressure, while right to left shunting of >30% reflects higher than 
systemic pressures.211, 223 It is possible to estimate the pulmonary pressures from the 
ductal shunt peak velocity using the modified Bernoulli equation but this is more 
complex than for the TR jet and not practicable for routine clinical use.223 Interrogation 
of the ductal Doppler pattern tends to be most useful in the context of PPHN where 
there is persistence of the foetal circulation and not in the assessment of late pulmonary 
hypertension in preterm infants as the duct has often closed by the time pulmonary 
pressures rise. 
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Figure 15:  Bidirectional shunting through patent ductus arteriosus  
 
Left to right above the baseline and right to left below 
 
Shortened acceleration time on MPA Doppler 
The time taken for the MPA systolic flow to reach its peak velocity tends to become 
shorter as the pressure and resistance to flow increases. In paediatric and adult 
populations the pulmonary artery acceleration time (AT) divided by the right ventricular 
ejection time (RVET) on Doppler ultrasound has been shown to have an inverse 
correlation with pulmonary artery pressure on cardiac catheterisation.224, 225 This ratio 
may be affected by heart rate. Corrected AT:RVET can be calculated by dividing by the 
square root of the R-R interval on electrocardiogram.  
AT:RVETc  has been show to rise in premature infants over the first seven days of life 
being most pronounced for the first three days (thought to reflect decreasing pulmonary 
artery pressure) then stabilise at approximately 0.54-0.57.226, 227 The rise over the first 
three days occurs more slowly in infants who go on to develop BPD and the mean 
AT:RVETc after seven days is lower compared to those who do not develop BPD.226  
Severe pulmonary hypertension will often cause a saw-tooth appearance to the MPA 
Doppler. However, it is sometimes difficult to accurately determine where to measure 
the peak of acceleration in some Doppler recordings. In particular it is often not able to 
be measured in the context of a hemodynamically significant duct due to the turbulence 
in MPA flow (Fig.16). At high heart rates this parameter can become less reliable and it is 
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crucial to consistently place the Doppler sampling gate at the midpoint of the MPA just 
below the pulmonary valve. RV dysfunction will also prolong the acceleration time such 
that even with significant pulmonary hypertension AT:RVETc may be normal.198 It has 
been suggested that a ratio of < 0.23 is likely to represent high pulmonary artery 
pressure and an intermediate level of 0.24-0.35 to reflect moderate pressure but that 
pulmonary hypertension cannot be excluded if this ratio is normal.223  There is 
considerable debate about the reliability of this measure with many studies having small 
numbers of infants and wide confidence intervals. 
 
 
Figure 16: MPA Doppler with turbulent flow pattern secondary to PDA 
 
Right ventricular hypertrophy and right ventricular dilatation 
After chronic exposure to high pulmonary pressures the RV hypertrophies in an attempt 
to compensate. Eventually this fails and the RV begins to dilate and right ventricular 
failure ensues.228, 229 When RV hypertrophy or dilation is seen it is important to exclude 
RV outflow tract obstruction or causes of RV volume overload. This is a subjective 
assessment. Attempts to calculate RV volume are complicated by the geometry of the RV 
and the challenges of getting a consistent view using a two dimensional imaging 
modality. RV volume is best assessed by cardiac MRI.  Although RV hypertrophy and 
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dilation are not sensitive measures of pulmonary hypertension and subjectivity may 
affect reliability, their presence signals severity and chronicity.  
Septal wall flattening 
The interventricular septal wall normally bows into the RV during systole. If pulmonary 
pressures are moderately raised then the septum will be flat at end systole. Further 
elevation of pulmonary pressures will cause the septum to bow into the LV. Septal wall 
flattening, has shown reasonable correlation with right ventricular systolic hypertension 
in children.230 This is sometimes represented as the eccentricity index, which is a 
measurement of the maximal LV diameter parallel to the interventricular septum divided 
by the LV diameter perpendicular to the septum (Fig.17). It can be measured at end-
systole or end- diastole and is normally approximately 1, but in the presence of raised 
right sided pressures is >1, with RV function becoming impaired in premature infants at 
levels of ≥1.3.206  Septal flattening is commonly present in very preterm infants with late 
pulmonary hypertension with many infants who demonstrate this sign on day 7 going on 







Advanced Cardiac Ultrasound  
Advanced ultrasound techniques that may be useful in assessing for pulmonary 
hypertension include the right index of myocardial performance, tricuspid annular plane 
of systolic excursion, tissue Doppler interrogation of the tricuspid valve and speckle 
tracking echocardiography. 
Right Index of Myocardial Performance (RIMP)  
RIMP or right Tei index is a marker of global RV function that is inversely correlated with 





Figure 17: Left ventricular eccentricity index LVEI = D1/D2 
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assesses both systolic and diastolic time intervals and is determined using conventional 
or tissue Doppler imaging (TDI). TDI interrogates a point on the myocardium measuring 
myocardial tissue velocities. TDI RIMP allows the measurements to be done on a single 
image enhancing accuracy. It has been shown to correlate well with RV ejection 
fraction.232 It has been used widely to assess RV function in adults demonstrating 
prognostic value and utility in monitoring changes in pulmonary hypertension over 
time.233 In preterm neonates the RIMP has been shown to fall to a steady state level after 
24 hours.234 RIMP is age dependent, decreasing with time after birth but may remain 
elevated in infants with evolving BPD.235 It does not appear to be affected by heart rate, 
blood pressure, PDA and gestational age and birth weight effects appear to drop out 
when infants with and without BPD are assessed separately.235   
Tricuspid Annular Plane of Systolic Excursion (TAPSE) 
The orientation of fibres in the right ventricle means that contraction occurs in a 
predominantly longitudinal plane.  TAPSE is the measure of systolic displacement of the 
tricuspid annulus reflecting systolic right ventricular function and correlating with RV 
ejection fraction.236 TAPSE is measured by examining the total excursion of the tricuspid 
annulus during ventricular systole on M-mode using apical four chamber view. A sample 
image can be found in methods chapter.  It is simple to perform and highly 
reproducible.236 Diminished TAPSE has been demonstrated in pulmonary hypertension 
and cardiac failure in adult and paediatric populations with diagnostic and prognostic 
implications.236, 237 TAPSE values increase with age and are affected by body surface area 
but not gender or heart rate.238 Reference ranges and z scores have recently been 
published for preterm neonates.209 
Tricuspid annulus S’, E’, A’, E/A, E/E’  
Doppler interrogation of the inflow through the tricuspid valve generates a double wave 
form, the peak early diastolic flow velocity (E) and the peak atrial systolic flow velocity 
(A). An example image can be found in methods chapter. E corresponds to early diastolic 
relaxation, A corresponds with atrial contraction. The tricuspid valve E/A ratio has been 
used for evaluating RV diastolic function in adults However, it is affected by heart rate 
and can be  difficult to obtain in children and neonates due to high resting heart rates 
which often result in fusion of the waves. In adults a tricuspid E/A ratio of < 0.8 suggests 
impaired RV relaxation and a level of >2.1 suggests restricted filling.218  Although there 
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are a few studies of these measures in preterm infants in the first few days of life there is 
a paucity of longitudinal data.213, 239, 240 
Because of the longitudinal plane of myocyte contraction the point of focus for right 
heart tissue Doppler interrogation is on the TV annulus along the RV free wall.  TDI allows 
the systolic and diastolic function to be analysed simultaneously. A tissue Doppler tracing 
generates a systolic wave (S’), an early diastolic wave (E’) and a late diastolic wave (A’). 
Sample image in methods chapter. TDI myocardial velocity measurements have been 
validated against cardiac catheter data and have been used to assess and monitor 
myocardial dysfunction in adult cardiology.241 In the presence of pulmonary hypertension 
significant reductions in systolic (S’) and early diastolic (E’) tricuspid myocardial velocities 
are seen.242 The E/E’ ratio has been found to be a good marker for right atrial pressure 
and RV end-diastolic pressure in adults.243 
Paediatric and neonatal reference values for tricuspid annulus S’, also known as tricuspid 
annulus peak systolic velocity (TAPSV) have recently been published.214, 244 TAPSV 
correlates with RV systolic function and is reduced in pulmonary hypertension secondary 
to congenital heart disease.242 Early diastolic tissue velocity (E’) has been found to 
increase with age with preterm born infants reaching term equivalent age demonstrating 
tissue velocities that are comparable to term born infants.222 Infants with moderate BPD 
have been shown to have a higher early Doppler inflow velocity to the early tissue 
Doppler velocity ratio (E/E’).245 The E’ wave has also been shown to be reduced or absent 
in infants with pulmonary hypertension.246 However, there is some overlap in myocardial 
velocities with some infants with pulmonary hypertension showing preserved myocardial 
velocities.246 
Speckle tracking echocardiography  
During contraction the myocardium undergoes deformation in a longitudinal, 
circumferential and rotational plane. When the myocardium is imaged by ultrasound a 
speckle pattern is visible due to interference and acoustic reflections with each part of 
the myocardium having a different speckle signature. Measurement of right ventricular 
longitudinal deformation using speckle tracking echocardiography appears to be a 
feasible and reproducible technique for assessing regional RV function in the preterm 
infant and it may be a useful addition to current tools for the diagnosis and monitoring of 
pulmonary hypertension, however it requires specialised software.200, 201 247 
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Summary 
Invasive cardiac catheterisation remains the only way to accurately measure pulmonary 
pressures and exclude anatomical abnormalities of the pulmonary vasculature. 
Conventional heart ultrasound measurements may be inadequate to reliably detect the 
late pulmonary hypertension associated with prematurity. Newer, more advanced 
ultrasound techniques have not been widely studied in the preterm population. 
Ultrasound provides, at best, indirect estimates of pulmonary pressure many of which 
are subjective and lack validity in the diagnosis of prematurity-associated late pulmonary 
hypertension. It is therefore important that clinicians interrogate the heart serially using 
multiple techniques to evaluate for rising pulmonary pressures. 
Gaps in current knowledge 
More research is needed to determine the optimum diagnostic protocol in the 
population of preterm infants at risk of late pulmonary hypertension. 
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The Role Oxygen Saturation Monitoring 
 in the Prevention and Detection of  
Pulmonary Vascular Disease 
 
Introduction 
Respiratory support is a key component of care for babies born very prematurely. 
Improvements in perinatal care including oxygen saturation monitoring, antenatal 
steroids, surfactant treatment and non-invasive respiratory support have dramatically 
improved survival rates, yet rates of bronchopulmonary dysplasia remain static.69, 248 In-
utero and post-natal factors are thought to contribute to BPD. Supporting 
developmentally immature lungs while avoiding the potentially harmful effects of 
therapy is a delicate balancing act.249 Understanding the relationship between oxygen 
and the developing lung is crucial to understanding the evolution of bronchopulmonary 
dysplasia and associated pulmonary vascular disease. 
Pathological effects of hyperoxia  
The foetal lung is programmed to develop in a low oxygen environment. The partial 
pressure of oxygen in the umbilical vein (delivering oxygen to the foetus) is 
approximately 4.7kPa compared to 10.5kPa in adult arterial blood and 19.6kPa in air at 
sea level.250 Foetal blood is at best only 80-90% saturated which is considerably lower 
than the >94% seen in healthy infants, children and adults.250 During the first stage of 
labour the mean blood oxygen saturation in the foetus may be as low as 50%+-10%.251 
However, foetal haemoglobin is adapted to these low concentrations with enhanced 
oxygen uptake but decreased tissue delivery.  
Premature birth suddenly exposes the developing lung to relative hyperoxia, even in 
room air, and a gradual switch from foetal to adult haemoglobin. Adult haemoglobin has 
decreased oxygen uptake but enhanced tissue delivery better suited to the relatively 
higher oxygen supply and increased tissue demands of post-natal life. Historically 
preterm infants were also exposed to high levels of supplemental oxygen with 
devastating effects on vision secondary to the development of retinopathy of 
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prematurity.252 Retinopathy of prematurity develops in two phases. The first phase is 
triggered by excess oxygen which suppresses VEGF and inhibits normal retinal blood 
vessel growth. The second phase occurs when the insufficient retinal vessels cannot 
meet the oxidative metabolic demands of the retina inducing a rise in VEGF and an 
excessive proliferation of abnormal retinal vessels.   
There are parallels that can be drawn between the pathophysiology of retinopathy of 
prematurity and pulmonary vascular disease with excess oxygen front and centre. 
Alveolar hyperoxia  is  known  to have toxic effects on the lung, triggering an 
inflammatory cascade that results in damage to the alveolar-capillary barrier with 
endothelial cell death, resultant vascular leak, impaired gas exchange and ultimately 
epithelial cell death.74 253 Preterm infants have underdeveloped anti-oxidant strategies to 
combat the damaging effects of oxygen free radicals although the modulation of oxygen 
sensitivity is more complex than simply the relative levels of antioxidant enzymes.254  
Many factors have been identified to be involved in both lung development and the 
inflammatory process induced by exposure to excess oxygen. HIF is a master 
transcription factor released in response to hypoxia and involved in the regulation of 
hundreds of genes including that of VEGF. VEGF is involved in endothelial cell 
development and remodelling of vascular tissue including pulmonary vessels. This 
process is essential for alveolar development.55, 56 HIF levels in the lungs of premature 
animals are reduced when mechanically ventilated. 255, 256 Infants who go on to develop 
BPD have significantly lower levels of VEGF detected.257 Prolonged exposure to hyperoxia 
leads to an initial surge of VEGF, coinciding with the initial period of vascular damage, 
followed by a decrease in VEGF leading to poor vascular repair and regeneration and 
consequent poor alveolar development and malformed pulmonary vasculature.56 
Activation of VEGF in experimental models of BPD restores alveolar development with 
VEGF fulfilling Koch’s alveolarization postulate (Fig.18). 
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Figure 18: Illustration of VEGF's fulfilment of Koch's alveolarization postulate 
 
1) Inhibition of VEGF signalling impairs alveolar development  
2) Conversely impaired alveolarization in human and experimental BPD is associated with decreased VEGF 
signalling  
3) Overexpression of activation of VEGF in experimental BPD restores normal alveolar development 
 
Reprinted with permission of the American Thoracic Society. Copyright © 2018 American Thoracic Society. 
Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic 
growth factors in chronic lung disease. Am J Respir Crit Care Med. 2007;175(10):978-85.The American Journal 
of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society 
 
Studies of oxygen toxicity have focused primarily on continuous exposure at high 
concentrations. Chronic exposure of newborn rodent and preterm baboon animal 
models to high levels of oxygen results in a BPD-like lung injury.258, 259 However, with 
modern intensive care premature babies are more likely to be exposed to intermittent 
alveolar hyperoxia. Surprisingly short exposures have been shown to cause oxidative lung 
damage.260 However, even with continuous exposure there is the propensity for recovery 
and an adaptive response in human newborns. The impact of hyperoxia is modifiable. 
Antenatal exposure to corticosteroids or inflammatory mediators may decrease the 
deleterious effects of oxygen exposure while intrauterine growth restriction or poor 
postnatal growth may increase sensitivity to oxygen toxicity.248, 261, 262  Prior exposure to 
oxygen can also prime the lung to tolerate the effects of prolonged hyperoxia. More 
work is needed to understand the impact of mild intermittent hyperoxia exposure. 
Impact of hypoxia 
Hypoxemia can also cause harm to the developing foetus and newborn. Foetuses with 
intrauterine growth restriction secondary to poor placental function are exposed to 
chronic hypoxemia in-utero. Hypoxemia in the preterm neonate is caused by the 
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complex interplay between an immature respiratory centre and mechano and chemo 
receptors (causing central apnoea), an underdeveloped airway and bronchial tube 
network (prone to obstruction) and an immature gas exchange interface (with smaller 
surface area, alveoli prone to oedema and inflammatory reaction, a greater distance 
between alveoli and pulmonary vessels and poorly developed pulmonary capillaries 
prone to vasoreactivity leading to ventilation-perfusion mismatch).263 In addition 
hypoxemia can have iatrogenic causes such as obstruction or displacement of 
endotracheal tube or nasal cannula or poor positioning leading to airway compromise.  
Persistent severe hypoxemia ultimately leads to cell death. The foetus or neonate may 
be able to adapt to chronic sustained hypoxemia of less severity but there is a cellular 
cost. Poor placental function can result in chronic oxygen and nutritional deprivation. 
The chronic hypoxia associated with intrauterine growth restriction results in an 
increased risk of pulmonary hypertension in the neonatal period. 92, 264 Adaptive 
mechanisms that occur in-utero, such as redistribution of blood flow to vital organs, 
result in myocardial and vascular remodelling which may persist and increase risk of 
cardiovascular disease in adulthood.265  
Infants born very prematurely frequently experience chronic intermittent hypoxemia 
which has been linked to increased incidence of retinopathy of prematurity, need for 
prolonged respiratory support and adverse neurodevelopmental outcome. 266-268 269.66 A 
low baseline oxygen saturation of ≤90% has also been shown to be associated with an 
increased risk of subsequent chronic intermittent hypoxemia.267  
In the modern era of neonatal intensive care with carefully monitored oxygen 
saturations it is rare for an infant to be exposed to excessively high or low levels of 
oxygen for prolonged periods. It is more likely that infants will experience intermittent 
hyperoxia and hypoxia. Our understanding of the consequences of this, and how best to 
avoiding swinging saturations is still evolving. It is also sobering that babies born 
prematurely in resource poor countries remain at high risk of the completely 
preventable iatrogenic damage caused by excessive oxygen. 
Oxygen saturation monitoring  
Pulse oximetry monitors allow the non-invasive continuous estimation of blood oxygen 
saturation. Two light emitting diodes are used to transmit red and infrared light through 
the skin (Fig. 19). Deoxygenated haemoglobin absorbs more red light and oxygenated-
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haemoglobin absorbs more infrared light. A photoreceptor placed opposite the diodes 
compares the ratio of absorbed light and uses a pre-programmed algorithm to calculate 
the peripheral capillary oxygen saturation (SpO2). As oximeters detect pulsatile blood in 
order to estimate arterial rather than venous blood oxygen saturation, movement can 
cause artefact. Modern Masimo oximeters (Masimo Corporation, Irvine, California) 
utilise signal extraction technology which greatly reduces the signal noise caused by 
movement and gives a performance index (percentage time SpO2 is within 7% of control 
value) of 94%.270  Hypothermia and poor skin perfusion may cause falsely low readings 
and the relative ratio of foetal to adult haemoglobin may also affect reported SpO2 levels 
as will the quality of the stored normative data on which the algorithm is based. Masimo 
oximeters also have the capacity to store data which can be downloaded for analysis of 
trends over time using software such as PROFOX (PROFOX Associates Inc, Escondido, 
California). 
 
Figure 19: Photo of oxygen saturation probe and monitor 
 
Oxygen saturation targeting 
The understanding that insufficient oxygenation increases mortality and 
neurodevelopmental morbidity and exposure to excessive oxygen causes pathological 
lung and eye injury has led to practice of oxygen saturation targeting. Identifying the 
range that offers the best cost-benefit ratio has proved challenging.249, 271  A number of 
large multicentre trials have attempted to answer the question of optimum saturation 
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targets in preterm infants to prevent the adverse effects of hyperoxia and hypoxia. The 
STOP-ROP trial looked at whether randomisation to two different levels of oxygen 
saturation targeting (89-94% or 96-99%) would affect the incidence and progression of 
retinopathy of prematurity. Although they found no difference in ROP, the group 
randomised to the higher oxygen saturations had a greater evidence of the effects of 
lung injury.272 The BOOST trial demonstrated that infants randomised to higher oxygen 
saturation targets (95-98% versus 91-94%) were more likely to be dependent on oxygen 
at 36 weeks PMA  and had a longer duration of oxygen therapy. 273  
Neonatal Oxygenation Prospective Meta-analysis(NeOProM) is a collaborative 
metanalysis of the results from five similarly designed, large, international, multicentre 
trials(BOOST-II, COT, SUPPORT) targeting oxygen saturations of either 85-89% or 91-95% 
in infants born at < 28 weeks from birth to 36 weeks PMA.274-276 There were concerns 
raised over issues with the pulse oximeter algorithm and differences in the definition of 
neurological impairment. 249, 277 Although there were differences in the outcomes of 
individual trials, the metaanalysis demonstrated that the higher oxygen target was 
associated with a lower risk of death and a lower rate of necrotising enterocolitis but a 
higher rate of oxygen use at 36 weeks PMA. Pulmonary hypertension was not a reported 
outcome of these trials. There is evidence from a retrospective cohort study that 
targeting higher versus lower oxygen saturations may lead to lower rates of prematurity-
associated pulmonary hypertension.278 Debate continues, but on balance, current 
evidence suggests that targeting oxygen saturations of 91-95% in extremely preterm 
infants, with access to high quality ROP screening, offers the best risk-benefit profile for 
oxygen therapy. However, there is concern that this change in practice may lead to a rise 
in ROP emphasising the tremendous challenge in defining and maintaining optimal 
oxygen saturations in preterm neonates.279 
Despite the practice of oxygen saturation targeting, the AVIOX trial reported preterm 
infants spend between 16-64% time within their targets with infants above the target 
range 20-73% of the time.280 Laptook et al also reported time in target to be 58%.281 
Hypoxemia may be multifactorial however, hyperoxemia is a potentially preventable 
source of iatrogenic harm. Pulse oximeters estimate the percentage oxygen saturation of 
haemoglobin but do not measure the partial pressure of dissolved and unbound oxygen. 
Due to the shape of the oxygen dissociation curve it is important to recognise that small 
changes in SpO2 above 90% are associated with relatively large changes in arterial 
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oxygen tension.282 An additional challenge with oxygen saturation targeting is that even 
with a clearly defined unit policy compliance with alarm limits has been shown to be 
poor and variability amongst nursing opinion and practice high.283 284 
In addition not all premature infants are alike with regards to oxygen saturation stability. 
Some infants develop a propensity for saturations that swing from sudden lows to highs 
that makes nursing care challenging. It is not clear why this subset of infants develop 
such variability in their oxygen saturation signature. There are likely to be many 
contributing variables including in-utero environmental programming however, one 
possibility is that these infants have dysfunctional pulmonary microvasculature prone to 
sudden vasospasm leading to areas of the lung that are ventilated but not perfused 
and/or shunting of deoxygenated blood into the arterial system.59  
Nursing observation charts, although meticulous, are blunt instruments for observing the 
second to second variability of oxygen saturations and heart rate. With the development 
of pulse oximeters with downloadable memory we now have the ability to review this 
with greater precision. Time above, below or within certain saturation levels can be 
analysed and mean saturation and standard deviation derived. The coefficient of 
variation (CV), which describes the ratio of the standard deviation to the mean, is a 
measure of instability that captures both variability around the mean and those infants 
whose mean is lowered by frequent hypoxic episodes. The CV appears to have more 
discriminating value than the mean or standard deviation.285 The optimal measures of 
oxygen saturation instability in premature infants are still unclear and further work needs 
to be done if we are to better evaluate our care and avoid iatrogenic harm from too little 
or too much oxygen. 
Summary 
Hyperoxia contributes to the development of pulmonary vascular disease in very 
premature infants. Improving our understanding of pulse oximetry instability may allow 
us to use pulse oximetry analysis to refine respiratory support for individual babies 
within the broad framework of oxygen saturation targeting guidelines and reduce risk of 
iatrogenic harm. Deeper analysis of individual pulse oximetry data over time may also 
potentially identify infants with evolving pulmonary vascular disease. 
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Key Points 
What is known: 
 Premature birth is common and is associated with poor growth and long term 
cardiorespiratory and neurodevelopmental sequelae 
 Infants born very prematurely are at risk of pulmonary hypertension  which 
carries a significant morbidity and mortality risk prompting calls for screening for 
this condition 
 N-terminal pro-BNP is a cardiac hormone released by ventricles under volume or 
pressure stress that is cardioprotective and can be used for diagnosis and 
prognosis in adults with heart failure and pulmonary hypertension and has been 
shown to rise during transitional circulation in preterm infants 
Clinician performed heart ultrasound is a useful tool for evaluating transitional 
circulation including persistent pulmonary hypertension of the newborn using 
conventional techniques 
 Exposure of the developing lung to excessive oxygen is implicated in the 
development of pulmonary hypertension but maintaining oxygen saturations in 
an optimal target range is challenging in very preterm infants. 
 Gaps in current knowledge: 
 Although screening is recommended the optimal approach to screening very 
premature infants for pulmonary hypertension is uncertain 
 The evolution of NTproBNP levels over time in preterm infants beyond the 
period of transitional circulation and the factors that affect these levels are still 
unclear. The relative proportions of circulating BNP isoforms are unknown in 
preterm infants. Whether NT-proBNP can be used as a biomarker of late 
pulmonary hypertension is not yet established 
 There is currently no consensus on heart ultrasound criteria for the diagnosis of 
late pulmonary hypertension in premature infants. The feasibility and utility of 
incorporating more advanced ultrasound techniques into clinician performed 
heart ultrasound has not been tested 
 There is a lack of data on patterns of oxygen saturation instability over time in 
very preterm infants and the best way to assess instability. Human factors that 
may contribute to hyperoxia have been understudied
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HYPOTHESIS & METHODS 
 
  
    





Pulmonary vascular disease is an insidious complication of the lung disease of extreme 
prematurity and is associated with cardiac dysfunction, increased morbidity and 
mortality.62, 64, 67, 114, 115, 117 Early identification of pulmonary vascular disease or its impact 
on cardiac function may allow early intervention improve outcomes. Screening has been 
recommended but screening protocols are debated and consensus has not been 
reached, in part due to knowledge gaps.86, 87 The risk of BPD-associated or late 
pulmonary hypertension is uncertain in a general population of premature infants as 
published data have been drawn from highly selected populations referred to centres 
specialising in pulmonary hypertension.64, 80-82  A better understanding of the evolution of 
this disease is needed which necessitates serial observation of a population of at risk 
infants. 
Very preterm infants with clinical risk factors for pulmonary hypertension would benefit 
from a sensitive and specific biomarker of cardiac stress that enables clinicians to identify 
early cardiac compromise and to triage infants who warrant further investigation. 
NTproBNP is a sensitive marker of myocardial stress caused by volume and pressure 
overload. Serial levels may have merit as a marker of rising pulmonary pressures in 
premature infants but this has not yet been fully evaluated. Changes in this hormone 
over time and factors that affect levels and processing in very prematurely born infants 
are understudied and not adequately described.   
Cardiac catheterisation is the gold standard for measuring pulmonary vascular pressures 
but is invasive and carries risk. There is currently no consensus on heart ultrasound 
criteria for the diagnosis of late pulmonary hypertension in preterm infants. 
Conventional heart ultrasound assessment alone may be inadequate for identifying very 
preterm infants with late pulmonary hypertension and more advanced ultrasound 
techniques that provide accurate quantitation of cardiac function are yet to be fully 
evaluated in this population.  
Hyperoxia is a contributing factor to pulmonary hypertension in very premature infants 
and hypoxia can precipitate pulmonary hypertensive crises in affected infants. 
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Furthermore, oxygen saturation stability is perturbed by pulmonary vascular disease due 
to dysmorphic vessels exhibiting dysfunctional vasoreactivity. Changing patterns of 
oxygen saturation levels over time have not be studied as possible indicators of evolving 
pulmonary hypertension. More data is needed to better understand the oxygen 
saturation patterns in very preterm infants over time and how we can reduce iatrogenic 
hyperoxia that may contribute to pulmonary hypertension. 
Hypotheses 
NTproBNP 
1. NTproBNP levels will change over time in very preterm infants and will be higher in 
infants with: 
- haemodynamically significant patent ductus arteriosus 
- bronchopulmonary dysplasia 
- pulmonary hypertension 
2. NTproBNP will not vary significantly with gestational age at birth, hypoxia, mechanical 
ventilation or haemoglobin levels but will be higher in the context of renal impairment 
3. There will be additional circulating forms of BNP in very preterm infants, other than 
BNP(1-32) and NTproBNP (1-76), and the types of isoforms will differ in infants with BPD  
and/or HsPDA compared to infants without these conditions  
 
Heart ultrasound 
4. Specific quantitative markers of RV function will be measureable in very preterm 
infants by clinician performed heart ultrasound but some parameters will be more 
difficult to consistently attain and less useful than others 
5. The temporal profile of these quantitative measures of RV function will reflect growth 
and developmental changes in cardiac function  
 
Oxygen saturation  
6 . The pattern of oxygen saturation instability will vary over time in very preterm infants 
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7. Infants who develop BPD or later pulmonary hypertension will have evidence of 
greater oxygen saturation instability  
8. Poor compliance with oxygen saturation alarm limits is a contributing factor to 
exposure to hypoxia and hyperoxia in neonatal units 
Health and Neurodevelopmental Outcomes 
9. Our very preterm cohort will experience high rates of respiratory morbidity in the first 
two years of life and morbidity will be greater in those with BPD 
10. Our cohort will experience similar rates of neurodevelopmental impairment to rates 
reported by ANZNN for the time period of the study 
11. Higher NTproBNP levels in the neonatal period will be associated with poorer 
cardiorespiratory health in the first two years of life and with higher rates of 
neurodevelopmental impairment at two years 
12. Poorer right heart function in the neonatal period will be associated with higher rates 
of cardiorespiratory morbidity in the first two years of life and higher rates of 
neurodevelopmental impairment at two years 
13. Greater oxygen saturation instability in the neonatal period will be associated with 
higher rates of cardiorespiratory morbidity in the first two years of life and higher rates 




1.  To determine the range and temporal profile of NTproBNP levels in infants born at 
<30 weeks gestation at day of life 3, 10, 28 and at 36 weeks PMA  
2. To determine the utility of NTproBNP levels to diagnose haemodynamically significant 
PDA, diagnosed by pre-specified ultrasound criteria  
3. To determine the utility of NTproBNP levels to diagnose bronchopulmonary dysplasia 
4. To determine the utility of NTproBNP levels to diagnose pulmonary hypertension on 
the basis of pre-specified conventional heart ultrasound criteria 
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5. To investigate whether NTproBNP levels are affected by gestational age, ventilation, 
hypoxia, renal impairment or haemoglobin level 
6. To determine the types of circulating isoforms of BNP in very preterm infants and to 
investigate whether BNP isoforms differ in premature infants with BPD and/or HsPDA 
and those without these conditions 
Heart ultrasound 
7. To assess a cohort of infants born at < 30 weeks gestation for pulmonary hypertension 
using conventional heart ultrasound criteria 
8. To evaluate the feasibility of clinician-performed quantitative heart ultrasound 
measures of RV function  
9. To document the temporal changes in quantitative measures of RV function in a 
cohort of very preterm infants and investigate their relationship to body surface area and 
BPD 
Oxygen saturation 
10. To conduct detailed analysis of 72 hour recordings of oxygen saturation data using a 
variety of measures of instability at four time intervals from birth to 36 weeks PMA and 
to compare these measures in infants with and without BPD and/or pulmonary 
hypertension   
11. To audit unit compliance with oxygen saturation alarm protocols and to survey 
nursing opinion of oxygen saturation targeting in the NICU 
   Health and neurodevelopmental outcomes 
12. To describe the mortality, growth, health and neurodevelopmental outcomes in the 
first 2 years of life in a modern, well characterised cohort of preterm infants 
13. To investigate whether early NTproBNP, TAPSE, TAPSV or oxygen saturation CV 
correlate with key outcomes, specifically: 
- duration of NICU stay 
- number of hospital readmissions in first 2 years 
- duration of hospital readmissions in first 2 years 
- neurodevelopmental impairment at 2 years 
 
    




Prospective observational cohort study. 
Setting and participants 
This trial was conducted at the Christchurch Women’s Hospital NICU, Christchurch, New 
Zealand. This is a tertiary level NICU that serves the region of Canterbury, that in 2013 
had a population of 539,436 (annual births of 6,543) and the West Coast with a 
population of 32,148 (annual births of 385).286  
Inclusion criteria:  
Infants born at < 30 weeks gestation between March 2013 and April 2015 and cared for 
in Christchurch Neonatal Intensive Care Unit. Infants were enrolled by 72 hours of age. 
Exclusion criteria:  
Known structural airway or lung anomalies, congenital anomalies of the pulmonary 
arteries or pulmonary veins, major systemic vessel-to-pulmonary artery collateral 
vessels, congenital heart disease (except those with patent ductus arteriosus, patent 
foramen ovale or secundum atrial septal defect < 5mm or tiny restrictive muscular 
ventricular septal defect), severe liver disease, or persistent pulmonary hypertension of 
the newborn on day 3 heart ultrasound (defined as severe hypoxia associated with 
estimated main pulmonary artery pressure >25mmHg). If infants had a grave prognosis 
such that they were not expected to survive to day 3 they were also excluded. 
Ethical considerations 
This study complied with the Declaration of Helsinki regarding the ethical principles for 
medical research involving human participants. The parents of all eligible infants were 
approached about the study either prior to delivery or within 72 hours of delivery, 
offered a spoken and written explanation of the study and invited to consent to their 
child participating. A copy of the patient information and consent form is included in 
Appendix B.  Written informed consent was obtained from the parents of all study 
participants prior to day 3 testing commencing. Ethical approval was granted by the 
University of Otago Human Ethics Committee (12/298). Local study approval was granted 
after consultation with Māori through Te Komiti Whakarite and the study was conducted 
in accordance with the principals of the Treaty of Waitangi.1 The study team was granted 
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additional ethical approval to place a recordable pulse oximetry monitor on all eligible 
infants after delivery prior to written consent being granted as it was acknowledged that 
it is standard clinical practice to monitor oxygen saturations in this population after birth 
and on the understanding that any data collected would be deleted if parents 
subsequently refused consent.  
Participation was entirely voluntary and no compensation was awarded for participation 
in this trial. Patient safety was paramount with all care taken to ensure patient comfort 
and well-being during testing. In the event of an injury secondary to participation in this 
study participants may be eligible for compensation by the New Zealand Accident 
Compensation Corporation (ACC) according to the provisions of the Injury Prevention, 
Rehabilitation, and Compensation Act 2001. 
Outcomes  
Primary outcome measures: 
1) Bronchopulmonary dysplasia 
This was defined using the following two definitions, the first being a binary definition 
and the second allowing grading by severity: 
1) Persistent oxygen or respiratory support requirement at 36 weeks PMA 
(definition utilised by the ANZNN in 2013) OR 
2)  Oxygen requirement for at least 28 days and BPD graded at 36 weeks PMA 
according to the following National Institute of Child Health and Human 
Development (NICHD) criteria (Table 3).287  
Table 3: NICHD criteria for BPD severity 
Grading Criteria 
Mild BPD Breathing room air 
Moderate BPD Need for <30% oxygen 
Severe BPD Need for ≥30% oxygen and/or positive pressure  
respiratory support 
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At the time of this study in the Christchurch NICU the need for oxygen or respiratory 
support at 36 weeks PMA was not determined by a standardised physiological 
challenge288 but by clinical decision usually after analysis of a 24 hour pulse oximetry 
study. 
2) Pulmonary hypertension 
This was defined by conventional heart ultrasound criteria (Table 4).81, 199  
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Table 4: Criteria for diagnosis of pulmonary hypertension using conventional ultrasound parameters 
Criteria if tricuspid regurgitation jet 
present: 
Criteria if no tricuspid regurgitation jet 
present: 
 
1. Estimated RV pressure >33% systemic 
pressure:289 
RV pressure estimated using TR jet peak 
velocity and the modified Bernoulli 
equation (pressure gradient=4xjet 
velocity2).  
OR 
2. TR jet >= 3m/s 
 
 
Demonstration of at least 2 of the following 
echocardiographic findings in the absence 
of pulmonary stenosis or RV outflow tract 
obstruction (subjectively assessed): 
1. right ventricular enlargement 
2.  right ventricular hypertrophy 
3. interventricular septal flattening or 
bowing right to left 
4. abnormal pulmonary artery Doppler 
(saw-tooth pattern or shortened 
acceleration time)  
 
Secondary outcome measures: 
1) Haemodynamically significant PDA defined based on commonly accepted criteria:180 
1. Ductal diameter ≥ 1.5mm (on B-mode greyscale, high parasternal true sagittal view) 
AND  
2. Pulsatile flow pattern (Fig.20)  
PLUS at least one of the following: 
A) left atrial to aortic diameter (LA:Ao) ≥ 1.5 (M-mode through the aortic root and left 
atrium) 
B) reversed diastolic flow in descending aorta (Doppler gate placed in descending aorta 
below insertion of duct) 
C) turbulent MPA flow, diastolic peak > 0.2m/s (Doppler gate place just below the 
pulmonary valve). 
2) Duration of neonatal admission  
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3) Number and duration of readmissions to hospital in first two years of life  
4) Neurodevelopmental impairment at 2 years 
Neurodevelopmental impairment was determined by review of clinical notes and/or 
ANZNN data collected for results of formal neurodevelopmental evaluation 
examination by a paediatrician and either Bayleys III assessment by a developmental 
psychologist or equivalent developmental evaluation by an Early Intervention provider. 
Cognitive, language and motor delay was graded as mild, moderate or severe. Severe 
delay was defined as scores <-3 standard deviations (SD), moderate delay as scores -3 
SD to <-2 SD, and mild delay as scores -2 SD to <-1 SD relative to the mean. The mean 
(SD) of these scales is 100 (15), giving cut-points  of: severe <55, moderate 55–69, and 
mild 70–84. Children who did not qualify for formal testing had their hospital records 
reviewed for information relating to neurodevelopment at the nearest assessment 
point to 2 years.  
Blindness was defined as vision < 6/60 in the best eye as assessed by an 
ophthalmologist. Significant hearing impairment was defined as requiring unilateral or 
bilateral hearing aids or cochlear implant. Cerebral palsy is a non-progressive motor 
disability present from birth. The functional level of disability can be graded from 1-5 
using the Gross Motor Functional Classification System (GMFCS).290  In this study 
cerebral palsy was identified based upon a diagnosis of cerebral palsy by a paediatrician 
or paediatric neurologist.  
Any neurodevelopmental impairment was defined as deficit in any domain requiring 
additional support or intervention. Mild neurodisability was defined as mild cerebral 
palsy (GMFCS <3) or documented impairment in vision, hearing, cognitive, motor or 
language delay not meeting criteria for moderate to severe. Moderate to severe 
neurodisability was defined as: moderate or severe cerebral palsy (GMFCS ≥3), visual 
acuity <6/60 in better eye, sensorineural deafness with hearing aids, developmental 
quotient less than –2 SD relative to reference standard.7 
5) Growth at two years (weight, height, head circumference) 
6) Death in the first 2 years of life 
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Figure 20: Doppler flow patterns across ductus arteriosus (Images taken by author) 
  
Testing 
On day of life 3, 10 and 28 and at 36 weeks PMA participants had the following tests 
performed: 
1. Plasma NTproBNP level 
2. Clinician performed heart ultrasound  
3. Pulse oximetry recording of heart rate and oxygen saturation for approximately 72 hours 
prior to blood test 
4. Blood pressure recording 
When there was a clinical suspicion of infection a blood C reactive protein was also checked to 
screen for possible sepsis. 
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NTproBNP testing 
A minimum of 0.6ml of arterial, venous or capillary blood was taken for NTproBNP testing as 
close in time as possible to the heart ultrasound. Samples were coordinated with clinical care 
blood tests to minimise infant discomfort. Oral sucrose (0.1-0.2ml) was given for analgesia. 
Blood was collected in tubes containing ethylene diamine tetra acetic acid (EDTA). Samples 
were immediately refrigerated at 4⁰ C until collection that day or within 72 hours if over a 
weekend. Samples were then centrifuged at 3000 rpm and plasma subsequently frozen at -
80⁰C minimum.  
NTproBNP levels were batch processed using an electro chemiluminescent sandwich enzyme-
linked immunoabsorbant assay using a ROCHE e411 Cobas analyser. Levels are reported in 
pmol /L. This testing kit is unaffected by bilirubin level, haemolysis or lipaemia.  
If infant was suspected of having sepsis or had CRP >10 then NTproBNP level was deferred until 
sepsis improved to prevent a confounding effect on NTproBNP levels. Renal function was 
assessed by urine output, blood pressure and urea and creatinine level was monitored as part 
of routine clinical care.  
BNP isoform testing 
Further testing was done to establish the relative proportions of circulating BNP isoforms in our 
cohort and the presence of any post-translational glycosylation. Plasma volume remaining after 
initial NTproBNP testing was used for isoform testing. Low available plasma volumes 
necessitated pooling of samples from several infants and across all four testing times. These 
groups were selected on the basis of the presence or absence of BPD and day 3 HsPDA. This 
grouping is detailed further in the BNP chapter isoforms results chapter. This testing was 
conducted using a combination of Luminex® Assay (Luminex Corp, Austin Texas) and High 
Performance Liquid Chromatography (HPLC). 
Luminex assay and high performance liquid chromatography techniques 
Residual unused plasma was pooled according to the clinical groupings detailed in the BNP 
isoforms results chapter. These samples were concentrated on SepPak C18 cartidges and 
assessed on the CHI Luminex assay system. They were then characterised using HPLC in order 
to determine the relative proportions of circulating forms of BNP.  
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Assays, Reagents and Antibody 
Table 5 outlines the epitopes identified in BNP isoform testing. Reagents EDC [1-ethyl-3-
(dimethylaminopropyl) carbodiimide hydrochloride] and Sulfo-NHS (N-
hydroxysulfosuccinimide) were purchased from Thermo Scientific. MES [2-(N-
morpholino)ethanesulfonic acid] was obtained from Sigma-Aldrich Corp. Color-coded 
carboxylated magnetic beads were from Luminex Corporation. Recombinant ProBNP1-108 
from Hytest; BNP1-32 from Bachem, N-terminal pro-BNP1-76 from Phoenix. PBS containing 
0.1% BSA, 0.04% Tween-20 and 0.05% sodium azide (PBS/TBN) was used as the assay and wash 
buffer. MES buffer (50 mmol/L, pH 5) was used for conjugating antibodies to beads. 
Monoclonal antibodies were purchased from Hytest, or raised by Christchurch Heart Institute. 
Phycoerythrin conjugates were purchased from Moss Inc. 
Table 5: Epitopes identified in BNP isoform testing  
Assay Epitopes Detection target and cross-reactivity 
BNP 24C5: epitope BNP11-22 and 50E1: 
epitope BNP26-32 
Cross reacts with BNP and proBNP 
BNP H43  50E1: epitope BNP23-32 and 
polyclonal Ab rabbit H43: epitope 
BNP1-13 
Specific for BNP 
NTproBNP general 15F11: epitope NTproBNP13-24 and 
24E11: epitope NTproBNP67-76 
Cross reacts with NTproBNP and 
proBNP 
NTproBNP specific 15F11: epitope ntBNP13-24 and 
polyclonal Ab rabbit J25: epitope 
NTproBNP62-76 
Specific for NTproBNP 
proBNP 50E1: epitope BNP23-32 and 16F3: 
epitope NTproBNP13-20 
Detects glycosylated and non-
glycosylated proBNP 
RSproBNP 24C5: epitope BNP11-22 and 16F3: 
epitope NTproBNP13-20 
Detects glycosylated and non-
glycosylated proBNP with ring 
structure closed 
T71proBNP 24C5: epitope BNP11-22 and 24E11: 
epitope NTproBNP67-76. 
 
Detects intact non-glycosylated 
proBNP 
 
Capture antibody (24C5, 50E1 or 15F11, 10 μg per 6.25 × 106 beads) was coupled to Luminex 
magnetic microspheres using the Luminex sample protocol for 2-step carbodiimide coupling of 
protein to carboxylated microspheres.291 Confirmation of coupling was assessed using 
streptavidin-phycoerythrin (PE), or anti-rabbit phycoerythrin. Antibody coupled microspheres 
were stored in the dark at 2–8 °C until required.  
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Working standards of BNP1-32, NTproBNP1-76 were prepared by serial dilution of a stock 
standard with PBS/TBN. Working standards for proBNP were prepared by serial dilution of a 
stock standard with diluted stripped donated plasma. 
Luminex BNP assay 
For BNP, BNP H43 and NTproBNP general, specific standards, QC, or sample (50 μL) were added 
to duplicate wells of a clear 96-well plate followed by appropriate coupled microspheres (2500 
beads/25-μL well), 25 μL of diluted detection antibody was added and the plate was covered 
and mixed (750 rpm) on an orbital plate shaker for 25 h (±10 min) at 4 °C. 
After a wash step, anti-rabbit PE was added to each plate (50 μL/well, 4 μg/mL), and the plate 
incubated for a further 30 min with shaking. 
After a subsequent wash step, the beads were resuspended in 100 μL assay buffer before 
reading the plate on the Luminex 200 system. Median fluorescent intensity (MFI) data was 
uploaded to an immunoassay program (StatLia, Brendan Scientific), and results interpolated off 
a fitted standard curve. 
Luminex NTproBNP assay 
For NTproBNP general, specific standards, QC, or sample (50 μL) were added to duplicate wells 
of a clear 96-well plate followed by appropriate coupled microspheres (2500 beads/25-μL well) 
the plate was covered and mixed (750 rpm) on an orbital plate shaker for 3 h (±10 min) at 4 °C. 
After a wash step 50 μL of diluted detection antibody was added and the plate was covered and 
mixed (750 rpm) on an orbital plate shaker for 30 minutes at Room Temperature. 
After a wash step, streptavidin-PE was added to each plate (50 μL/well, 4 μg/mL), and the plate 
incubated for a further 30 min with shaking. 
After a subsequent wash step, the beads were resuspended in 100 μL assay buffer before 
reading the plate on the Luminex 200 system. Median fluorescent intensity (MFI) data was 
uploaded to an immunoassay program (StatLia, Brendan Scientific), and results interpolated off 
a fitted standard curve. 
Luminex proBNP assay 
For proBNP, RSproBNP and T71proBNP, specific standards, QC, or sample (50 μL) were added 
to duplicate wells of a clear 96-well plate followed by appropriate coupled microspheres (2500 
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beads/25-μL well) the plate was covered and mixed (750 rpm) on an orbital plate shaker for 16-
18 h at 4 °C. 
After a wash step 50 μL of diluted detection antibody was added and the plate was covered and 
mixed (750 rpm) on an orbital plate shaker for 30 minutes at Room Temperature. 
After a wash step, streptavidin-PE was added to each plate (50 μL/well, 4 μg/mL), and the plate 
incubated for a further 30 min with shaking. 
After a subsequent wash step, the beads were resuspended in 100 μL assay buffer before 
reading the plate on the Luminex 200 system. Median fluorescent intensity (MFI) data was 
uploaded to an immunoassay program (StatLia, Brendan Scientific), and results interpolated off 
a fitted standard curve. 
High performance liquid chromatography 
Plasma extracts were subjected to size-exclusion HPLC (SE-HPLC) at room temperature on a 
TSK-Gel G2000SW peptide column (Toyosoda, Tokyo, Japan) using isocratic conditions of 20% 
acetonitrile/0.1%trifluoroacetic acid (TFA) at a flow rate of 0.5ml/minute. Fractions were 
collected at 1 minute intervals and subjected to Luminex or Roche NTproBNP assay. The SE-
HPLC column was calibrated using dextran blue (Vo), cytochrome C (~Mr 12,400), aprotinin 
(~Mr 6,500), urotensin II (~Mr 1,600) and glycine (Vt). 
Heart Ultrasound Protocol                                                                              
Personnel 
Heart ultrasounds were performed by neonatologists with training in clinician performed 
cardiac ultrasound (Drs Harris, Dixon and More). Of the 202 scans performed, 90% were 
performed by Dr Harris to reduce interobserver variability.  All three clinician-scanners had 
received basic and advanced training in neonatal cardiac ultrasound through the Australasian 
College of Ultrasound Medicine and Dr Harris received additional one on one training on TAPSE 
and tissue Doppler parameters   with a cardiac ultrasonographer at Starship Children’s Hospital.  
An average of 10-15 measurements were taken for each parameter where possible to reduce 
intraobserver variability. Off-line measurements were all done by Dr Harris using software on 
the heart ultrasound machine or if measurements were delayed measurements were done 
using Synapse® Cardiovascular software (Fujifilm, Australia). Heart ultrasound analysis was 
conducted by Dr Harris who was blinded to NTproBNP results and not involved in the clinical 
care of the infants but not blinded to the pulse oximetry results. A paediatric cardiologist from 
Starship Hospital in Auckland, New Zealand, Dr Clare O’Donnell, reviewed all 36 week PMA 
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scans for signs of pulmonary hypertension using pre-defined criteria (Table 4). Dr O’Donnell 
was blinded to NTproBNP results, pulse oximetry results, previous heart ultrasound scan results 
and clinical history of the infant.   
Equipment 
A Toshiba Aplio 500 ultrasound machine was used with neonatal cardiac presets and a 6.5MHz 
probe. No infant was on a muscle relaxant at the time of the heart ultrasound. No angle 
correction or respiratory gating was used. A concurrent electrocardiogram heart rate tracing 
was recorded through the ultrasound machine. 
Infant Considerations 
Scans were performed at the bedside after discussion with bedside nurse regarding current 
stability of the infant and throughout the scan infant comfort and health were paramount. Oral 
sucrose was administered for analgesia if required. Scans were terminated if the infant became 
clinically unstable or unduly distressed during the scanning.  
Timing of Scans 
 
Heart ultrasounds were performed on day 3 (as close to 72 hours of age as practicable), day 10, 
day 28 and when the infant reached 36 weeks PMA.  Scans were paired as close as practicable 
in time to NTproBNP sampling.  
Ultrasound Images  
Standard views were imaged according to guidelines recommended by the Australasian Society 
of Ultrasound Medicine and the American Society of Echocardiography (Appendix C). A summary 
of views is presented in Table 6.204 More advanced quantitative measures were selected based 
on a review of literature in this field.218 Further detail is provided on some of the advanced 
quantitative measures in Figs. 21-25 and equations 1-3. Several images or video clips were taken 
of each view with calculations averaged over 10-15 cycles. Measurements were conducted 
offline where possible to reduce scanning time.
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Table 6: Summary table of cardiac ultrasound views 
Window Views Modality Detail 
Subcostal Transverse situs view
  
1.2D grey scale 
2. Colour Doppler 
 to show normal situs of the abdominal great vessels 
 
 Aortic view 1. 2D grey scale  
2. Colour Doppler  
 anterior sweep of great vessels to the subcostal view of ascending aorta. 
 
 Atrial septal view  
 
1. 2D grey scale 
2. Colour/pulse Doppler 
 zoomed image of right and left atrium and atrial septum 
 measurement of any septal defect 
 colour Doppler of atrial septum to interrogate atrial shunt 
 pulse Doppler of any interatrial shunt 
Apical  
   





1. 2D grey scale 
2.Pulse/continuous wave Doppler 
3. M mode 
4. Tissue Doppler 
 Clip of atria and ventricles demonstrating relationship and relative size of all four chambers and 
atrioventricular valves 
 colour Doppler of flow across mitral and tricuspid valves (Fig. 21) 
 pulse/continuous wave Doppler of inflow across mitral and tricuspid valves 
 pulse/continuous wave Doppler of any tricuspid regurgitation, peak velocity measured off-line 
 M mode of tricuspid annulus free wall with cursor aligned perpendicular to the movement of 
the annulus, off-line measure tricuspid annular plane of systolic excursion (TAPSE) (Fig. 22). 
 tissue Doppler image (TDI) of tricuspid annulus, off-line measurement of E’, A’, S’ and 
calculation of right index of myocardial performance (RIMP) using equation 1 (Figs. 23, 24). 
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Biventricular sweep  
 
 
Left ventricular view 
 
 
Right ventricular view 
 
1. 2D grey scale 
2. Pulse and colour Doppler 
3. M Mode 
 sweep from left ventricle, through intraventricular septum to right ventricle 
 image intraventricular septum, left ventricle, mitral valve, left atrium and aortic valve 
 measure any intraventricular septal defect 
 colour Doppler across intraventricular septum and pulse Doppler any defect 
 M –Mode across aortic root and left atrium, measure LA:Ao ratio off-line 
 M-Mode perpendicular to intraventricular septum at level of mitral valve, measure fractional 
shortening off-line using following equation 2 
 image RV, right atrium and tricuspid valve 
 colour Doppler across tricuspid valve 





1. Aortic valve view 
 
2. Biventricular view 
 
3. Pulmonary valve and 
artery view 
 
1.2D grey scale  
2. Colour/pulse Doppler 
 
 2D grey scale image/clip of aortic valve demonstrating tri-leaflet arrangement 
 sweep from base to apex of ventricles and intraventricular septum 
 colour/pulse  Doppler of any ventricular septal defects 
 clip to assess intraventricular septal position at end systole 
 2D grey scale image/clip of right ventricular outflow tract to exclude obstruction 
 colour Doppler clips of flow across pulmonary valve, main pulmonary artery and into left and 
right pulmonary arteries 
 pulse wave Doppler of main pulmonary artery flow just distal to pulmonary valve, offline 
measure acceleration time (time to peak velocity) and right ventricular ejection time and 
calculate ratio (AT:RVET) and correct for heart rate using  equation 3 (Fig. 25) 
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2. Aortic arch view 
 
3. Pulmonary vein view 
 
1. 2D grey scale 
2. Colour/pulse Doppler 
 Sweep across aorta and main pulmonary artery demonstrating patent ductus arteriosus if 
present, measure ductal diameter 
 Colour Doppler and pulse wave Doppler of ductus 
 
 2D grey scale image of aortic arch and origin of main branches 
 colour Doppler and pulse wave Doppler of aorta distal to origin of ductus 
 
 colour Doppler demonstrating four pulmonary veins entering left atrium 
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Figure 21: Tricuspid E (early) and A (late) diastolic waves by conventional Doppler 
 
Figure 22: Tricuspid Plane of Systolic Excursion measurement using M mode 
 
Cursor placed on tricuspid annulus and aligned perpendicular to the movement of annulus. 
 
Figure 23: Indices for the measurement of RIMP. RVOT = RV outflow tract, TCO= tricuspid opening time. ET = RV 
ejection time  
Reused with permission from Rudski LG et al. Journal of the American Society of Echocardiography: official publication 
of the American Society of Echocardiography. 2010;23(7):685-713 
 
E A 
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Figure 24: Tissue Doppler image of tricuspid annulus 
  
 E', A' peaks (below baseline) and S' wave (above baseline) 
 
Equation 1: Right Index of Myocardial Performance 
 
 
LVEDD = left ventricular end-diastolic dimension 




Equation 2: Left ventricular Fractional Shortening 
E’ A’ 
S’ 
    






At least two blood pressure measurements recorded on the day of the scan. Invasive 
recordings were used if an arterial catheter was in place otherwise non-invasive recordings 
were taken using an automated device.  
Oxygen Saturation Monitoring 
Eligible infants had pulse oximeter recordings commenced at birth and data was recorded for 
72 hours. Subsequent recording periods were 72 hours prior to day 10, 28 and 36 weeks PMA 
NTproBNP blood testing.  
Oxygen saturation data was collected using a Masimo Radical 7 Signal Extraction CO-oximeter 
(Masimo Corporation, Irvine, California) with upgraded software. Sample averaging time was 
set to 2 seconds. Masimo sensor probes designed for preterm infants were placed on the right 
wrist either side of the radial arterial pulsation (unless there was a contraindication to this). A 
cable connected the Masimo oximeter with the bedside cardiorespiratory monitor to allow 
heart rate and oxygen saturation data collected by the Masimo to be displayed on the bedside 
monitor which nurses used to guide care.  
Oxygen saturation targets and alarm settings remained as per unit protocol at the time. Nurses 
responded to alarms as per the unit’s standard of care at the time. Oxygen saturation targeting 
protocols changed in August 2013, detailed in Table 7, after publication of the BOOST II trial of 
oxygen saturation targeting.292 The new protocol was a local decision based on unit consensus 




AT:RVETc = (AT/RVET) 
R-R interval 
Figure 25 and Equation 3: Ratio of main pulmonary artery acceleration time to right ventricular 
ejection time(RVET)  corrected for heart rate 
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Table 7: Oxygen saturation targets before and after August 2013 
Corrected GA Old targets on 
oxygen 
New targets on 
oxygen 
Old targets in air New targets in air 
< 32 weeks 88-92% 90-92% 88-100% 90-100% 
32-36 weeks 92-95% 92-95% 92-100% 92-100% 
≥36 weeks 95-98% 95-98% 95-100% 95-100% 
 
Oxygen saturation data was downloaded and analysed by Dr Harris using Profox software 
(PROFOX Associates Inc, Escondido, California). Prior to analysis the downloaded data was 
reviewed by Dr Harris and any large areas of aberrant data suggestive of a prolonged period of 
lack of contact (ie. where there was no heart rate detected) were manually deleted. The data 
was then scanned automatically for aberrant data and these points reviewed by Dr Harris and 
manually edited if they appeared to represent aberrant data (eg. where there is a complete gap 
in data collection or a single aberrant saturation that appeared artefactual).  
Data analysis included mean oxygen saturation, 4% desaturation index (DSI4%), defined as the 
average number of times per hour that the oxygen saturation level decreased by ≥4%, DSI4% >10 
seconds, coefficient of variation (CV = (standard deviation/mean of measurements) x 100), the 
percentage of time infants spent outside of the target saturation range, and percentage of time 
infants spent with oxygen saturations <88% and <80%. 
 The clinical team was not made aware of the pulse oximetry data for the day 3, 10 or 28 
collections. A copy of the results of the 36 week data collection was given to the clinical team as 
collecting these data this was part of normal clinical care at the time.  
Demographic and in-hospital clinical data 
Clinical and demographic data was collected by chart review.  Data collected is itemised in 
Table 8.
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Table 8: Clinical and demographic data collected 


















Rupture of membranes 
>24 hours before delivery 
Preeclampsia 
Chorioamnionitis 
Birthweight & z score 
Birth length &  z score
  
Birth head circumference 
& z score  
Birth body surface area 
(BSA)    
Day 10 weight & z score 
Day 10 length & z score 
Day 10 head 
circumference & z score 
Day 10 BSA  
Day 28 weight & z score 
Day 28 length& z score  
Day 28 head 
circumference & z score 
Day 28 BSA  
 
Intubated at birth 
Surfactant given 







NICHD BPD grade  
Diuretics for BPD 
Hours conventional 
ventilation 






























- any developmental 
support  required 
- blindness 
- deafness 
- cerebral palsy 
- Bayleys III / Carolina 
Curriculum assessment 
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General Antenatal Growth/Nutrition/GI Respiratory Cardiovascular Infection Neurology Ophthalmology 
36 week weight & z score 
36 week length & z score 
36weeks head 
circumference &z score 







Hours BIPAP  
Hours HiFlow  
Home on oxygen 















Steroid course total 
dose  
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Post-discharge data collection  
1. Respiratory Health at 1 year 
When participants were 1 year of age a respiratory health questionnaire designed for 
this study and not previously validated was sent to parents (Appendix D). The aim of this 
questionnaire was to identify frequency of presentations to primary and secondary 
health care and respiratory morbidity in the first year of life. Consent was also sought to 
check responses against general practice and hospital health records. 
2. Hospital Encounters in first 2 years of life 
Hospital records were checked for health encounters beyond discharge from the 
neonatal unit up to 2 years PMA. 
The following data were collected: 
1. Number of readmissions 
2. Total days in hospital 
3. Type of admission 
4. Weight, height and head circumference at 2 years 
5. Visual problems 
6. Hearing problems  
7. Chronic respiratory symptoms 
8. Seizures 
9. Hydrocephalus 
10. Cerebral palsy 
3. Neurodevelopmental Outcome 
Outpatient clinic records were checked for neurodevelopmental assessments done as 
part of routine follow-up of very preterm infants and when completed results for Bayley 
Scale of Infant and Toddler Development (BSID-III) were recorded. 293 
Sample size calculations  
A biostatistician was engaged to assist with statistical planning and analysis. At the time of 
study design there was very little published data on NTproBNP levels in preterm infants 
and the association of these with BPD and no data on NTproBNP and BPD-associated 
pulmonary hypertension.. Sample size calculations for the design of this study were based 
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on a small single unit sample of Israeli infants <34 weeks gestation, looking at the 
association between NTproBNP levels and BPD.186 This study produced correlations 
between NTproBNP levels and measures of respiratory distress around day 28 in the 
region of 0.40-0.50. Based on this study and other published data suggesting an incidence 
of pulmonary hypertension of approximately one third of infants with BPD estimates from 
standard power tables294 suggested that for our study to have 80% power to detect 
correlations in excess of 0.40 with alpha = 0.05 would require a minimum sample size of 
45 infants. Allowing for a small potential sample loss due to failure to complete the full set 
of assessments such as due to transfer to another centre or withdrawal of infant from 
study a target sample size of N = 50 infants was recommended.  
At study inception approximately 60% of infants <30 weeks gestation admitted to 
Christchurch Women’s Hospital neonatal unit had ongoing oxygen/respiratory support 
requirements at 36 weeks PMA, and just under half were <28 weeks gestation. 
Consideration of sample power to detect mean differences in a continuous outcome 
between subgroups defined on the basis of these or similar characteristics suggests that 
with a sample size of 50 the sample has between 75%-80% power with alpha = 0.05 to 
detect a mean difference between groups in excess of 0.80 SD. This corresponds to a 
‘large’ effect size as defined by Cohen 294 
While the study is adequately powered to detect large effects, statistical power to detect 
more moderate effects is substantially reduced. For example, the sample has only 50% 
power to detect a correlation in excess of .25, and approximately 40% power to detect a 
‘moderate’ effect size difference between groups in excess of 0.50 SD; and only 10% 
power to detect small effects (correlations in excess of .10, between group differences of 
0.20 SD). 
The availability of repeated measures data is likely to enhance the study’s power to 
examine change in measures over time or to detect between group differences.295 
However, the extent to which power is enhanced by the repeated measures design is 
dependent on the nature and type of the relationships being examined. 
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Statistical methods  
General Principles  
In general quantitative variables are described by mean and standard deviation (SD) or 
median and interquartile range (IQR) depending on whether they are normally 
distributed or not. Qualitative variables are described by frequency and percentages. For 
bivariate analyses parametric tests were used for normally distributed data and non-
parametric tests for non-normally distributed data. Regression models were extended to 
control for relevant demographic, perinatal or clinical factors. Where data were non-
normally distributed appropriate data transformations (eg logarithmic) were conducted. 
A p value of < 0.05 was considered statistically significant. Data was stored using 
Microsoft Excel and statistical analysis was performed using Microsoft Excel, Stata 15, 
SAS 9.4 and GraphPad InStat Software. 
Specific Analyses  
Distribution of NTproBNP levels and factors affecting NTproBNP 
Standard graphical methods (eg box and whisker plots) were used to display the 
distribution of NTproBNP levels at each age (days 3, 10, 26 and 36 weeks PMA). As the 
distribution was skewed a natural log transformation was applied. Fitted regression 
models were used to examine the relative contributions of birth gestational age, 
ventilation status and renal function on day 3 and 10 NTproBNP levels. The strength of 
the association between hypoxia and NTproBNP and the association between 
haemoglobin and NTproBNP was calculated using the Spearman’s rank correlation 
coefficient. 
Associations between NTproBNP levels and clinical factors (HsPDA,BPD, pulmonary 
hypertension, gestational age, ventilation, hypoxia, renal impairment,  haemoglobin level) 
A combination of graphical and tabular methods were used to display the bivariate 
associations between NTproBNP levels and HsPDA or BPD or pulmonary hypertension 
outcomes depending on whether the outcome is continuous (eg severity of BPD) or 
dichotomous (eg diagnosis of BPD or HsPDA or pulmonary hypertension). In each case 
regression models (linear regression for continuous outcomes, logistic regression for 
dichotomous outcomes) were fitted to the data to examine the nature of the association 
and the strength of the association was summarised by the R-squared statistic. 
Regression models were extended to control for relevant demographic, perinatal or 
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clinical factors. Where data were non-normally distributed appropriate data 
transformations (eg logarithmic) were conducted. Receiver Operating  Characteristic 
curve analysis296  was conducted to examine the extent to which it is possible to 
distinguish at an early age between those infants who do/do not have a 
haemodynamically significant PDA and those who go on to develop BPD by day 3 and day 
10 NTproBNP. A predictive cut-off value was chosen to maximise sensitivity and 
specificity. 
BNP isoform frequency 
Frequency of BNP isoforms/fragments was described graphically according to clinical 
group status. 
Feasibility of advanced heart ultrasound techniques and changes over time 
The frequency of attainment of ultrasound parameters is described. Changes over time 
in quantitative parameters are described using mean (SD) or median (IQR). Comparisons 
of ultrasound parameters between sub-groups stratified by BPD status were tested for 
statistical significance using standard tests - Chi square test of independence for 
dichotomous outcomes; t-test for independent samples or analysis of variance for 
continuous measures; or Mann-Whitney rank-sum test in cases where the data was 
strongly non-normally distributed. Box and whisker plots were used to display results 
graphically. 
Changes in measures of oxygen saturation instability and effect on clinical outcomes 
Changes over time in quantitative measures are described using mean (SD) or median 
(IQR). Unpaired t tests were used to compare means. Repeated measures ANOVA analysis 
was used to assess effect of group and time interactions. Box and whisker plots or scatter 
plots were used to display results graphically. The strength of the association between 
measures of oxygen saturation instability and neurodevelopmental outcomes was 
assessed using Spearman correlations. Statistically significant associations were adjusted 
using linear regression methods to control for gender, birthweight z score, gestation, BPD 
status, antenatal steroids, maternal smoking and presence of HsPDA on day 3. Repeated 
measures ANOVA analysis was used to assess effect of BPD status and time interactions.  
Mean differences in oxygen saturation measures by BPD status over time adjusting for 
gender, gestation, birthweight z score and day 3 HsPDA were estimated from linear 
regression models fitted to repeated measures data for each fitted within a Generalising 
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Estimating Equation framework.297 
Audit of alarm compliance and survey of oxygen saturation targeting 
Audit results were tabulated according to relevant clinical subgroups with frequencies 
expressed as percentages. Survey results were described using percentages for 
frequency of particular responses. 
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Baseline Demographics and In-Hospital Outcomes 
 
Background 
Pulmonary hypertension is an important complication of premature lung disease that is 
associated with increased morbidity and mortality.62, 64, 67, 114, 115 The incidence of 
pulmonary hypertension in infants with BPD is estimated to be 17-37% but none of these 
studies were conducted in Australasia and regional differences in practice may alter this 
incidence.64, 80-82, 115  With recent guidelines suggesting screening for this condition local 
data is needed from prospective cohorts to establish the potential magnitude of this 
issue before screening can be considered.86, 87 Although cardiac catheterisation is the 
gold standard for diagnosis for pulmonary hypertension, it is invasive and only available 
at specialist centres. Hence heart ultrasound is used by most centres to identify raised 
pulmonary pressures but there are currently no validated diagnostic criteria for late 
pulmonary hypertension in very preterm infants. Prospective data on the feasibility and 
utility of advanced quantitative heart ultrasound measures for the evaluation of late 
pulmonary hypertension in very premature infants is needed. Investigation of the 
potential role for biomarkers such as NTproBNP and oxygen saturation instability is 
warranted. This chapter describes the baseline demographics and in-hospital outcomes 
for our study which attempts to address some of these questions. 
Aims 
1. To describe recruitment and retention for this study 
2. To describe the data available for analysis at all assessment points 
3. To describe baseline demographic characteristics and in-hospital outcomes of this 
cohort as a whole and by HsPDA and BPD status 
4. To compare our cohort to contemporaneous national data and Australasian Neonatal 
Network data to evaluate how representative our cohort is of this data 
 
Data on the incidence of pulmonary hypertension in our cohort (as diagnosed by pre-
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This study was conducted at the Christchurch Neonatal Unit, a tertiary neonatal intensive 
care unit, serving Canterbury and the West Coast and the neonatal surgical centre for 
the Canterbury, West Coast and Otago regions. 
Participants  
All infants born at < 30 weeks gestation between March 2013 and April 2015 and cared 
for at Christchurch Neonatal Unit were invited to participate.  
Exclusion criteria were known structural airway or lung anomalies, congenital anomalies 
of the pulmonary arteries or pulmonary veins, major systemic vessel-to-pulmonary 
artery collateral vessels, congenital heart disease (except those with patent ductus 
arteriosus, patent foramen ovale or secundum atrial septal defect < 5mm or tiny 
restrictive muscular ventricular septal defect), severe liver disease, or persistent 
pulmonary hypertension of the newborn on day 3 heart ultrasound (defined as severe 
hypoxia associated with estimated main pulmonary artery pressure >25mmHg). If infants 
had a grave prognosis such that they were not expected to survive to day 3 they were 
also excluded. 
Data collection 
Participants had paired heart ultrasound, NTproBNP levels and oxygen saturation data 
collected on days 3, 10, 28 and at 36 weeks PMA. The testing protocol and heart 
ultrasound criteria for pulmonary hypertension are described in detail in methods 
chapter. Demographic and in-hospital clinical outcome data was sourced from hospital 
records and outcome data submitted to the Australian and New Zealand Neonatal 
Network and collated and analysed in a de-identified form by study number using 
Microsoft Excel.  
Data Analysis 
Data acquisition was described by frequency. Whole cohort descriptive statistics were 
performed using percentages, means (SD) or medians (IQR) where the data was non-
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normally distributed. T tests were done for the comparison of means of independent 
samples and Chi squared test for the comparison of percentages. 
Where possible contemporary data from the Australian and New Zealand Neonatal 
Network (ANZNN) report for 2014298 and national data from the New Zealand census299 
and the Ministry of Health300 is presented for comparison.  
Results 
Recruitment 
Figure 26 shows the flow diagram of recruitment and retention. Sixty-five infants were 
eligible on the basis that they were born at less than 30 weeks gestation Christchurch 
Women’s’ Hospital during the study period. However, three babies had a grave prognosis 
and died before day three and were excluded on this basis. One infant was an out of area 
transfer who was excluded as they would be transferred back to their base hospital once 
stable and a bed became available making them unable to participate in the study. One 
infant had uncertain gestation and was thought to be close to 30 weeks and was 
excluded due to this uncertainty. Seven other families were approached but declined to 
participate. Of the fifty-three infants initially recruited two had to be excluded after the 
day three scan due to significant cardiac anomalies. The causes of death for the two 
children who died between day 28 and 36 week PMA testing were respiratory failure 
secondary to severe BPD and pulmonary haemorrhage secondary to Escherichia coli 
sepsis. 
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Figure 26: Recruitment and retention  
 
Data collection 
Table 9 shows the number of participants for which NTproBNP, heart ultrasound and 
pulse oximetry data were available for analysis. 
Table 9: Number of patients for which data was available for analysis at each data collection point 
 Day 3 Day 10 Day 28 36 weeks PMA 
NTproBNP 50 51 51 48 
Heart USS 51 51 51 49 
Pulse oximetry 51 51 51 48 
 
One infant missed their data collection at 36 weeks PMA and had all assessments done 
at 7 weeks post term. The median (IQR) time between heart ultrasound and NTproBNP 
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testing was 4 (1.5-7.3) hours. The mean (SD) hours of valid oxygen saturation data 
analysed was 68 (9.2) for day 3, 69 (9.4) for day 10, 70 (8.6) for day 28 and 70 (7) for 36 
weeks PMA.  
Clinical characteristics of cohort 
Antenatal and post-natal clinical characteristics 
Tables 10 and 11 present relevant antenatal variables, baseline demographic, clinical 
characteristics and in-hospital morbidities for the cohort as a whole. Mean gestational 
age was  27.8 weeks with 53% less than 28 weeks gestation (24weeks = 2, 25 weeks = 3,  
26 weeks = 7, 27 weeks=15, 28 weeks=8 29 weeks=16). No infant in our cohort met our 
criteria for a diagnosis of pulmonary hypertension and this is discussed further in chapter 
5. Tables 12 and 13 compares characteristics of the cohort by BPD status (ANZNN 
definition) and by day 3 HsPDA status as these are important clinical covariates.  
Table 10: Antenatal characteristics (whole cohort) 
 Clinical Characteristic  n=47 pregnancies 
Singleton pregnancy 84% 
Maternal smoking while pregnant  19.6%  
(21.6% of infants exposed due to 
twins) 
Antenatal steroids (any/complete) 92/61% 
Magnesium sulphate given 58.8% 




Chorioamnionitis suspected clinically 19.6% 
Chorioamnionitis on placental histology 58%  (28% mild-moderate, 30% 
severe)* 
IUGR pregnancy 7.8% 
* Placental histology available for 50 infants 
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Table 11: Infant characteristics and in-hospital morbidity (whole cohort) 
 Clinical Characteristic  n=51 
Infant ethnicity 
(infants with more than one ethnic group 
identified were counted in each of these 
groups) 
11.8 % Māori   
56.9% New Zealand European 
7.8% Pasifika 
19.6% Asian 
7.8% other European 
3.9% other 
% Male/Female 55/45 
Mean(SD) GA(weeks) 27.8(1.5) 
Mean(SD) birthweight(g) 1104(225) 
Mean(SD) birthweight z score -0.10(0.88) 
Surfactant administered 82% 
Never ventilated 13.7% 
Postnatal steroids 5.9% 
Median(IQR) duration of ventilation (hours) 16 (7-54) 
Median(IQR) duration of all respiratory support 
(hours) 
1087 (676-1628) 
Median(IQR) duration of oxygen (hours) 631 (173-1325) 
Discharged on home oxygen 15.7% 
Mean(SD) duration of hospitalisation (days) 98 (34) 
Alive at discharge 96% 
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 Clinical Characteristic  n=51 
Treated with caffeine 100% 
Treated with doxapram for apnoea 17.6% 
BPD (n=49) 63% 
HsPDA day 3 49% 
IVH any grade 17.6% 
IVH grade 3 or 4 2.0% 
NEC   0% 
ROP 3.9 %(stage 1 only) 
Culture positive sepsis 15.7% 
Treated for gastroesophageal reflux 62.7% 
First milk feed breastmilk 100% 
Any breastfeeding at discharge* 
(n=45) 
71% 
* Breastfeeding at discharge may have been part of a mixed feeding plan and may have been given by bottle 
in infants who were not able to manage feeding at the breast. 
Clinical characteristics by BPD status 
Table 12 shows the clinical characteristics of our cohort according to whether they 
developed BPD or not. In two infants death before 36 weeks PMA precluded 
determination of a diagnosis of BPD. However, both infants were grouped with BPD 
infants as at the time of death as one had evidence of severe lung disease and was 
ventilator dependent (died at 32 weeks PMA) and the other had persistent oxygen 
requirement and need for non-invasive respiratory support (died at 34 weeks).   Infants 
with BPD had significantly lower gestational age and birth weight (but not birth weight z 
score) and longer duration of ventilation. 
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% Male  55 50 58 0.60 
% Any antenatal steroids 92 89 94 0.52 
% Complete antenatal steroids 
** 
61 56 64 0.57 
% Maternal smoking in 
pregnancy 
21.6 22.2 21.2 0.93 
% Never ventilated  14 6 18 0.21 









Median(IQR) hours  








% Received surfactant 82  78 85 0.70 
% Treated with doxapram*** 18 11 21 0.46 
% HsPDA day 3 51 33 58 0.10 
% Inotropic support  12 6 15 0.41 
*Chi square or Fisher’s exact tests for comparison of percentages and t-test for independent samples for 
comparison of means. Mann Whitney for comparison of medians where distribution was non-
Gaussian**Complete steroids defined by 2 doses < 7 days before delivery 
***For prevention or treatment of apnoea of prematurity  
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Clinical characteristics by HsPDA status 
Table 13 documents clinical characteristics of our cohort according to whether they had 
HsPDA on day 3 of life. There were no significant between group differences. 
The changing PDA status of the cohort over time is displayed in Fig.27.  By day 3 half of 
the cohort had a closed or non-haemodynamically significant duct. None of the infants 
who were classified as having closed or non-significant duct on day 3 received treatment. 
No infants had PDA treatment prior to day 3. 7/25 of those classified as having HsPDA at 
day 3 had medical treatment with 2 of those infants subsequently going on to have 
ligation after day 28. Only one of the 7 infants treated had a change in the 
haemodynamic significance of their duct by day 10. One infant who had a closed or non-
significant duct on day 3 developed HsPDA by day 10. Of the 16 infants with HsPDA on 
day 10 a PDA was still detectable on day 28 in 10 of them.  
 






% (n) Male 46.2 (12) 64.0 (16) 0.201 
Mean (SD) gestation (wk) 28.1 (1.5) 27.4 (1.4) 0.082 
Mean (SD) birthweight (g) 1132 (219) 1054 (230) 0.222 
Mean (SD) birthweight z-score -0.13 (0.66) -0.08 (1.08) 0.842 
Mean (SD) hours ventilation 43 (145) 224 (413) 0.042 
% (n) Bronchopulmonary dysplasia 53.8 (14) 70.8 (17) 0.221 
% (n) Necrotizing enterocolitis 0.0 (0) 4.0 (1) 0.493 
% (n) Retinopathy of prematurity 3.9 (1) 4.0 (1)  0.513 
% (n) Intraventricular haemorrhage 11.5 (3)  24.0 (6)  0.243 
% (n) Death 0.0 (0) 8.0 (2) 0.243 
1Chi-square test 2 t-test for independent samples 3 Fisher’s exact test. 
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Figure 27: Flow chart of changing PDA status over time
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Growth Outcomes  
Mean z scores at birth, day 10, day 28 and 36 weeks PMA were calculated for weight and 
head circumference using the methods used by ANZNN and based upon British WHO 
1990 data files (Table 14). Length z scores could not be calculated for day 3, 10 or 28 as 
for most of the infants their corrected age was out of range for the calculator. Weight 
and head circumference z scores fell from birth to day 10 and day 28 but recovered 
beyond this. All growth parameters were + or- <1 SD from mean at 36 weeks PMA. 
Table 14: Growth parameters across time for whole cohort 
Mean (SD) 
z score 
Birth Day 10 Day 28 36 weeks PMA  
Weight  -0.10 (0.88) -0.65 (0.76) -0.66 (0.77) 0.15 (0.86) 
Length  No z score data No z score data No z score data -0.63 (0.98) 
Head 
circumference 




The proportion of singleton to multiple births in our cohort is higher than that seen 
across ANZNN.  In 2014 ANZNN reported 74% singletons in the 24-30 week gestational 
age bracket.298 Antenatal smoke exposure was in line with New Zealand census data from 
2013 in which 20.6% of women aged 18-44 years smoked.299 Rates of antenatal steroid 
administration are similar with 89.5% of ANZNN mothers treated.298 A complete course 
of antenatal steroids is considered to be two doses 24 hours apart with delivery > 24 
hours and < 7 days after last dose. This is often more difficult to achieve due to the 
rapidity of spontaneous preterm labour and safety considerations around delaying 
delivery if mother or baby are compromised. Despite this almost two thirds of our cohort 
achieved complete steroid cover prior to delivery. Rates of antenatal magnesium 
sulphate, a neuroprotectant, were almost the same with 53% of ANZNN mothers 
receiving this.298 We are unable to compare rates of intrauterine growth restriction 
because of the varying definitions of this condition. We recorded this if this was 
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documented in maternal notes as a clinical problem. Similarly preeclampsia is often 
recorded within the umbrella term of ‘hypertensive disorders’ and we were unable to 
directly compare the incidence. It is interesting to note the discrepancy between the rate 
of chorioamnionitis suspected antenatally and the three times higher rate confirmed 
histologically. 
Postnatal 
Race has been shown to influence the rate of preterm birth.301-303 Maori, Pacific and 
Asian ethnicities were higher in our cohort than the general population. This may reflect 
differing fertility rates and the increased rate of poorer maternal health in some minority 
groups.  
Māori were well represented in our infant sample with 11.8% identifying as Māori 
compared to 2013 Canterbury census representation of 7.8%.299 Those that identified as 
European (NZ European and other European) were underrepresented in our sample 
compared to the Canterbury and national data respectively (64.7% : 86.9% :74.0%) while 
Pacific people (7.8% : 2.5% : 7.4%) and Asians (19.8% : 6.9% : 11.8%) were 
overrepresented.299 There were slightly more males in our cohort and it is important to 
note that male babies born preterm have worse outcomes than female babies.304 Male 
babies were also over-represented among NICU admissions in New Zealand in 2014 
(58.1% of the New Zealand registrants compared to 51.7% of total live births in New 
Zealand).  
The mean New Zealand Deprivation Index Decile 305 for our cohort was 6.7 where decile 
1 represents low deprivation and decile 10 represents high deprivation. These deciles are 
equally distributed across the New Zealand population as a whole and are based on 
home address and as such are a crude estimate of social deprivation. 
The rate of BPD in our cohort was unexpectedly high compared to ANZNN data.298 There 
is no global consensus regarding the definition of BPD although attempts have been 
made.287 This has made it difficult to compare studies. There has long been concern 
regarding the wide inter-unit and geographic variations in BPD rates. In addition 
traditional definitions of BPD do not correlate with long term respiratory outcomes 
calling into question the utility of this diagnostic label.306 At the time of this study a 
diagnosis of BPD was made if an infant had premature lung disease and had an ongoing 
need for oxygen or respiratory support at 36 weeks PMA. There was no standardised 
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protocol or physiological challenge performed to determine whether an infant needed 
the level of support they were on.  In the Christchurch unit it was usual practice to 
perform a 24 hour oxygen saturation analysis and on the basis of the subjective 
interpretation of this a clinician would make a decision about ongoing respiratory 
support. It is likely that there were differences in practice between clinicians and across 
the units in the network with regards to determining a diagnosis of BPD. Because of this 
a “shift test” based on a modified Walsh test was introduced after this study was 
conducted.307 This involves a room air challenge for infants on low levels of oxygen or 
respiratory support. As this was not done for our cohort it is possible that infants with 
mild oxygen or respiratory support requirements would not have been classified as 
having BPD if they had had a physiological challenge.  As the deleterious effects of 
invasive ventilation have become apparent, neonatology has been moving towards non-
invasive respiratory support strategies. This has included continuous positive airway 
pressure (CPAP), humidified high flow and low flow oxygen. Of our cohort, 13% were 
never ventilated and those who were had low total hours of ventilation in line with this 
strategy.  
Our cohort had a mean gestational age of approximately 28 weeks and a mean 
birthweight of just over 1100g. A gestational age of less than 28 weeks or a birthweight 
of less than 1000g is conventionally chosen to represent the most vulnerable group of 
preterm infants and as our cohort is relatively small we have only small numbers at the 
extremes of gestational age and birthweight. Small for gestational age babies were not 
over represented in our cohort with mean birthweight z score of -0.10. Survival was high 
in our cohort, however, infants who were not expected to survive the first few days of 
NICU admission were excluded from our study. This compares to ANZNN survival rates of 
68.4% at 24 weeks gestation and up to 96.7% at 29 weeks gestation.298  
Artificial surfactant administration, given to help stabilise preterm lung disease, was 
higher in our cohort than the 72% reported in 2014 by ANZNN.298 Only three of our 
infants received intratracheal surfactant but were not subsequently ventilated. Most 
babies in our cohort required a period of intubation and ventilation, although, the 
duration of assisted invasive ventilation varied widely. Our cohort had a shorter duration 
of invasive ventilation compare to the Network (ANZNN 2014: median(IQR) hours for  24-
25 weeks =274.5 (97.5–611.5), 26-27 weeks = 64 (17–199) , 28-29 weeks =22  (10–
71)).298 However, our cohort had a much higher rate of BPD (63% compared to 37%).298 
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Post-natal steroid use for severe lung disease, resistant hypotension or severe 
hypoglycemia was slightly lower than the 7.2% of all ANZNN registrants.298 All of our 
infants had caffeine therapy which was started early and prophylactically for the 
prevention of apnoea of prematurity and due to evidence of beneficial effects on short 
term respiratory function and long term neurodevelopmental outcome.308-310 Doxapram, 
a respiratory stimulant, was also used to treat oxygen saturation instability in several of 
our cohort but there is no comparative ANZNN data for this.  
A haemodynamically significant duct was a common problem affecting half of our cohort 
in the first three days which is not unexpected in this group of very to extremely preterm 
infants. It is difficult to compare rates due to differing definitions of haemodynamic 
significance.  
Rates of intraventricular haemorrhage within the brain were low in our cohort with 17% 
having any degree of bleeding (compared to 23% in ANZNN) but only 2% having a 
significant bleed that may be associated with long term consequences.298  
Rates of retinopathy were very low in our cohort but not dissimilar to rates in recent 
years. Only 3.9% of our cohort had ROP and this was only stage 1 with no stage 2-4 
disease. ANZNN infants are eligible for the recommended screening if they are born at < 
31 weeks gestation and/or have a birthweight of < 1250g. Of those ANZNN registrants 
who were screened 6.3% had stage 3-4 ROP.298  
Sepsis rates were similar to the 14.7% of 2014 ANZNN 24 to < 30 weeks infants who had 
sepsis during their admission.298 ANZNN defined systemic sepsis as a clinical picture 
consistent with sepsis, and either a positive bacterial or fungal culture of blood and/or 
cerebrospinal fluid.  
Breastmilk feeding is the preferred enteral nutrition for preterm infants with many short-
term and long term health benefits including a reduction in the risk of necrotising 
enterocolitis. All of our babies received breastmilk as the first milk and there were high 
rates of breastmilk feeding at neonatal discharge that were comparable to the 72% seen 
in ANZNN.  
We had no cases of necrotising enterocolitis, a gastrointestinal complication of 
prematurity that can result in death or devastating short gut syndrome and prolonged 
need for parenteral nutrition. This condition is known to have wide geographic variations 
in incidence but the incidence across ANZNN in 2014 was also low at 1.3%.  
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Our cohort generally had a healthy post-natal growth trajectory which has been shown 
to correlate with better short-term and long-term outcomes.264, 311-313 Our high rates of 
breastmilk feeding were likely contributed to by our Baby Friendly Hospital Initiative 
accreditation, specialised in-unit lactation consultants and the opening of a Human 
Donor Milk Bank in February 2014. The Baby Friendly Hospital accreditation is a WHO, 
UNICEF initiative that ensures that Maternity and Neonatal services adopt practices that 
protect, promote and support breastfeeding. Suspected gastroesophageal reflux disease 
was treated with milk thickeners and acid suppression in almost two-thirds of our cohort. 
Summary 
In comparison with the contemporaneous regional ANZNN neonatal network and New 
Zealand population data, infants recruited to this study were generally representative of 
babies born at less than 30 weeks gestation and admitted to NICU with the exception of 
a higher rate of BPD, lower rate of invasive ventilation and a low rate of ROP. However, 
approximately half of our cohort was >28 weeks with only small numbers of babies born 
at the extremes of prematurity which may reduce the likelihood of detecting  morbidity. 
With regards to other risk factors for pulmonary hypertension our cohort had a high 
incidence of BPD, HsPDA and chorioamnionitis but only a handful of pregnancies were 
complicated by preeclampsia or growth restriction. 
In conclusion, our cohort, although modest in size, is a fair representation of New 
Zealand NICU babies born at less than 30 weeks gestation in whom clinicians may 
consider screening for pulmonary hypertension. Outcomes for this cohort would not 
however, be generalizable to resource poor neonatal settings, populations with a low 
ethnically European population or NICUs where invasive ventilation is use is high and 
non-invasive respiratory support low.  
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Interpretation of biomarker assay results necessitates an understanding of the biology of the 
chosen marker within a selected patient population and an appreciation of the factors that may 
affect accurate quantification from sampling to analysis. This is particularly important when 
assays that have been developed and validated for an adult population are used in a paediatric 
setting. 
BNP is a cardiac hormone that has a cardioprotective function mediating natriuresis, diuresis, 
vasodilation, inhibition of sympathetic activity and reducing pathological myocardial 
remodelling. It is released predominantly from the cardiac ventricles as a prohormone from 
which the biologically active BNP and the inert NTproBNP fragment are cleaved. Details of 
release and degradation of BNP are outlined in Fig. 11 in the background chapters.  BNP is part 
of a foetal cardiac gene programme thought to be involved in cardiac development.166 
Reactivation of this foetal cardiac gene programme can occur as a cardioprotective mechanism 
during times of cardiac stress.48, 54 BNP and NTproBNP are released under conditions of 
increased wall stress due to ventricular volume or pressure loading and as such have proved 
useful as a diagnostic and prognostic biomarker of heart failure in adults.145-149 They may also 
have potential as biomarkers of cardiac dysfunction in preterm infants, however, targeted 
research in this population is needed due to the developmental differences in the preterm 
heart and the unique pathophysiology experienced after premature birth.  
It has been suggested that the characteristics of an optimal cardiac biomarker are that they 
should be completely cardiac specific, well characterised, easy to measure accurately, stable 
when stored, not usually found in the normal circulation in high concentrations and for which a 
clinical role has been clearly defined.314 Many of these questions remain unanswered for 
NTproBNP in the preterm population which has hindered use in this clinical setting. Reference 
levels, particularly beyond the period of transitional circulation, have not been well 
characterised in premature infants.53, 172, 176  
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In-vivo factors that may affect NTproBNP levels in premature infants 
There are many reasons why levels of NTproBNP in premature infants may be different from 
those in adults or indeed term-born infants. BNP is part of the foetal cardiac gene programme 
and high levels are known to be present in healthy foetuses early in gestation.166 Levels 
subsequently decline prior to birth then rise again with transitional circulation before declining 
to steady state levels. However, cardiac maturation is not yet complete when premature 
infants are born and have to complete the transition from foetal to neonatal circulation.  
In addition, clearance is also likely to be different due to the reduced renal function in 
prematurely born infants. More than 60% of nephrogenesis occurs in the final trimester of 
pregnancy and even in term infants glomerular filtration rate is reduced secondary to low 
perfusion pressure, increased tone of the efferent arteriole and relatively high blood 
viscosity.315 Premature infants also face multiple potential insults to kidney function during the 
course of their hospital admission.  
The biological variability (or relative change value) of NTproBNP levels is currently accepted to 
be 25% in adults with stable heart failure, meaning that a 25% change in NTproBNP levels is 
likely to represent a clinically significant change (either deterioration or improvement) in the 
patient’s physiological state.196 The accepted relative change value for healthy adults is higher 
at approximately 50% reflecting lower levels, meaning that smaller absolute changes in peptide 
levels produce a greater percentage change. The degree of normal variability of NTproBNP in 
preterm neonates has not been established. 
We know that NTproBNP levels are higher in preterm infants compared to term infants. 
However, this does not appear to be related to gestational age per se but rather secondary to 
conditions that are more prevalent in premature infants.316  Levels are elevated in infants with 
significant intrauterine growth restriction.170 There is some evidence that levels may be 
predictive of persistence of a haemodynamically significant PDA, however, clinicians have been 
unable to adopt this biomarker into clinical practice due to inconsistencies in trial design, lack 
of consensus regarding the definition of a clinically significant PDA and variable predictive 
thresholds.176, 180, 317  
Other conditions that are specific to the preterm population and may affect levels have not 
been fully investigated. Some studies have suggested that BNP and NTproBNP levels are higher 
in infants who develop BPD, however, little is known about the effects of ventilation on these 
levels. 185, 186, 318 Pulmonary hypertension may complicate BPD and cause right ventricular strain, 
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which could be a stimulus for BNP synthesis. Small, mostly retrospective studies of highly 
selected populations have suggested BNP or NTproBNP levels may be predictive of pulmonary 
hypertension and mortality.187-189 To date, no neonatal studies have examined the effect of 
renal function in premature infants on levels of NTproBNP. As hypoxia may stimulate the 
release of BNP via hypoxia-inducible factor the relationship between exposure to hypoxia and 
NTproBNP levels warrants examination.319 Due to similarities in the BNP gene promotor and 
that of the globin gene it is plausible there may be a relationship between haemoglobin and 
NTproBNP levels.320 This is relevant as premature infants are at increased risk of anaemia and 
are transitioning from foetal to adult haemoglobin. The relationship between BNP/NTproBNP 
and the inflammatory cascade is not yet fully understood but there also appears to be a 
relationship between significant inflammation and BNP/NTproBNP levels.321  
Data regarding post-translational processing of BNP are now emerging with evidence of a 
number of other circulating forms of BNP in adults. There are currently no data on BNP 
isoforms in the preterm population and this is investigated further in the next chapter. 
In-vitro factors that may affect NTproBNP levels in premature infants 
In addition to in-vivo factors, in-vitro laboratory factors may affect NTproBNP levels. Assay 
manufacturers product information states that samples that are collected in EDTA are stable 
for 3 days at room temperature or longer at 4 °C. Levels are unaffected by haemolysis 
(haemoglobin <0.621 mmol/L or <1.0 g/dL), lipaemia (triglycerides <17.1 mmol/L), 
hyperbilirubinaemia (bilirubin <428 μmol/L), or common pharmaceuticals. If, however, the 
patient is on high-dose biotin therapy, sampling should be delayed at least 8 hours after the last 
dose as this interferes with the assay.  
Gaps in current knowledge 
The range and temporal profile of NTproBNP levels from transition to neonatal discharge are 
not well established. Although the cardiac effects of a large patent ductus arteriosus and renal 
impairment are known to increase NTproBNP levels the effects of gestational age, 
chronological age, mechanical ventilation, hypoxia, haemoglobin, BPD and late pulmonary 
hypertension are not clear. There are also no published data on relative forms of circulating 
BNP molecules in the preterm population.
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Hypotheses 
1. NTproBNP levels will change over time in very preterm infants and will be higher in infants 
with: 
- haemodynamically significant patent ductus arteriosus 
- bronchopulmonary dysplasia 
- pulmonary hypertension 
2. NTproBNP will not vary significantly with gestational age at birth, hypoxia, mechanical 
ventilation or haemoglobin levels but will be higher in the context of renal impairment  
Aims 
1.  To determine the range and temporal profile of NTproBNP levels in infants born at <30 
weeks gestation at day of life 3, 10, 28 and at 36 weeks PMA  
2. To determine the utility of NTproBNP levels to diagnose haemodynamically significant PDA, 
diagnosed by pre-specified ultrasound criteria  
3. To determine the utility of NTproBNP levels to diagnose  bronchopulmonary dysplasia 
4. To determine the utility of  NTproBNP levels to diagnose pulmonary hypertension on the 
basis of pre-specified conventional heart ultrasound criteria 
5. To investigate whether NTproBNP levels are affected by gestational age, ventilation, hypoxia, 
renal impairment or haemoglobin level 
Methods 
Participants and setting 
This trial was conducted at the Christchurch Women’s Hospital NICU, Christchurch, New 
Zealand.  
Infants born at < 30 weeks gestation between March 2013 and April 2015 and cared for in 
Christchurch Neonatal Intensive Care Unit were eligible for enrolment by 72 hours of age. 
Infants were excluded if they had known structural airway or lung anomalies, congenital 
anomalies of the pulmonary arteries or pulmonary veins, major systemic vessel-to-pulmonary 
artery collateral vessels, congenital heart disease (except those with patent ductus arteriosus, 
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patent foramen ovale or secundum atrial septal defect < 5mm or tiny restrictive muscular 
ventricular septal defect), severe liver disease, or persistent pulmonary hypertension of the 
newborn on day 3 heart ultrasound (defined as severe hypoxia associated with estimated main 
pulmonary artery pressure >25mmHg). If infants had a grave prognosis such that they were not 
expected to survive to day 3 they were also excluded. 
Testing 
NTproBNP testing was paired with clinician-performed heart ultrasound assessment and three 
days of oxygen saturation monitoring as described in detail in methods chapter.  
NTproBNP testing 
Sample collection and storage 
Serial NTproBNP levels were analysed from a minimum of 0.6ml plasma collected from 
capillary, arterial or venous blood. Sample collection occurred on days of life 3, 10, 28 and at 36 
weeks PMA. Samples were initially stored at 4⁰C, then centrifuged at 3000rpm with plasma 
subsequently frozen at a minimum of -80⁰C prior to being batch processed. 
Assay  
NTproBNP levels were determined using a Roche E411 Cobas analyser which uses the 
Elecsys/Cobas ProBNP II assay. This assay contains two monoclonal antibodies which recognise 
epitopes located in the N-terminal part (1-76) of proBNP. The Cobas e411 
electrochemiluminescence immunoassay (ECLIA) utilises a “sandwich” technique using a 
monoclonal capture antibody to amino acids 27-31 and a monoclonal detection antibody to 
amino acids 42-46. 
Pulse oximetry 
Oxygen saturations were recorded, as detailed in methods chapter, for approximately 72 hours 
prior to NTproBNP testing using a Masimo Radical 7 Signal Extraction CO-oximeter (Masimo 
Corporation, Irvine, California) with averaging time set to 2 seconds.  
Heart Ultrasound 
Heart ultrasound was performed by neonatologists, as detailed in methods chapter, on days 3, 
10, 28 and 36 weeks PMA using a Toshiba Aplio 500 scanner with neonatal cardiac presets and 
a 6.5MHz probe. 
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Haemoglobin 
Haemoglobin levels were not taken as part of this study so the closest levels taken to 
NTproBNP testing as part of routine clinical care were used in analysis.  
Definitions 
BPD was defined as persistent oxygen or respiratory support requirement at 36 weeks PMA 
(definition utilised by the Australian and New Zealand Neonatal Network in 2013) or graded 
according to the National Institute of Child Health and Human Development criteria as detailed 
in methods chapter.287 Pulmonary hypertension was defined according to the heart ultrasound 
criteria outlined in Table 4 in the methods section.81, 199HsPDA was defined according to 
commonly accepted ultrasound criteria detailed in methods chapter.180 
Hypoxia 
The percentage time spent with oxygen saturations less than 88% in the 3 days preceding 
NTproBNP testing was used as a marker of exposure to hypoxia. 
Statistical analysis 
Quantitative variables are described by mean and standard deviation (SD) or median and 
interquartile range (IQR). Box and whisker plots were used to display the distribution of 
NTproBNP levels at days 3, 10, 26 and 36 weeks PMA.  As the distribution was skewed a natural 
log transformation was applied.  
For bivariate analyses parametric tests were used for normally distributed data and non-
parametric tests for non-normally distributed data. Regression models (linear regression for 
continuous outcomes, logistic regression for dichotomous outcomes) were fitted to the data to 
examine the nature of the association and the strength of the association were summarised by 
the R-squared statistic. These models were extended to control for relevant demographic, 
perinatal or clinical factors. A p value of < 0.05 was considered statistically significant.  
Receiver Operating  Characteristic curve analysis296  was conducted to examine the extent to 
which it is possible to distinguish at an early age between those infants who do/do not have a 
HsPDA and those who go on to develop BPD, by day 3 and day 10 NTproBNP. A predictive cut-
off value was chosen to maximise sensitivity and specificity. The relationship between 
NTproBNP and BPD was analysed using both the dichotomous definition of BPD (need for 
oxygen or respiratory support at 36 weeks PMA) and the NICHD graded definition.287 As death 
before 36 weeks PMA precludes a diagnosis of BPD it was included in the dichotomous analysis. 
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For the analysis by BPD severity the infants with the two deaths before 36 weeks PMA were 
excluded as they could not be classified.  Data was stored using Microsoft Excel and statistical 
analysis was performed using Microsoft Excel and either Stata 15, SAS 9.4 or GraphPad InStat 
Software. 
Results 
NTproBNP levels over time 
Mean (SD) and median (IQR) NTproBNP levels at the four time intervals are shown in Table 15 
Data are non-normally distributed and particularly skewed on days 3 and 10. A repeated 
measures analysis of variance using log transformation was performed to stabilise variance. 
There was a significant fall in NTproBNP over time (p<0.001). Fig. 28 shows distribution of 
NTproBNP values over time using a logarithmic scale to facilitate data display. Initially there is a 
wide distribution of NTproBNP levels most noticeable on days 3 and 10. By day 28 most infants 
fall within a narrower range of levels. 
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Table 15: Mean (SD) and Median (IQR) NTproBNP (pmol/L) over time 
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Figure 28: Distribution of log scale NTproBNP values over time. 
 
NTproBNP by PDA Status 
To explore what factors might be contributing to the wide distribution in NTproBNP levels on 
days 3 and 10 we examined the effect of HsPDA. Baseline characteristics of those infants with 
and without HsPDA on day 3 are documented in the methods chapter. The change in PDA 
status over time is detailed in Fig. 27 in the baseline demographics and in-hospital outcomes 
chapter.  
Table 16 compares mean NTproBNP levels over time by day 3 HsPDA status. Significantly higher 
mean NTproBNP levels were seen on day 3 and day 10 in infants who had HsPDA identified on 
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day 3. By day 28 levels were not significantly different but by 36 weeks PMA the relationship 
had reversed with infants who had not had HsPDA on day 3 having significantly higher mean 
NTproBNP levels.  
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39 – 95 
56 
37 – 185 
 
0.21 




78 – 194 
68 
30 – 115 
 
0.01 
1 t-test for independent samples using log-transformation to stabilise variance. Repeated measures analysis 
of variance for NTproBNP by HsPDA day 3: main effect of HsPDA F(1,45)=25.4 p<0.001; main effect of time 
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Figure 29 compares the distribution of NTproBNP (log scale) over time between those 
who had HsPDA on day 3 and those who had a closed or haemodynamically non-
significant PDA. This demonstrates a general decline from day 3 to day 28 which is 
steeper in those with HsPDA as they start at a higher level. There is an overlap in the 
range of levels on days 10, 28 and 36 weeks PMA. Levels appear to rise between day 28 
and 36 weeks PMA in those without HsPDA. The median (IQR) day 3 NTproBNP of the 
infants who had day 3 HsPDA but no treatment and who subsequently had a closed or 
non-significant duct on day 10 was 931pmol/L (378-1395) compared to 1844pmol/L 
(1419-2433) in those infants with day 3 HsPDA and no treatment and a persistent HsPDA 
on day 10. The median (IQR) day 3 NTproBNP of the infants who had a closed or non-
significant duct by day 10 was 192pmol/L (122-372) compared to 2272 (1435-3002) in 
those with HsPDA on day 10. 
 
Figure 29: Distribution of NTproBNP values (log scale) over time by day 3 HsPDA status 
 
Receiver Operating Curves (ROC) for the prediction of HsPDA on day 3 and day 10 by day 
3 NTproBNP level are shown in Fig.30. A chosen cut-off day 3 NTproBNP value of >= 287 
pmol/L for the prediction of haemodynamically significant PDA on day 3 correctly 
classified 92% with a sensitivity of 92% and a specificity of 92%. A chosen cut-off 
NTproBNP value of >= 1010 pmol/L on day 3 for the prediction of a hemodynamically 
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significant PDA on day 10 correctly classified 88% with a sensitivity of 94% and a 
specificity of 85%. 
 
 
Figure 30: ROC curve for prediction of HsPDA 
A) On day 3 from day 3 NTproBNP  
(SE 0.0127, 95% CI  0.96, 1.00) 
B) On day 10 from day 3 NTproBNP  
(SE 0.0327, 95% CI 0.87, 1.00) 
 
Table 17 reveals a small but statistically significant difference in mean (SE) log10 
NTproBNP levels at 36 weeks PMA by day 3 HsPDA status which persists after adjustment 
for gestation and birthweight z-score. 
Table 17: Mean (SE) log10 NTproBNP levels at 36 Weeks PMA by Day 3 HsPDA status unadjusted and 
adjusted for gestation, birthweight z-score 





Unadjusted 2.09 (0.07) 1.79 (0.09) -0.38 0.01 
Adjusted 2.08 (0.08) 1.80 (0.08) -0.35 0.02 
 
Relative effect of gestational age, HsPDA, ventilation and creatinine level on 
NTproBNP levels 
A fitted regression model (Table 18) was used to examine the relative contributions of 
gestation at birth, HsPDA status, ventilation on days 3 and 10 and day 3 creatinine level 
(as a surrogate for renal function) on day 3 and day 10 NTproBNP levels. The fitted 
model assumes that: (1) gestation is causally related to PDA status and need for 
A B 
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ventilation; (2) PDA status and ventilation are correlated over and above the causal 
effects of gestation; (3) all three variables are predictive of NTproBNP. This model 
demonstrates that although there is a negative correlation between gestation at birth 
and NTproBNP levels this is mediated predominantly via the effect of PDA status, but 
also ventilation and to some degree early renal function.  
Table 18: Fitted regression models predicting NTproBNP levels on days 3 and 10 
Predictor β (SE) p β 
Day 3 NTproBNP 
Gestation (wk) -116.6 (80.4) 0.15 -0.15 
HsPDA Day 3 1598.7 
(218.6) 
<0.0001 0.69 
Ventilated Day 3 458.7 (319.1) 0.16 0.15 
Creatinine Day 3 (umol/L) -6.9 (8.9) 0.44 -0.08 
 Adjusted R2 = 0.56 
Day 10 NTproBNP 
Gestation (wk) -28.2 (65.4) 0.67 -0.04 
HsPDA Day 10 1295.1 
(187.6)  
<0.0001 0.59 
Ventilated Day 10 1483.1 
(396.2)  
<0.001 0.34 
Creatinine Day 3 (umol/L) 20.4 (6.9) 0.005 0.26 
 Adjusted R2 = 0.66 
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NTproBNP and bronchopulmonary dysplasia 
Table 19 shows higher NTproBNP values on days 3, 10, 28 in infants with BPD/death 
(ANZNN BPD definition) but lower levels at 36 weeks PMA. However, repeated measures 
ANOVA analysis demonstrated there was no significant overall effect of group status or 
group by time interaction, but there was a highly significant effect of time that was 
similar in both groups. Fig. 31 represents this using a box and whisker plot on a log scale. 
There is considerable overlap in values at all time periods. 
 








Median 240 1010 0.31 
IQR 147 – 725 150 – 1976  
Day 10 
Median 97 225 0.09 
IQR 88 – 185 83 – 910  
Day 28 
Median 57 83 0.13 
IQR 40 – 79 39 – 156  
36 weeks PMA 
Median 156 78 0.07 
IQR 78 – 190 34 – 140  
1 t-test for independent samples using log-transformation to stabilise variance. Repeated measures ANOVA: 
Effect of Group (BPD or Death) F(1,45)=1.37, p=0.25; Effect of Time F(3,135)=28.5, p<0.001; Group x Time 
interaction F(3,135)=3.0, p=0.03 
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Figure 31: Distribution of NTproBNP values over time (log scale) by BPD status (ANZNN definition) 
 
Table 20 shows the differences in NTproBNP levels by NICHD grade of severity of BPD. 
Fig. 32 shows log scale NTproBNP level over time according to NICHD BPD grade with 
those with severe BPD showed greater variability in levels and higher levels on day 3 and 
day 10 compared to those with no BPD. However, by 36 weeks PMA those with severe 
BPD had lower levels than those with no BPD. Mean NTproBNP levels varied significantly 
with BPD severity, time and severity by time. 
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Day 3 Median  
(IQR) 
244  
(126 – 725) 
184  
(81 – 1010) 
1443  
(1102 – 2935) 
<0.005 
Day 10 Median  
(IQR) 
95  
(63 – 235) 
117 
 (47 – 163) 
910  
(225 – 1958) 
<0.001 
Day 28 Median  
(IQR) 
73  
(40 – 109) 
46  
(39 – 61) 
156  






(68 – 184) 
89  
(43 – 159) 
72  
(34 – 111) 
0.30 
1 One way analysis of variance using log transformation to stabilise variance. Repeated measures analysis of 
variance for NTproBNP by NICHD severity: main effect of NICHD severity F(2,44)=8.6, p<0.001; main effect of 
time F(3,132)=31.8, p<0.001, NICHD severity x time interaction F(6,132)=4.8, p<0.001 
 
 
Figure 32: Distribution of NTproBNP levels over time (log scale) by BPD grade (NICHD definition) 
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Table 21 compares area under the curve (95% CI) for prediction of BPD status for varying 
definitions of BPD from NTproBNP levels at different time periods. Receiver operating 
curves for the prediction of severe BPD (NICHD) on the basis of day 3 and day 10 
NTproBNP are shown in Fig. 33. The area under the curve for both day 3 and day 10 is 
modest at 0.80 (SE 0.07, 95% CI 0.66-0.94) and 0.83 (SE 0.07, 95% CI 0.69- 0.98) 
respectively. With a chosen cut-off value of >= 1102 pmol/L this analysis shows day 3 
NTproBNP has a sensitivity of 76% and a specificity of 80% and correctly classifies 79% of 
infants with severe BPD. With a chosen cut-off value of >= 189.2 pmol/L. This analysis 
shows day 10 NTproBNP has a sensitivity of 84% and a specificity of 75% correctly 
classifying 77% of infants with severe BPD.
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Table 21: Area under the curve (95% CI) for prediction of BPD status from NTproBNP level (Day 3, 10, 28) for 
varying definitions of BPD 













(0.44 – 0.77) 
0.65 
(0.49 – 0.81) 
0.63 
(0.45 – 0.80) 
0.80 
(0.66 – 0.94) 
Day 10 
0.63 
(0.47 – 0.79) 
0.69 
(0.54 – 0.86) 
0.70 
(0.53 – 0.87) 
0.83 
(0.69 – 0.98) 
Day 28 
0.59 
(0.43 – 0.75) 
0.53 
(0.35 – 0.71) 
0.62 
(0.43 – 0.81) 
0.67 
(0.45 – 0.89) 
 
 
Figure 33: ROC curve for severe BPD (NICHD definition) 
A) By day 3 NTproBNP (AUC 0.8022) 
B) By day 10 NTproBNP (AUC 0.8333) 
No significant difference in mean (SE) log10 NTproBNP level across all time periods was 
found for infants classified as no BPD compared to those with BPD or death by 36 weeks 
PMA (Table 22). Mean (SE) log10 NTproBNP levels on days 3, 10 and 28 did vary 
significantly by NICHD scale severity of BPD (Table 23). However, this was no longer 
significant once adjusted for gestation, birthweight z-score and day 3 PDA status. 
Adjusting for the total duration of ventilation made no difference. 
A B 
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Table 22: Mean (SE) log10 NTproBNP levels by BPD status unadjusted and adjusted for gestation, birthweight 




BPD or Death 
(N=33) 
p 
Day 3    
Unadjusted 2.50 (0.12) 2.71 (0.11) 0.22 
Adjusted 2.69 (0.08) 2.64 (0.06) 0.67 
Day 10    
Unadjusted 2.11 (0.10) 2.45 (0.11) 0.05 
Adjusted 2.29 (0.11) 2.35 (0.08) 0.68 
Day 28    
Unadjusted 1.79 (0.06) 1.97 (0.08) 0.14 
Adjusted 1.82 (0.10) 1.95 (0.07) 0.35 
36 weeks PMA    
Unadjusted 2.08 (0.10) 1.87 (0.07) 0.08 
Adjusted 2.03 (0.10) 1.90 (0.07) 0.30 
 
 
Chapter 4  120 
 
Table 23: Mean (SE) log10 NTproBNP levels by NICHD grade of BPD unadjusted and adjusted for gestation, 










Day 3     
Unadjusted 2.48 (0.10) 2.43 (0.23) 3.06 (0.14) 0.007 
Adjusted 2.63 (0.07) 2.55 (0.11) 2.70 (0.11) 0.66 
Day 10     
Unadjusted 2.10 (0.09) 2.12 (0.16) 2.35 (0.17) <0.001 
Adjusted 2.22 (0.09) 2.17 (0.15) 2.57 (0.15) 0.14 
Day 28     
Unadjusted 1.84 (0.05) 1.72 (0.09) 2.19 (0.17) 0.02 
Adjusted 1.85 (0.09) 1.72 (0.13) 2.17 (0.13) 0.07 
36 weeks PMA     
Unadjusted 2.02 (0.07) 1.95 (0.14) 1.81 (0.12) 0.31 
Adjusted 1.95 (0.08) 1.92 (0.13) 1.96 (0.13) 0.96 
 
Effect of late pulmonary hypertension on NTproBNP level  
None of our cohort met the predefined criteria for pulmonary hypertension at the 36 
week scan so no analysis could be undertaken to determine effects of this condition on 
NTproBNP levels.  
Effect of haemoglobin on NTproBNP level 
The mean number of days between haemoglobin testing and NTproBNP testing was 0.3. 
There was evidence of a significant (p<.001) negative bivariate correlation between 
haemoglobin and NTproBNP on days 3 and 10 but not at later ages (Spearman 
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correlation was -0.50 on day 3, -0.45 on day 10). However, haemoglobin was not a 
significant predictor of NTproBNP levels at these ages when other factors associated with 
NTproBNP levels were taken into account, notably HsPDA status. 
Effect of hypoxia 
The percentage time spent with oxygen saturations less than 88% in the 3 days 
preceding NTproBNP testing was used as a marker of exposure to hypoxia. The 
percentage time oxygen saturations were less than 88% showed a similar but less 
consistent pattern of association with NTproBNP levels to haemoglobin. Spearman 
correlation at day 3 (0.21, p=.14) and day 10 (0.52, p<.001), weaker and non-significant 
associations at later ages. In summary, exposure to hypoxia defined as percentage time 
less than 88% was not an independent predictor of NTproBNP when other factors, in 
particular PDA status, were taken into account. 
Effect of chronological age on 36 week NTproBNP 
Although the day 3, day 10 and day 28 NTproBNP levels were all taken at the same 
chronological age this was not the case for the 36 week PMA samples which varied 
according to gestation at birth.  The median (IQR) NTproBNP level at this time point was 
97 pmol/L (40-168) with 90% of the cohort having levels <250pmol/L. Fig. 34 shows that 
there is no relationship between NTproBNP levels at 36 weeks PMA and chronological 
age. This may have been influenced by four outliers (only one of whom had PDA 
persisting at 36 weeks and BPD, the remaining three had neither HsPDA or BPD). If these 
outliers are excluded there may be slight inverse relationship between chronological age 
and NTproBNP level which is consistent with the known gradual decline over childhood 
to puberty.177 
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Figure 34: Relationship between NTproBNP levels at 36 weeks PMA and chronological age 
 
Discussion 
This study is the first to document temporal changes in NTproBNP in a cohort of very 
preterm infants and to investigate a range of potential factors that may influence levels. 
NTproBNP levels generally declined as has been shown in other studies.53, 177 The 
haemodynamic effect of a patent ductus arteriosus is a strong influence on levels with 
renal impairment also causing an increase in levels. The effect of evolving BPD appears to 
be modest with ventilation, exposure to hypoxia and haemoglobin not significantly 
influencing levels in our cohort.  
Our study confirmed that gestational age has a negative correlation with early NTproBNP 
levels but that this is primarily mediated by PDA status. Although chronological age 
affected NTproBNP levels during the first month of life this again appeared to be 
mediated by transitional circulation and PDA status and, once a relative steady state had 
been reached, age alone was not a significant influence on levels. This is consistent with 
the very slow decline to adult levels over the first ten years shown in other studies.322 
Further study is needed on larger cohorts of premature infants from birth to beyond 
term equivalent age to better establish reference ranges over time for NTproBNP.   
Although the overall trend for our four collection times was for NTproBNP levels to 
decline from a peak at day 3 to a more steady level, some infants had an increase in 
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had an increase in NTproBNP between day 28 and 36 weeks PMA. Day 3 NTproBNP levels 
were significantly higher in infants with HsPDA and day 3 NTproBNP levels demonstrated 
high sensitivity and specificity for the prediction of HsPDA on day 3 and 10.  Infants 
classified as having a closed or non-significant duct on day 3 reached low NTproBNP 
levels within the first few days of life whereas the decline was slower in those with 
HsPDA.  Ductus arteriosus patency and increased left to right shunting appears to be the 
key factor influencing the wide distribution of NTproBNP levels on day 3 and day 10 and 
is likely to be the main reason behind any increase in levels between days 3 and 10. Any 
effect of gestational age in our cohort appeared to be primarily mediated by PDA status. 
The cause of a late rise in NTproBNP is unclear. Infants with no HsPDA on day 3 tended 
to have higher levels at 36 weeks PMA than those who had experienced HsPDA. This 
finding is unexpected, unexplained and warrants further investigation. 
In this study only a third of infants classified as having HsPDA on day 3 were treated by 
clinicians.  There remains considerable debate around the criteria for a clinically 
significant PDA and despite recognised short term consequences of PDA, treatments 
have failed to improved long term outcomes.323 The low numbers of infants treated in 
this cohort reflects this clinical uncertainty. The decision to treat was likely influenced by 
other factors such as gestational age, the clinical condition of the infant including 
ventilation status and relative contraindications to treatment.  Heart ultrasound criteria 
alone may be inadequate to guide PDA triage and broader scoring systems have been 
suggested.324, 325 NTproBNP has potential to be a valuable adjunct to clinical and 
echocardiographic triage tools and should be considered in future PDA trial design.  
Levels of NTproBNP in our cohort were considerably higher than those seen in the 
healthy adult population age even at 36 weeks PMA.  In the adult setting an NTproBNP 
level of <300pg/ml (35pmol/L) in dyspnoeic patients has a negative predictive value of 
99% for a diagnosis of congestive heart failure with levels of >53pmol/L making heart 
failure highly likely.326  In our cohort, at 36 weeks PMA, 34/48(71%) of levels were 
>53pmol/L. Published data from Nir et al suggest a median steady state NTproBNP level 
in healthy infants beyond the period of transitional circulation, using a Roche assay, of 
17pmol/L with the 97.5th percentile  being 118pmol/L.192 The study by Montgomery et al 
suggested levels above this at 36 weeks PMA predict pulmonary hypertension with a 
sensitivity of 100% and a specificity of 94% in a high risk population.189 In our cohort 
18/48(37%) at 36 weeks PMA had an NTproBNP level >118pmol/L but none met our 
ultrasound criteria for pulmonary hypertension. This may reflect the lower pre-test 
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probability in our general population of premature infants or differences in criteria used 
to define pulmonary hypertension.  
The BPD rate in this cohort by the ANZNN definition at the time was 63%. This was higher 
than anticipated when compared to a BPD rate of 35% for those born 24-29 weeks in 
ANZNN units in 2013. A diagnosis of BPD at 36 weeks PMA without a physiological test 
may be influenced by unit policy regarding oxygen saturation targets and individual 
clinician opinion.288, 327 It is possible our BPD group may have included babies who may 
not have met the criteria for BPD by a physiological challenge. For this reason the cohort 
was also analysed according to the NICHD scale for BPD which classifies infants into no, 
mild, moderate or severe grades.287 ANZNN now incorporate a physiological challenge to 
prior to a diagnosis of BPD. 
Modest differences in NTproBNP between the infants with and without BPD (ANZNN) did 
not achieve statistical significance. This was true for comparisons between BPD (NICHD) 
grade when adjusted for gestational age at birth, birthweight z score and day 3 PDA 
status. At 36 weeks PMA regardless of BPD grade NTproBNP levels are very similar. So 
even in the face of severe lung disease, provided it develops gradually, the preterm heart 
appears to adapt well. The long term cardiac effects of prematurity are currently an 
active area of research with both structural and functional differences found in the 
hearts of adults born prematurely.45, 328 It is possible that there may be a long-term 
trade-off for some of these early adaptive mechanisms. 
NTproBNP levels in our cohort did not demonstrate good ability to predict BPD although 
day 10 NTproBNP did have a modest ability to predict severe BPD. Sellmer et al found 
the risk of death or BPD increased 1.7 times for every 1 unit increase of natural log 
NTproBNP on day 3 which held for infants with or without PDA.185 Some of our infants 
had an unexplained increase in levels between day 28 and 36 weeks PMA. Infants with 
severe BPD are at greatest risk for developing pulmonary vascular disease and 
pulmonary hypertension although this often takes weeks to evolve and may not be 
clinically apparent until after term equivalent age. Whether NTproBNP levels at 36 weeks 
PMA and beyond are higher in infants who go on to develop pulmonary hypertension 
requires further studies that incorporate heart ultrasound monitoring and follow-up 
beyond hospital discharge.  
Strengths of our study include its prospective design, paired NTproBNP and heart 
ultrasounds over four time intervals with criteria for HsPDA clearly defined and heart 
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ultrasound analysis blinded to NTproBNP. As entry criteria were broad our study 
population is of interest to clinicians. However, this is a small study powered only to 
detect moderate to large effects. Any unplanned subset analysis may be subject to bias. 
The lack of an association between ventilation, hypoxia and haemoglobin may reflect 
cohort size, but does suggest that these variables are not dominant determinants of NT-
proBNP. The heart ultrasounds and analysis in this study were performed by 
neonatologists, not cardiac ultrasonographers or cardiologists, however this is unlikely to 
have significantly weakened the quality of our ultrasound data. In addition the 
neonatologists were not blinded to the clinical status of the infant. A standardised 
treatment protocol would have allowed us to better assess the ability of NTproBNP to 
predict PDA closure. However, this is a modest sized but well described cohort 
strengthened by the combination of biochemical, ultrasound and oxygen saturation data 
with clinical data to 2 years of age and goes some way to filling gaps in knowledge 
regarding NTproBNP in very prematurely born infants. 
Implications for practice 
We are the first to show the temporal changes in NTproBNP in a very preterm cohort 
from day 3 through to 36 weeks PMA. We demonstrated that NTproBNP is a highly 
sensitive and specific biomarker for the prediction of ultrasound-defined HsPDA. 
NTproBNP may help stratify infants for PDA treatment by identifying those who not only 
have a significant duct but are also showing signs of cardiac compromise and those less 
likely to achieve spontaneous closure. NTproBNP therefore has potential as an adjunct 
blood marker to heart ultrasound to reduce the frequency of scanning of fragile infants. 
Given the significant impact of the transitional circulation on natriuretic peptide release, 
the known natural decline in BNP over childhood and the inherent biological variability of 
BNP and NTproBNP it is likely serial monitoring, supported by heart ultrasound, is going 
to offer the greatest value to clinicians. 
Early NTproBNP was a modest predictor of severe BPD in our cohort and may have utility 
as part of a prognostic scoring system. Most of our cohort had NTproBNP levels within a 
relatively narrow range at 36 week PMA compared to the first month of life. This is useful 
information and deserves to be repeated in a larger cohort which would help inform 
clinicians on a normal range of NTproBNP at a time period when screening for pulmonary 
hypertension in at risk infants is recommended.86-88  
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Understanding the usual pattern of NTproBNP levels over time, and the factors that may 
influence levels, as we have demonstrated, will also help clinicians monitor cardiac 
function over time in preterm infants. This is important to better understand the 
developmental origins of cardiovascular disease in adulthood. 
Conclusion 
This study is the first to show the temporal changes in NTproBNP levels in very preterm 
infants from the period of cardiac transition to 36 weeks PMA, a time at which screening 
for pulmonary hypertension has been proposed. We have demonstrated the key 
determinants of NTproBNP levels and shown NTproBNP is a strong predictor of HsPDA 
and a modest discriminator of severe BPD. NTproBNP may help to better stratify infants 
with HsPDA in need of treatment by identifying those infants who not only have a large 
duct but are also have evidence of cardiac compromise.
 





It is now understood that post-translational processing of proBNP, NTproBNP and BNP 
results in a number of other circulating natriuretic peptide derived molecules, which can 
complicate the interpretation of assays.329 Validated commercial assays for the major 
circulating congeners BNP and NT-proBNP are available and widely used.  Although our 
understanding of the post-translational processing of BNP and NTproBNP and the 
potential impact on bioactivity and assay performance in adults is emerging there are 
currently no published data in premature infants.  
Studies of adults with chronic heart failure have shown significant variation in the 
circulating forms of the B-type Natriuretic Peptides.330, 331 Unprocessed proBNP is often 
present in high amounts in the circulation of adults with heart failure.332, 333 In adult 
patients with advanced heart failure proBNP is the predominant circulating form, and 
has greatly reduced biological activity compared to BNP.334 Peripheral processing of 
proBNP appears to be important in the regulation of BNP activity.335  As currently 
available commercial assays do not distinguish between proBNP and BNP, patients with 
chronic heart failure may in fact have an effective deficiency of BNP activity despite assay 
results suggesting high levels of circulating peptide. It is not clear whether this 
paradoxical relative abundance of proBNP is due to increased production of proBNP 
primarily, or to increased clearance of 1-32 BNP or impaired processing of proBNP, 
although all three mechanisms are relevant. 
Processing of BNP congeners within the cardiomyocyte and circulation is detailed in 
Fig.35. The BNP gene is activated predominantly by ventricular wall stress but also by 
local myocardial ischaemia, cytokines, angiotensin II and endothelin-1. This activation 
stimulates translation of messenger RNA in the endoplasmic reticulum of cardiac 
ventricular myocytes to the 143 aa preproBNP. Cleavage of the proBNP (108 aa) 
molecule from its signal peptide occurs in the Golgi apparatus. Glycosylation of ProBNP 
may occur at this point. ProBNP is then cleaved into the 1-76 aa residue NTproBNP and 
the biologically active 77-108 aa BNP.  Although then released in a 1:1 ratio, plasma level 
plasma levels of NTproBNP are several-fold higher than BNP and this is thought primarily 
to be due to differences in clearance – with NT-proBNP clearance primary being renal, 
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while BNP also undergoes clearance via the NPR-C receptor as well as enzymatic 
degradation by neutral endopeptidase.134 Processing of proBNP is predominantly 
thought to occur at the moment it is released into the circulation via the actions of two 
convertase enzymes, furin and corin.195 The action of furin produces BNP 1-32 and corin 
BNP 4-32. Glycosylation of proteins after translation is common and potentially serves 
multiple functions. ProBNP processing by corin and furin appears to be inhibited by the 
presence of glycosylation of proBNP at Thr71. 336 Circulating proBNP can be found in a 
form that is glycosylated at Thr71 (and therefore not available for convertase processing) 
and a form that is not glycosylated at Thr71 (and therefore available for convertase 
processing). It is not clear why both forms of proBNP are released into the circulation.  
However, the non-glycosylated form suggests that some processing within the plasma 
may occur providing a circulating reserve of BNP.195  
In addition, glycosylation of NTproBNP can occur at a number of threonine and serine 
residues within the N-terminal region. Seferian et al identified glycosylation sites in the 
central region (aa residue 28-56) of NTproBNP.337 Significant inter-individual variability in 
glycosylation of proBNP and NTproBNP has been found and patients with chronic heart 
failure appear to have a greater degree of glycosylation when compared to patients with 
acute heart failure. 331, 337, 338 Further processing of NTproBNP has also been 
demonstrated. Fragments which are smaller than the 76 aa NTproBNP molecule have 
been detected in the circulation of adults with heart failure demonstrating that 
NTproBNP undergoes extensive N- and C-terminal proteolytic processing.330 329 Assays 
should therefore avoid simultaneously targeting the extreme N and C-terminals and the 
central region of O-glycosylation in order to detect all NTproBNP in the sample.  
The Roche Elecsys ProBNP II assay has been shown to detect non-glycosylated proBNP 
(1-108) and non-glycosylated NTproBNP (1-76) but not glycosylated proBNP or 
glycosylated NTproBNP. 339 In addition, NTproBNP assays may not only detect free 
NTproBNP (1-76) but also proBNP (1-108) which has NTproBNP still attached. However, 
evidence to date suggests the major commercial NTproBNP assay, the Roche Cobas e411 
or Elecsys, detects only NTproBNP.340  
In premature infants BNP and NTproBNP have been shown to be elevated during 
transitional circulation but little is known about what isoforms or fragments of either 
molecule predominate during or beyond this early period of cardiac adaptation when, 
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due to chronic lung disease, the right ventricle, in particular, may be under chronic 
strain. 
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Figure 35: Schematic representation of BNP processing 
 
PKC = protein kinase C, MAP kinase =mitogen-activated protein kinase, cGMP = cyclic guanosine monophosphate 
Reproduced from Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Minamino N, Nakao K. Complexity of molecular forms of B-type natriuretic peptide in heart failure. Heart. 2013;99(10):677-
9. ©2018, with permission from BMJ Publishing Group Ltd
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Gaps in current knowledge 
There is currently no published data on circulating isoforms of BNP and BNP fragments in 
premature infants. We do not know whether there is significant glycosylation of BNP 
molecules in this population and whether this and relative proportions of BNP isoforms 
differ under different clinical conditions. As glycosylation can interfere with assay 
interpretation and fragments other than BNP (1-32) have weaker biological activity this is 
important information for clinicians when interpreting neonatal BNP results.  
Hypotheses 
1. There will be additional circulating forms of BNP other than BNP (1-32) and NTproBNP 
(1-76) in very premature infants 
2. Post-translational processing of BNP and NTproBNP will differ in patients with BPD 
and/or HsPDA compared to those without 
 
Aims 
1. To determine the types of circulating isoforms of BNP in very preterm infants 
2. To investigate whether BNP isoforms differ in premature infants with BPD and/or 
HsPDA and those without these conditions 
Methods 
Participants and setting 
This trial was conducted at the Christchurch Women’s Hospital NICU, Christchurch, New 
Zealand.  
Infants born at < 30 weeks gestation between March 2013 and April 2015 and cared for 
in Christchurch Neonatal Intensive Care Unit were eligible for enrolment by 72 hours of 
age. Infants were excluded if they had known structural airway or lung anomalies, 
congenital anomalies of the pulmonary arteries or pulmonary veins, major systemic 
vessel-to-pulmonary artery collateral vessels, congenital heart disease (except those with 
patent ductus arteriosus, patent foramen ovale or secundum atrial septal defect < 5mm 
or tiny restrictive muscular ventricular septal defect), severe liver disease, or persistent 
pulmonary hypertension of the newborn on day 3 heart ultrasound (defined as severe 
hypoxia associated with estimated main pulmonary artery pressure >25mmHg). If infants 
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had a grave prognosis such that they were not expected to survive to day 3 they were 
also excluded. 
Plasma volume remaining after initial NTproBNP testing was used for isoform testing. 
Low available plasma volumes necessitated pooling of samples from several infants and 
across all four testing times. Among 15 infants with adequate residual plasma, we 
identified sub-groups based on clinical features and performed analyses of pooled 
plasma from these subgroups. Table 24 details the groupings used for pooled testing and 
the total plasma volume available for testing. Group 1 were well babies who had low 
NTproBNP throughout all testing points, had no HsPDA and no BPD. Group 2 had high 
early NTproBNP levels, HsPDA on day 3 but no BPD. Group 3 were the sickest babies, had 
high early NTproBNP, HsPDA on day 3 and BPD. 
Table 24: Clinical groupings for pooled plasma analysis of BNP isoforms 
 HsPDA BPD Total pooled 
plasma volume (µl) 
Group 1 n=4 No No 3950 
Group 2 n=3 Yes No 4010 
Group 3 n=8 Yes Yes 6205 
 
Definitions 
BPD was defined as persistent oxygen or respiratory support requirement at 36 weeks 
PMA. HsPDA was defined according to ultrasound criteria detailed further in methods 
chapter. 
NTproBNP isoform testing 
Sample collection and storage 
Plasma was collected from capillary, arterial or venous blood in a cohort of 51 infants 
born before 30 weeks gestation. Sample collection occurred on days of life 3, 10, 28 and 
at 36 weeks PMA. Samples were initially stored at 4⁰C until collection within 72 hours, 
then centrifuged at 3000rpm with plasma subsequently frozen at a minimum of -80⁰C 
prior to being batch processed. 
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Assays and HPLC 
NTproBNP levels were ascertained by electro chemiluminescent sandwich enzyme-linked 
immunoabsorbant assay using a Roche E411 Cobas analyser. Residual plasma was then 
analysed for BNP isoforms and glycosylation using a combination of Luminex assay and 
high performance liquid chromatography as detailed in methods chapter.  Details of the 
epitopes identified to detect isoforms of BNP are detailed in Table 25. 
Table 25: Epitopes identified in BNP isoform testing 
Assay Epitopes Detection target and cross-
reactivity 
BNP 24C5: epitope BNP11-22 and 
50E1: epitope BNP26-32 
Cross reacts with BNP and 
proBNP 
BNP H43  50E1: epitope BNP23-32 and 
polyclonal Ab rabbit H43: 
epitope BNP1-13 
Specific for BNP 
NTproBNP general 15F11: epitope NTproBNP13-
24 and 24E11: epitope 
NTproBNP67-76 
Cross reacts with NTproBNP 
and proBNP 
NTproBNP specific 15F11: epitope ntBNP13-24 
and polyclonal Ab rabbit J25: 
epitope NTproBNP62-76 
Specific for NTproBNP 
proBNP 50E1: epitope BNP23-32 and 
16F3: epitope NTproBNP13-20 
Detects glycosylated and non-
glycosylated proBNP 
RSproBNP 24C5: epitope BNP11-22 and 
16F3: epitope NTproBNP13-20 
Detects glycosylated and non-
glycosylated proBNP with ring 
structure closed 








Frequency or proportion of BNP isoforms/fragments was described graphically according 
to clinical group status. 
Results  
BNP Isoforms 
Figures 36-38 show results of BNP isoform testing on pooled plasma.  
Group 1 (low NTproBNP at all time points, no BPD, no HsPDA):  showed a small amount 
of total, likely cleaved, BNP (dark circles). There was no intact BNP1-32 (red line, open 
circles). The green and yellow lines demonstrate that most of the immunoreactivity is 
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exclusively due to NT-proBNP with no proBNP at all.  
Group 2 (high initial NTproBNP, HsPDA but no BPD): Similar to group 1, but lacking in the 
BNP form (dark circles). NTproBNP predominates with no proBNP.  
Group 3 (high initial NTproBNP, HsPDA and BPD): The majority of immunoreactivity is NT-
proBNP but on closer inspection the results are more complex than Group 1 and 2.  The 
BNP assay detected both proBNP and BNP forms (approximately 50:50). The specific 
BNP1-32 assay also picked up a tiny amount of that peptide. Intact, non-T71 glycosylated 
proBNP is present (pale blue line). The T71 amino acid region is where proBNP gets 
cleaved by furin but in this group the proBNP is present and not cleaved. The yellow line 
shows that NT-proBNP predominates just like in Group 1 and 2.  
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Figure 36: BNP isoform by HPLC testing: Group 1 (no HsPDA, no BPD) 
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Figure 38: BNP isoform by HPLC testing: Group 3 (HsPDA, BPD)  
 
 Bottom graph shows enlarged detail of top graph 
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Discussion 
NTproBNP appears to be the predominant isoform across each of our clinical groups in 
our pooled sample analysis. It is not possible to comment on any changes over time as 
these samples were grouped together across time periods due to low remaining sample 
volume. Based on this data, it does not look likely that the differences in NTproBNP levels 
between infants with and without BPD and HsPDA seen at 36 weeks PMA are primarily 
due to differences in glycosylation status, although this cannot be definitively ruled out 
as a contributing factor. The small amount of larger than proBNP material at Fraction 22 
seen in group 3 could be a covalently bound, dimer or trimer of proBNP, possibly formed 
by opposing cysteines from each proBNP that link to an opposing proBNP, instead of to 
the other cysteine on their own peptide. Such observations have been made for a larger 
form of the related atrial natriuretic peptide molecule in human plasma.341 This observed 
material eluting from the SE-HPLC column is unlikely to be immunoglobulin G-bound 
proBNP as the conditions of the HPLC column would necessarily separate an antibody-
antigen complex. However, in a more benign SE-HPLC buffer, any immunoglobulin G 
bound to NTproBNP may still be present and should be the subject of further 
investigations. 
The major weakness of this study is that BNP isoform testing was not part of our original 
study protocol and this necessitated using what plasma was remaining after standard 
NTproBNP testing. As sample volumes taken from very premature infants are minimised 
to reduce iatrogenic anaemia this meant we were unable to test for differences in 
isoforms in all patients and at all times separately and had to pool samples. Care was 
taken with the chosen techniques to ensure we had adequate volumes to produce 
reliable results. However, to better understand changes in post-translation BNP 
processing and the effects of clinical condition and time, analysis should be conducted 
on larger samples of individual patient plasma at different time intervals. An additional 
limitation is that we cannot exclude the possibility of some enzymatic degradation of 
peptide during the processing and storage of samples. As the majority of samples were 
promptly separated and frozen, the impact is likely to be small. The inventory system 
used for the study did not document processing times and therefore did not allow you to 
evaluate any impact of delays in processing. This is, however, to the best of our 
knowledge, the first time BNP isoforms have been investigated in a very preterm sample 
and we have produced some novel results. Although some parallels could be drawn 
clinically between the chronic ventricular wall stress seen in adult heart failure and 
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effects on the right heart of chronic lung disease (BPD) in very premature infants we did 
not find, as is seen in adults, high amounts of circulating unprocessed proBNP. This 
suggests that all circulating BNP is likely to have full biological activity.  
In summary, this novel study of BNP isoforms in a very preterm population suggests NT-
proBNP is the major circulating form and that there appears to be minimal degradation 
in plasma. This suggests it is likely to be a robust marker in this clinical setting. However, 
we did find some subtle differences in detected isoforms in the infant group who had 
experienced HsPDA and BPD and this deserves further study to determine whether 
infants who experience both significant left and right heart strain have differential 
processing of BNP. 
 
Chapter 6  139 
 
 
Heart Ultrasound for the Diagnosis of Pulmonary 
Hypertension in Premature Infants 
Background 
The period after birth is a time of tremendous physiological change. Precipitous preterm 
delivery necessitates the rapid adaptation of an immature heart from a foetal circulation 
to neonatal circulation which may have long term consequences. Birth precipitates a 
switch in cardiomyocytes from hyperplastic to hypertrophic cardiac programming.44, 342 
The preterm myocardium is stiffer and demonstrates relative diastolic dysfunction 
compared to the term heart making it vulnerable to rises in preload and afterload.343, 344 
Premature birth exposes developmentally immature cardiomyocytes to relative 
hyperoxia combined with a sudden increase in systemic vascular resistance and a fall in 
pulmonary vascular resistance that alters the relationship between the left and the right 
side of the heart before cardiac maturation is complete. There is mounting evidence that 
these physiological changes or stressors cause alterations in cardiac structure and 
function that persist into adulthood.45, 328 
Premature infants have a more globular heart shape at birth with reduced heart mass 
and volume relative to body size.345 By three months of age biventricular hypertrophy is 
evident, the degree of which is negatively correlated with gestation at birth.345 At 6 
years, the left ventricle and left ventricular outflow tract of extremely preterm born 
children is significantly smaller with concentric rather than longitudinal contraction and 
evidence of diastolic dysfunction.346 The changes in the right ventricle have not been well 
characterised and are of particular relevance due to the potential impact of 
bronchopulmonary dysplasia. The onset of right ventricular dysfunction in adults with 
heart disease is closely associated with symptomatic decline, loss of functional capacity 
and reduced survival.237 Cardiac magnetic resonance imaging studies in adults born 
preterm have revealed smaller right ventricular cavity size with evidence of right 
ventricular hypertrophy and dysfunction that is proportional to gestational age at birth.45 
A study of adolescents born preterm demonstrated higher pulmonary artery pressures 
than term born controls with those with BPD having the highest pressures.71 Swedish 
population registry data also suggests preterm born adolescents and young adults have a 
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several fold increased risk of pulmonary hypertension (OR 8.5) even after adjusting for 
congenital heart disease and chronic pulmonary disease.70 Furthermore a study of adults 
born preterm with no evidence of resting pulmonary hypertension showed an 
exaggerated and abnormal rise in pulmonary artery pressure on exercise stress 
echocardiogram compared to term born controls but unexpectedly this was 
demonstrated primarily in those without a previous history of BPD.347 In addition a 
cardiac catheter study performed on well adults born preterm without known 
cardiorespiratory disease demonstrated preterm subjects had higher mean pulmonary 
arterial pressures with borderline pulmonary hypertension in 27% and overt pulmonary 
hypertension in 18%.69 Those born preterm had evidence of a stiffer vascular bed at rest 
and were less able to augment cardiac index or right ventricular stroke work during 
exercise.69 The long term impact of premature birth on cardiovascular health in 
adulthood demands further study of longitudinal preterm cohorts with particular 
attention to cardiac adaptation to preterm birth. 
Cardiac catheterisation is the gold standard for identifying pulmonary hypertension but is 
rarely used in preterm neonates as it is not widely available, is invasive and carries a 
morbidity risk. Heart ultrasound is readily available and non-invasive and so the 
preferred modality for evaluating for pulmonary hypertension. The most commonly 
accepted surrogate measure of pulmonary artery pressure is the peak velocity of the TR 
jet. However, this is often not present meaning other evidence must be sought.199, 207 
Alternative commonly used  but subjective criteria if a TR jet is not present are RV 
hypertrophy, dilatation, shortening of the pulmonary artery acceleration time and 
evidence of interventricular septal flattening. Targeted neonatal echocardiography 
guidelines now recommend a quantitative assessment of the RV function as an 
important component of the serial assessment of cardiac function in premature infants, 
particularly when pulmonary hypertension is suspected.204 Our understanding of how the 
impact of premature birth on cardiac development can be detected or quantified by 
heart ultrasound parameters is still evolving and there is limited published data on the 
effect of gestational and chronological age, growth and disease processes on 
quantitative measures of RV function.  
There are a number of factors that make heart ultrasound challenging in preterm infants: 
physiological instability with handling, high heart rates and respiratory rates, small 
acoustic windows with often hyperinflated lungs, vibration when on high frequency 
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ventilation and rapid circulatory changes after birth.  Because of the shape of the RV, 
assessment of its size and function is also more difficult than for the LV. Historically, RV 
systolic function assessment has been largely qualitative and subjective. Interobserver 
agreement and reproducibility for subjective RV assessment are suboptimal. More 
recently there has been a push to adopt measures of RV function that are objective, 
quantitative and that have more acceptable reproducibility, retest variability and 
interobserver agreement. A number of these are now widely used in the assessment of 
adults but data is lacking in the preterm population.  RV systolic function is complex and 
involves longitudinal, radial and circumferential components. No single index can 
adequately summarise RV function, but, as for the LV, it appears that changes in RV 
longitudinal function can be quantified and these are sensitive markers of overall 
function. 
The additional quantitative measurements evaluated in this study were selected on the 
basis that they have all been shown to be affected by pulmonary hypertension in other 
clinical settings.  
TAPSE can be measured from M-mode and is an excellent marker of longitudinal RV 
function that has excellent temporal resolution and so is helpful at higher heart rates. It 
can also be measured using 2D imaging when alignment with longitudinal motion is not 
possible, which allows differentiation of longitudinal shortening of the heart from motion 
due to translation. TAPSE is decreased in the context of pulmonary hypertension and 
heart failure in adult and paediatric settings and reference ranges have recently been 
published for preterm neonates.236, 237, 348, 349 209 
The ratio of main pulmonary artery acceleration time to RV ejection time (AT:RVETc) is a 
simply acquired measure that reflects pulmonary vascular resistance, pulmonary arterial 
compliance and RV function. A level of <0.31 is suggestive of raised pulmonary artery 
pressures with a level of <0.23 correlating well with severe pulmonary hypertension.350, 
351There is some debate over whether it needs to be corrected for heart rate.  Both raw 
MPA acceleration time and AT:RVET have been shown to have high sensitivity and 
specificity for predicting pulmonary vascular disease and raised pulmonary pressures 
when compared to cardiac catheterisation. 351 Significant interatrial or ductal shunts 
However, may make it difficult to interpret this measure. 
Early diastolic (E) and late diastolic (A) waves measured by conventional Doppler at 
tricuspid inflow or at the tricuspid annulus by TDI (E’ and A’) can be a useful measure of 
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diastolic function. The initial E wave reflects passive RV filling while the A wave reflects 
atrial contraction. In healthy children and adults the ratio of E:A is >1. However, in 
preterm neonates this ratio may be <1 reflecting relative diastolic dysfunction.213 The 
early diastolic wave is also reduced in children with pulmonary hypertension. 246 
Although easy to measure these waves often become fused and cannot be distinguished 
at high heart rates. They may also be affected by volume status and the use of inotropes. 
In addition progressive diastolic dysfunction will cause a rise in atrial pressure which can 
cause a “pseudonormal” ratio. Severe progressive diastolic dysfunction will cause the E 
wave to become much taller than the A wave although this will be accompanied by 
significant symptoms of heart failure. There is little published data on the normal range 
for this parameter in the preterm population of the changes in E/A over time.  
RIMP or right Tei index has the advantage of evaluating RV systolic and diastolic function. 
Using TDI TV systolic and diastolic velocities can be measured simultaneously decreasing 
effect of time dependent variables. It has demonstrated good reproducibility, low 
interobserver variability and is independent of both blood pressure and heart rate.352 It is 
higher in the presence of raised pulmonary pressures.235 There is little published data on 
the changes in RIMP over time in premature infants. 
Another TDI measure, TV S’, also known as the tricuspid annulus peak systolic velocity 
(TAPSV), is also a highly reproducible marker of RV longitudinal systolic function and is 
less dependent on acoustic window but can be affected by loading conditions. It is 
reduced with pulmonary hypertension and correlates with RV ejection fraction.242, 353  
Limitations of TDI include aliasing if the myocardial velocities are higher than the velocity 
scale. It is also angle dependent and requires high frame rates to ensure temporal 
resolution. Normal ranges for preterm infants within the first 48 hours of life have been 
published.242   
As ventricles are interdependent it is important to also consider left ventricular function 
when assessing for RV dysfunction. Many of the indices described are also used to 
evaluate LV function: Left ventricular index of myocardial performance, mitral valve 
annular plane of systolic excursion, E and A waves. In addition left ventricular output can 
also be calculated or an estimate of left ventricular ejection fraction made. For the 
purposes of our study we chose left ventricular fractional shortening (FS) in combination 
with subjective assessment of LV hypertrophy and dilatation. FS offers an estimate of LV 
function However, there it has limitations. Many would argue that left ventricular output 
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is a better measure in preterm infants and that more than one measure is needed, 
however, this would have lengthened scanning time which had to be limited in these 
fragile babies but we acknowledge a compromise was made.  
Gaps in current knowledge 
There is currently no consensus for diagnosing late pulmonary hypertension in preterm 
infants by heart ultrasound. There is a paucity of data regarding normal ranges for 
quantitative indices for evaluating RV function and the developmental changes in these 
measures over time. 
Hypotheses 
1. Specific quantitative markers of RV function will be measureable in very preterm 
infants by clinician performed heart ultrasound but some parameters will be more 
difficult to consistently attain and less useful than others 
2. The temporal profile of these quantitative measures of RV function will reflect growth 
and developmental changes in cardiac function  
Aims 
1. To assess a cohort of infants born at < 30 weeks gestation for pulmonary hypertension 
using conventional heart ultrasound criteria 
2. To evaluate the feasibility of clinician-performed quantitative heart ultrasound 
measures of RV function  
3. To document the temporal changes in quantitative measures of RV function in a 




Infants born at < 30 weeks gestation at Christchurch Women’s Hospital gestation 
between March 2013 and April 2015 were eligible. Any infants with persistent pulmonary 
hypertension of the newborn on day 3 or structural heart disease apart from PDA or 
patent foramen ovale or secundum atrial septal defect less than 5mm or tiny restrictive 
muscular ventricular septal defect was excluded from the study (see exclusions in 
methods chapter).  
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Machine factors and scan acquisition  
Scans were performed by neonatologists trained in advanced neonatal heart ultrasound 
(SH, BD, KM) using a 6.5 MHz probe on a Toshiba Aplio500.  
Infants were scanned in a supine position. No infants were scanned under general 
anaesthetic. All infants were given oral sucrose prior to or during scanning for comfort. 
Infants were scanned in an incubator or under a radiant heater to ensure 
thermoregulation was maintained. If an infant became physiologically unstable or 
distressed during a scan the scan was paused or terminated so that the infant could be 
stabilised or comforted. Infants were scanned under a range of respiratory support 
conditions: no support, nasal prong oxygen, high flow oxygen, continuous positive airway 
pressure, bi-level positive airway pressure, conventional ventilation and high frequency 
ventilation.  
No respiratory gating was used. No angle correction was performed. Care was taken to 
optimise focal depth and cursor alignment and to minimise the acoustic window to 
enhance image quality. Several images were taken and the best quality images used for 
offline measurements. Several measurements were taken (10-15 over several cardiac 
cycles) and then averaged to reduce intraobserver variability. Most of the scans were 
performed by a single scanner (SH) to minimise interobserver variability. Interobserver 
variability was not formally assessed due to the impact of sequential scanning by a 
different operator on a medically compromised infant.  A paediatric cardiologist who was 
blinded to clinical condition of the infant, the results of previous scans, NTproBNP testing 
and pulse oximetry analysis, independently reviewed all scans performed at 36 weeks 
PMA for evidence of pulmonary hypertension according to predefined criteria 
(documented in Table 4 in methods chapter). 
Ultrasound imaging protocol 
Cardiac structure was assessed using the clinician performed heart ultrasound protocol 
described in methods chapter and based on recommendations by Australasian Society of 
Ultrasound Medicine (Appendix C). When a patent ductus arteriosus was present it was 
classified as haemodynamically significant by predefined criteria defined based upon 
those commonly employed in neonatal studies (described in methods chapter).180 
Concurrent blood pressure was measured (invasively if an arterial line was in situ or non-
invasively if not). 
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For our primary aim of assessing for pulmonary hypertension, conventional diagnostic 
heart ultrasound criteria were used based on the presence of a significant TR jet or 
alternative criteria if TR jet was absent. These criteria are described in detail in Table 4 in 
methods chapter. 
Additional quantitative heart ultrasound indices that were assessed are outlined below. 
For more detail on how these parameters were acquired see methods chapter. 
1. Tricuspid annular plane of systolic excursion (TAPSE): 
TAPSE was assessed by measuring total excursion of tricuspid annulus during ventricular 
systole with M-mode using the apical four chamber view. Care was taken to align the 
cursor with the direction of longitudinal movement of the tricuspid annulus. TAPSE z 
score was calculated using an online calculator (http://dev.parameterz.com/tapse) based 
on the reference data provided in the paper by Koestenberger.209 This reference dataset 
did not provide z scores for infants born at <26 weeks. The calculator developer states 
the 1SD values are calculated by first determining if the measured value (score) is above 
or below the mean, then dividing by two the difference between the mean and the 
appropriate 2SD value, e.g. SD = [+2SD - mean] / 2 . The z-score is then calculated in the 
conventional manner: z = [score - mean] / SD. 
2. Conventional Doppler E and A velocities: 
E and A wave velocities were evaluated using conventional pulse-wave Doppler on an 
apical four chamber view with the Doppler cursor sampling tricuspid inflow.  
3. TV tissue Doppler E’, A’ and S’ (TAPSV): 
E’, A’ and S’ velocities were interrogated using tissue Doppler imaging of the tricuspid 
annulus using an apical four chamber view. 
4. Right index of myocardial performance (RIMP) 
RIMP was interrogated using TDI of the tricuspid annulus and calculated using the 
formula: RIMP = (IVCT+IVRT)/RVET = TCOT-RVET/RVET  
(IVCT = isovolumetric contraction time. IVRT= isovolumetric relaxation time. RVET = right 
ventricular ejection time. TCOT= tricuspid closure to opening time). 
5. Ratio of pulmonary artery acceleration time to RV ejection time (AT:RVETc): 
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The ratio of main pulmonary artery time to peak acceleration to right ventricular ejection 
time was evaluated using pulse Doppler with the cursor sampling the main pulmonary 
outflow immediately below the pulmonary valve. An electrocardiograph tracing was run 
concurrently to measure heart rate and this ratio was corrected for heart rate (by RR 
interval on concurrent electrocardiogram) using the formula: 
AT:RVETc= (AT/RVET) 
                       √R-R  
6. LV fractional shortening (FS): 
Left ventricular end-diastolic diameter (LVEDD) and end-systolic diameter (LVESD) were 
evaluated using M-mode on a LV focussed parasternal long axis view with the M-mode 
cursor placed perpendicular to the intraventricular septum just below level of mitral 
valve. Fractional Shortening was then calculated using the formula: 
FS% =     (LVEDD-LVESD)  X 100 
  LVEDD 
 Statistical analysis 
Mean and standard deviation and/or median with interquartile ranges were performed 
for all quantifiable continuous heart ultrasound parameters. Dichotomous variables were 
reported as frequencies.  The relationship between BPD and these ultrasound 
measurements was compared for both the dichotomous BPD definition of need for 
oxygen or respiratory support at 36 weeks PMA as well as the NICHD graded BPD 
definition.287 Analysis of associations between BPD status and ultrasound parameters 
was conducted using Chi square or Fisher’s exact tests for comparison of percentages 
and t-test for independent samples for comparison of means.  
Changes in TAPSE were modelled using linear mixed effects regression in which the 
repeated assessments of TAPSE were modelled as a function of chronological age and 
predictors. Modelling was limited to the interval from day 3 to day 28 due to the high 
variability in chronological age at the 36 week assessment. A small number of 
observations (n=7) of body surface area at day 3 were missing due to missing data on 
length at birth. For the purposes of the regression modelling these observations were 
imputed using day 10 length to predict birth length. Marginal predicted trajectories 
(means and 95% CI) in TAPSE at varying centiles of body surface area were calculated 
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from the fitted model adjusting for other predictors. TAPSE at 36 weeks PMA was 
modelled using multiple linear regression. All analyses were conducted using Stata 15. 
With a sample size of 51 the study had 80% power at α2=.05 to detect a correlation 
between TAPSE and a predictor in excess of .40, suggesting that the study was 
adequately powered to detect only moderate to strong associations. 
A mixed effect regression model was used to predict TAPSV in which the repeated 
assessments of TAPSV were modelled as a function of chronological age and potential 




53 infants were recruited. Two were excluded due to a large VSD and multiple cardiac 
rhabdomyomas. Two infants died between day 28 and 36 weeks PMA. 31 of 49 survivors 
developed BPD. Mean (SD) gestational age 27.8 (1.5) weeks.  
Structural heart assessment findings 
Table 26 shows a summary of structural findings over time focussing on the right heart 
and presence of shunts. No infant had any abnormality of aortic or mitral valvular 
structure or function. At 36 weeks PMA one infant had mild LV dilatation, no infants had 
LV hypertrophy and LV contractility appeared normal.  
Table 26:  Clinician performed heart ultrasound summary findings on day 3,10,28 and 36 weeks PMA 






36 weeks  
n=49 
%(n) Pulmonary stenosis 0(0) 0(0) 0(0) 0(0) 
%(n) Pulmonary regurgitation* 16(8) 8(4) 16(8) 16(8) 
%(n) Significant tricuspid regurgitation** 0(0) 0(0) 0(0) 0(0) 
%(n) RV dilatation 0(0) 0(0) 0(0) 2 (1)*  
%(n) RV hypertrophy 0(0) 0(0) 0(0) 2 (1)*  
%(n) PFO/small ASD 74(38) 67(34) 57(29)  43(21) 
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36 weeks  
n=49 
%(n)VSD 0(0) 0(0) 0(0) 0(0) 
%(n) PDA 74(38) 51(26) 27(14) 24(12)  
%(n) HsPDA 49(25) 31(16) 16(8) 4(2) 
*All cases of PR were trivial and were not associated with any other signs of raised 
pulmonary pressure. All detected RV hypertrophy and dilatation was mild. ** TR jet 
considered significant if full envelope seen and peak velocity ≥ 3m/s  
Conventional ultrasound criteria for pulmonary hypertension 
Agreement between paediatric cardiologist (blinded to clinical details) versus neonatal 
paediatrician (not blinded) assessment for pulmonary hypertension, by predefined 
criteria, at 36 weeks PMA is summarised in Table 27. None of our study cohort met the 
predefined criteria for pulmonary hypertension at 36 weeks PMA as assessed by 
paediatric cardiologist or neonatologist. Some infants had interventricular septal wall 
flattening, however, there was disagreement on this between cardiologist and 
neonatologist (agreement occurring on only three infants). 
Table 27: Comparison of paediatric cardiologist versus neonatal paediatrician assessment of heart ultrasound 
at 36 weeks PMA for pulmonary hypertension 
Heart ultrasound parameter Number of infants  
(paediatric cardiologist 
assessment) n=49 
Number of infants 
(neonatal paediatrician 
assessment) n=49 
Significant TR jet* 0  0 
Right ventricular hypertrophy 0 1(mild) 
Right ventricular enlargement 1 (mild) 1(mild) 
Interventricular septal  
- flattening  







Shortening MPA acceleration 
time 
2 (mild) 2(mild) 
Meets criteria for pulmonary 
hypertension 
0 0 
* TR jet considered significant if full envelope seen and peak velocity ≥ 3m/s  
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Summary Statistics for Quantitative Heart Ultrasound Parameters 
The majority of quantitative heart ultrasound measures were reliably acquired in all 
subjects (Table 28). This was particularly true for TAPSE. The TDI E’/A’ ratio was unable to 
be acquired consistently due to wave fusion at high heart rates.  A significant discrepancy 
was noted between E/A and E’A’ early in analysis so further assessment of E’/A’ was 
abandoned.  
Table 28: Data acquisition for quantitative heart ultrasound measures 
Parameter Day 3  
n=51(%) 
Day 10  
n=51(%) 
Day 28  
n=51(%) 
36 weeks PMA 
n=49 (%) 
TAPSE 51(100) 50(98) 46(90) 48(98) 
TAPSV 47(92) 44(86) 45(88) 45(92) 
RIMP 46(90) 43(84) 45(88) 46(94) 
E/A  40(78) 39(76) 29(57) 28(57) 
AT:RVETc 33(65) 43(84) 45(88) 48(98) 
LV FS 51(100) 49(96) 49(96) 47(96) 
 
There were changes over time in some but not all ultrasound parameters of RV and LV 
function for the cohort as a whole (Table 29).  When stratified by BPD status (Table 30), 
between group differences just reached significance for TAPSE at day 10 and 36 week 
PMA and AT:RVETc on day 3. There were no significant differences found in any of these 
measures by BPD severity.  
Table 29: Summary statistics for heart ultrasound parameter values at days 3, 10, 28 and 36 weeks PMA 
Measure Day 3 Day 10 Day 28 36 Weeks 
TAPSE 
Median 5.60 6.45 7.95 10.6 
IQR 4.9 – 6.2 5.9 – 6.9 7.4 – 8.7 9.7 – 11.4 
Mean (SD) 5.56 (0.91) 6.45 (1.00) 8.00 (1.15) 10.50 (1.20) 
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Measure Day 3 Day 10 Day 28 36 Weeks 
TAPSE 
z-score 209 
Median 0.53 1.38 2.31 3.93 
IQR -0.67 – 1.69 0.55 – 2.66 1.11 – 3.65 2.71 – 4.93 
Mean (SD) 0.58 (1.56) 1.40 (1.69) 2.46 (1.97) 3.74 (1.71) 
RIMP 
Median 0.32 0.31 0.30 0.27 
IQR 0.26 – 0.45 0.25 – 0.39 0.23 – 0.37 0.23 – 0.35 
Mean (SD) 0.37 (0.14) 0.33 (0.11) 0.30 (0.09) 0.31 (0.11) 
TAPSV 
Median 5.8 6.7 7.9 9.2 
IQR 5.2 – 6.3 5.9 – 7.4 7.3 – 8.4 8.7 – 10.0 
Mean (SD) 5.73 (0.88) 6.70 (0.98) 7.81 (0.92) 9.09 (1.08) 
AT: RVETc 
Median 0.52 0.55 0.53 0.51 
IQR 0.45 – 0.58 0.47 – 0.64 0.44 – 0.59 0.46 – 0.59 
Mean (SD) 0.50 (0.10) 0.56 (0.13) 0.52 (0.10) 0.52 (0.11) 
E/A 
(Doppler) 
Median 0.64 0.70 0.68 0.80 
IQR 0.58-0.73 0.59-0.75 0.64-0.74 0.76-0.91 
Mean (SD) 0.64 (0.10) 0.70 (0.14) 0.70 (0.11) 0.84 (0.18) 
LV FS 
Median 39 38 36 37 
IQR 34 – 44 33 – 41 31 – 41 32 – 41 
Mean (SD) 38.5 (8.2) 37.8 (9.2) 35.9 (9.2) 35.5 (8.4) 
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Table 30: Mean (SD) heart parameter values at Days 3, 10, 28 and 36 Weeks PMA by ANZNN BPD or death 
classification 
Measure  No BPD (n=18) 




Day 3 5.7 (0.7) 5.5 (1.0) 0.50 
Day 10 6.9 (0.9) 6.2 (1.0) 0.02 
Day 28 8.3 (1.3) 7.9 (1.1) 0.22 
36 Weeks PMA 11.0 (1.1) 10.2 (1.2) 0.04 
TAPSE z-
score 
 Day 3 0.4 (1.3) 0.7 (1.7) 0.55 
Day 10 1.7 (1.7) 1.2 (1.7) 0.34 
Day 28 2.4 (1.9) 2.5 (2.0) 0.86 
36 Weeks PMA 4.2 (1.7) 3.5 (1.7) 0.16 
RIMP 
Day 3 0.36 (0.13) 0.37 (0.14) 0.94 
Day 10 0.34 (0.13) 0.32 (0.10) 0.48 
Day 28 0.33 (0.11) 0.29 (0.08) 0.20 
36 Weeks PMA 0.29 (0.14) 0.31 (0.10) 0.60 
TAPSV 
Day 3 5.7 (0.9) 5.7 (0.9) 0.94 
Day 10 6.4 (0.8) 6.8 (1.0) 0.18 
Day 28 8.0 (0.8) 7.7 (1.0) 0.29 
36 Weeks PMA 9.2 (1.0) 9.0 (1.2) 0.68 
AT: RVETc 
Day 3 0.56 (0.06) 0.47 (0.10) 0.01 
Day 10 0.60 (0.10) 0.53 (0.14) 0.08 
Day 28 0.54 (0.09) 0.51 (0.10) 0.23 
36 Weeks PMA 0.52 (0.11) 0.52 (0.10) 0.93 
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Measure  No BPD (n=18) 




Day 3 39.1 (8.2) 38.2 (8.4) 0.73 
Day 10 37.3 (7.8) 38.0 (10.1) 0.81 
Day 28 34.3 (7.8) 36.8 (9.9) 0.38 
36 Weeks PMA 34.6 (8.1) 36.0 (8.7) 0.59 
  
Tricuspid Annular Plane of Systolic Excursion (TAPSE) 
Ease of acquisition 
TAPSE was relatively easily acquired once care was taken to align sample beam 
perpendicular to the motion of the tricuspid annulus. Only 7 out of 202 TAPSE 
measurements were not recorded, with three being poor quality images due to incorrect 
angle of insonation and four not done. 
 
Change over time and factors affecting TAPSE 
TAPSE values increased in linear fashion over the period day 3 to day 28 (Fig. 39). A linear 
mixed effects regression analysis was conducted to model the change in TAPSE over time 
to day 28 (Table 31). This analysis showed statistically significant effects of age, gender 
and (time dynamically assessed) BSA. When other factors were taken into account mean 
TAPSE was higher for females and those with greater body surface area. However, 
increase in TAPSE was unrelated to gestation, use of antenatal steroids, BPD status or the 
presence of HsPDA on day 3. Tests for multiplicative age by predictor interactions 
showed no evidence of significant interactions, indicating that the rate of increase did 
not vary with levels of the predictor variables. From the fitted model estimates of 
average change in TAPSE at varying centiles of body surface area were made, adjusting 
for other predictors in the model (Table 32).  
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Figure 39: Individual TAPSE trajectories day 3 to day 28 and mean linear trajectory over time with 95%CI 
(shaded) 
 
Table 31: Linear mixed effects regression model predicting change in TAPSE day 3 to day 28 
Measure B(SE) p 
Intercept 6.2 (2.2) 0.006 
Age (days) 0.07 (.01) <0.001 
Female 0.41 (.18) 0.023 
Birth weight z-score 0.23 (.14) 0.10 
Gestation at birth (weeks) -0.10 (.10) 0.33 
Body surface area (m2) 23.1 (11.3) 0.041 
Antenatal steroids -0.40 (.32) 0.22 
BPD (or death) -0.16 (.21) 0.46 
HsPDA day 3 0.14 (.18) 0.44 
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Table 32: Observed centiles (25th, Mean, 75th) of body surface area (BSA) at days 3, 10, and 28, and 
predicted mean (95% CI) TAPSE(mm) by centiles of BSA adjusted for gender, gestation at birth, birthweight z-
score, receipt of antenatal steroids, BPD status and presence of HsPDA day 3 
Measure Day 3 Day 10 Day 28 
Centiles of Body Surface Area (m2)   
 25th Centile 0.091 0.099 0.118 
 Mean 0.100 0.106 0.127 
 75th Centile 0.107 0.115 0.139 
Predicted Mean TAPSE (95% CI)   
 25th Centile 5.49 (5.21 – 5.76) 6.15 (5.91 – 6.40) 7.83 (7.51 – 8.17) 
 Mean 5.70 (5.50 – 5.90) 6.32 (6.15 – 6.49) 8.04 (7.77 – 8.32) 
 75th Centile 5.86 (5.60 – 6.12) 6.53 (6.28 – 6.77) 8.32 (7.94 – 8.71)  
 
Predictors of TAPSE at 36weeks PMA  
As noted in methods, the wide variability in chronological age at the 36 week assessment 
made it difficult to incorporate data from this assessment in the mixed effects growth 
model above. A separate multiple regression analysis was conducted to examine 
predictors of TAPSE at 36 weeks PMA (Table 33). This showed that birthweight z-score 
was the only significant predictor of TAPSE (p=0.01). Other factors including BSA, 
gestation at birth, gender, receipt of antenatal steroids, BPD status, and presence of 
HsPDA were unrelated to TAPSE at 36 weeks PMA. 
Table 33: Multiple regression model predicting TAPSE at 36 weeks PMA 
Measure B(SE) p 
Intercept 10.2 (4.9) 0.044 
Female -0.40 (.35) 0.26 
Birth weight z-score 0.61 (.23) 0.013 
Gestation at birth (weeks) 0.07 (.12) 0.54 
Body surface area (m2) -3.5 (16.2) 0.83 
Antenatal steroids -0.63 (.82) 0.45 
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Measure B(SE) p 
BPD (or death) -0.56 (.35) 0.12 
HsPDA day 3 0.22 (.34) 0.52 
 
TAPSE z scores 
TAPSE z scores based upon the Koestenberger209 dataset increased over the four time 
periods (Table 29, Fig. 40). In our cohort mean (SD) TAPSE z-score at 36 weeks PMA was 
not significantly different between those with and without BPD (Table 30). 
 
Figure 40:  TAPSE z-scores over time 
 
Right Index of Myocardial Performance (RIMP)  
RIMP, interrogated by tissue Doppler imaging, was compared across the four time 
periods for the whole cohort and by BPD status. Technically this was a challenging 
parameter to acquire, being angle dependent and interfered with by high frequency 
ventilation vibrations, however, the overall RIMP data acquisition success rate was 89%. 
RIMP trended down over the four time intervals with no statistically significant 
difference seen between those who developed BPD and those who did not (Tables 29, 
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E/A ratio tricuspid inflow 
E/A ratio of Doppler-derived tricuspid inflow has been used in adults to look at RV 
dysfunction but due to high heart rates in our neonatal cohort the peaks were often 
fused on and it was often only measurable in approximately 2/3 of infants. Due to the 
high rate of missing E’ and A’ data (due to fusion of peaks at high rates) and a significant 
observed discrepancy between E/A and E’/A’ where data was available, no further 
analysis has been undertaken of E’/A’. Overall there was a trend toward increasing E/A 
over our four assessments times but the ratio remained <1 (Table 29). 
Tricuspid Annulus Peak Systolic Velocity (TAPSV) ( S’) 
TAPSV by TDI relied on the same technique as RIMP and as such suffered the same 
technical difficulties in acquisition. In this cohort TAPSV increased over time, however, 
there was no significant difference in TAPSV by BPD status (Tables 29, 30).  A mixed 
effect regression model (Table 34) for predicting TAPSV showed a highly significant effect 
for age and age-squared reflecting curvilinear growth but gestational age was non-
significant. Birthweight z score was highly significant but BSA was not.  





Age (days) 0.106 (0.014) <0.001 
Age2 -0.00074 (0.00017) <0.001 
Body surface area (m2) -0.068 (8.914) 0.99 
Gender 0.118 (0.158) 0.45 
Gestation at birth (weeks) 0.041 (0.097) 0.67 
Birthweight z-score 0.396 (0.119) <0.001 
 
AT:RVETc 
This ratio was unable to be assessed when there was turbulence in the main pulmonary 
artery such as secondary to a haemodynamically significant PDA. This resulted in a large 
amount of missing data for the day 3 scan. This ratio remained stable across the four 
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assessment periods with no significant difference seen in infants with and without BPD 
(Table 29, 30).  
Fractional Shortening (FS) of Left Ventricle 
This measurement was easily acquired but care needed to be taken to align the M-mode 
cursor perpendicular to the intraventricular septum. FS remained stable over time and 
there were no significant differences seen between infants with and without BPD (Table 
29, 30).  
Discussion 
General comments 
It has been estimated that pulmonary hypertension occurs in 18-37% of infants born 
prematurely usually in association with moderate to severe BPD. 64, 80-82 We present a 
study of a general population of infants born very preterm selected on the basis of 
gestational age rather than risk of pulmonary hypertension and followed prospectively.  
No infants in our study had pulmonary hypertension as defined by a set of conventional 
heart ultrasound parameters by 36 weeks PMA. It is likely the incidence is less in a 
general population of very preterm infants compared to higher risk or retrospectively 
selected populations and our study is in agreement with a similar study recently 
published in Australia. Stoecklin et al assessed for evidence of pulmonary hypertension 
and RV dysfunction at 36 weeks PMA in 197 infants born at <32 weeks gestation (73 with 
BPD) and found minimal evidence of pulmonary hypertension.354  Any screening or 
surveillance programmes will need to identify risk factors in addition to gestational age if 
they are to be cost-effective.   
There is currently no consensus for diagnosis of late pulmonary hypertension in very 
preterm infants and some may argue that our criteria were too conservative. 
Conventional diagnostic criteria may not be sensitive enough for detecting late 
pulmonary hypertension, which, unlike acute PPHN, develops gradually beyond the 
period of transitional circulation, allowing time for the heart to adapt and potentially 
masking dysfunction. The most widely accepted proxy for main pulmonary artery 
pressure, the peak velocity of the tricuspid regurgitation jet, is not present in all infants 
with pulmonary hypertension and may be underestimated due to an inadequate or off-
centre Doppler envelope.80, 199 Some pulmonary hypertension research groups would 
argue that simply the presence of RV hypertrophy or septal flattening is enough to 
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confirm abnormally high pulmonary pressures.80, 84 Septal flattening or bowing at end 
systole may hold promise as a marker of raised RV pressure which in the absence of 
pulmonary stenosis is likely to reflect raised pulmonary artery pressure. It is easily 
assessed and is also an indicator of the relative pressure difference between the left and 
right ventricle. However, evaluation is subjective and there was some disagreement 
between neonatologist and cardiologist on this parameter. It is likely that this finding will 
be more relevant if moderate to severe flattening is present although mild flattening 
may warrant a follow-up scan. Septal flattening may be better assessed using a 
quantitative measure such at LV eccentricity index which has been shown to have less 
interobserver variability.206  
Our assessment time of 36 weeks PMA may arguably be too early to exclude pulmonary 
hypertension. Studies have suggested that pulmonary hypertension may take many 
weeks to evolve and studies that have included scanning beyond term equivalent age 
have shown a median age at diagnosis of 2-4 months of age but some not detected for 
several months beyond term equivalent.62, 80, 112 The optimum time for screening for 
BPD-associated pulmonary hypertension has not yet been established. The absence of 
significant pulmonary hypertension in our cohort does not preclude the existence of 
occult pulmonary vascular disease with dysfunctional pulmonary vessels at risk of 
decompensation when put under stress such as a respiratory infection or general 
anaesthetic.  
When formulating a consensus definition of pulmonary hypertension using heart 
ultrasound criteria, the ease of acquisition and reproducibility must be considered. With 
some training we showed it was possible for more advanced, quantitative parameters to 
be incorporated into clinician performed heart ultrasound in preterm infants although 
some measures were more difficult to consistently acquire. It must be noted that 
acquiring these parameters considerably lengthens scanning time which may 
compromise the infant and behoves the clinician to only perform assessments that are of 
relevance to clinical care.  
TAPSE 
TAPSE is a simple and reproducible heart ultrasound parameter that can be mastered by 
neonatologists. TAPSE has been shown to have relatively low intraobserver variability and 
modest interobserver variability. Eriksen et al reported intraobserver variation of 5.5% and 
interobserver variation of 9.8%. 355 Jain et al reported intraclass correlation coefficient 
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(ICC) of 0.97 (95% CI 0.93-0.99) and coefficient of variation (CV) of 3.4% for intraobserver 
variability and an ICC of 0.52 (95%CI 0.11-0.78), CV 10.9% for interobserver variability.239  
Repeated examinations are therefore best done by the same examiner. This cohort 
demonstrated a linear trajectory for TAPSE. BPD had minimal effect on TAPSE in our cohort 
even when lung disease was severe. Although TAPSE z score at birth was similar to the 
Koestenberger cohort, z score subsequently and unexpectedly increased over time. This is 
unlikely to be explained by differences in growth as the reference dataset excluded infants 
who were small for gestational age and the mean birth weight z score of our cohort was -
0.10 and 0.15 by 36 weeks PMA.  TAPSE is affected by the angle of insonation.  However, 
if the beam is not correctly aligned with the direction of annulus displacement this would 
be expected to lower rather than increase TAPSE. The reference z scores for TAPSE in 
preterm infants are based on TAPSE measured within 48 hours of birth in a low risk healthy 
preterm population without BPD. The impact of preterm birth and subsequent neonatal 
course on TAPSE is not known. Levy et al have demonstrated that RV Fractional Area 
Change, another measure of RV function, increases at twice the rate over the first month 
of life in preterm infants compared to term infants.356 The increasing TAPSE z score beyond 
the period of transitional circulation may reflect functional adaptive changes of an 
immature myocardium to the challenges of preterm birth. TAPSE may well have diagnostic 
and prognostic utility in monitoring the impact of preterm birth on cardiopulmonary 
outcomes, however, further research with larger preterm cohorts is needed to establish 
reference ranges for TAPSE over time and to establish whether a failure of TAPSE to 
increase at the expected rate is associated with pulmonary hypertension, poor respiratory 
outcomes or increased mortality.  
 
RIMP 
Tissue Doppler RIMP was technically difficult to acquire. Even in the hands of skilled 
clinician scanner it may be difficult to obtain in some infants and may be prone to 
interobserver variability. Previous studies have suggested that RIMP tends to fall after 
birth but may be elevated in infants with BPD.235, 357 RIMP in our cohort did not vary 
greatly across our four assessment times. The relative stability across time suggests it 
may be independent of body size which could be a useful feature in circumstances where 
there is rapid growth. However, larger cohorts have found a greater difference over 
time.222 We could not demonstrate a significant difference between those with and 
without BPD consistent with the Di Maria cohort. 222 Low intraobserver variability (ICC 
 
Chapter 6  160 
 
0.97 (95% CI 0.92-0.98), CV 9.5%) but greater interobserver variability (ICC 0.80 (95% CI 
0.56-0.92), CV 20.9%) has been demonstrated for RIMP in term babies suggesting serial 
exams should be performed by the same person.239  
TAPSV 
TAPSV appears to be a useful measure of RV function over time. Koestenberger showed 
excellent ICC for interobserver (0.97) and intraobserver (0.98) variability.214 Jain el al also 
reported low intraobserver variability (ICC 0.96 (95%CI0.89 to 0.98), CV 3.7%) and low 
interobserver variability (ICC 0.94 (95%CI 0.86 to 0.98) CV 4.9%). 239  
TAPSV was able to be acquired for most scans in our cohort and increased over time in our 
cohort consistent with other studies.202, 214, 354 We could not demonstrate any significant 
differences in TAPSV in infants with and without BPD in agreement with the study by 
Stoecklin.358 The day 3 and 36 week values in our study were similar to that seen in a 
Scandinavian study of more mature premature infants scanned on day 3 and term 
equivalent age.202 When compared to the Koestenberger cohort who were born at a 
similar gestational age but only scanned within 48 hours of birth, the day 3 TAPSV was 
similar, however, by 36 weeks PMA the TAPSV in our cohort was closer to that of a 2-3 
month old term born infant.214 This suggests that chronological age has an impact on 
TAPSV and that infants reaching a corrected gestation will have higher TAPSV than those 
born at that gestation. Whether this reflects cardiac adaptation to preterm birth, and 
whether this persists beyond the neonatal period, requires further study.  
AT:RVETc 
Although relatively easy to acquire in the absence of a PDA, AT:RVETc could not be 
measured when there was pulmonary artery turbulence which is common with 
concurrent PDA. The assessment of MPA Doppler acceleration time has the potential to 
be highly subjective as it may not have a sharply defined peak leading to interobserver 
variability.359 All but one of our cohort had an AT:RVETc at 36 weeks PMA within the 
currently accepted normal range. We were not able to demonstrate a difference 
between those with and without BPD. It is likely to be a parameter that is useful if 
significant shortening is present but a normal AT:RVETc will not exclude pulmonary 
hypertension. In our cohort it did not appear particularly discriminating and could not be 
recommended alone as a means of determining the presence of raised right heart 
pressures. 
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E/A and E’/A’ 
Due to the high heart rates seen in preterm infants causing fusion of the early and late 
diastolic waves this measure cannot be consistently measured making it less useful to 
the neonatologist. Furthermore we found a discrepancy between Doppler and TDI 
acquired ratios and surmise that this may relate to E’ and A’ being angle dependent. Our 
mean day 3 E/A ratio was similar to those seen on day 1 in another preterm cohort.213 To 
the best of our knowledge there are currently no normal ranges in preterm infants 
outside of the first few days of life. As it may be affected by loading conditions it may be 
unreliable. However, it is interesting to note that across all time points we assessed the 
E/A ratio remained <1 suggesting some degree of diastolic dysfunction persists out to 36 
weeks PMA.  
Fractional shortening 
Although left ventricular output or LV ejection fraction(calculated by biplane Simpson's 
or five-sixths area x length method) are often the preferred measures of LV function in 
premature newborns they are more time consuming to acquire than FS. In view of the 
large number of ultrasound assessments that were undertaken as part of this study FS 
was selected to decrease scanning time. FS can be affected by septal wall flattening or 
paradoxical movement secondary to raised RV pressures. In our cohort FS was stable and 
well preserved across all four assessments even in infants with BPD. Our results are 
similar to those published by Kozak-Barany in a more mature preterm cohort scanned in 
the first four days of life and at 1 month.360 It is acknowledged that FS does not taken 
into account preload or afterload conditions and mean velocity of circumferential fibre 
shortening or TDI strain measurements may be more accurate for assessment of LV 
function.  
Strengths and weaknesses 
Strengths of our analysis include the longitudinal assessment of multiple indices of 
cardiac function over four clinically meaningful time periods in a well characterised 
prospective cohort.  Weaknesses include a small study population, lack of a local term 
control group for comparison, minimal left ventricular quantitative assessment and the 
scans being performed by a clinician-scanner rather than a cardiac sonographer or 
paediatric cardiologist. We acknowledge that having three investigators conduct the 
scans in a small cohort may have introduced interobserver variability.  However, we did 
attempt to reduce this by having Dr Harris perform 90% of the scans.  We acknowledge 
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some measurements, in particular TAPSE, should also have been indexed against 
ventricular length.203, 361 This recommendation came after we had completed most of our 
scans and it was felt that we could not guarantee that dedicated LV views had been 
imaged that would accurately represent LV length and so have not conducted this 
indexing.  LV eccentricity index, RV fractional area change and speckle tracking are other 
parameters that hold promise that we did not assess these and warrant evaluation in a 
larger preterm population.  With regards to the linear regression analysis for the 
prediction of change in TAPSE, our sample size may be too small to allow the inclusion of 
8 predictors and there may be some collinearity between gestational age, BSA and 
birthweight z score. Further evaluation of all of our studied parameters in much larger 
preterm cohorts is needed. 
Conclusion 
It is feasible for advanced cardiac ultrasound parameters to be incorporated into clinician 
performed targeted neonatal echocardiography for the assessment of late pulmonary 
hypertension. However, consultation with paediatric cardiologist would be 
recommended if there is evidence of raised pulmonary pressures, particularly prior to 
commencing pulmonary vasodilators. It is essential the limitations of these 
measurements are understood and more work is needed to establish reference ranges in 
this population. In view of the complex three-dimensional orientation and movement of 
myocardial fibres we would recommend serial scanning utilising more than one type of 
tool to assess left and right ventricular function.  In our cohort right ventricular function 
appeared to be surprisingly well preserved in the face of even moderate to severe 
premature lung disease. We speculate that the foetal heart develops adaptive strategies 
after premature birth which may offer a short term survival benefit but could potentially 
lead to premature cardiac dysfunction in adulthood.
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Oxygen Saturation Targeting:  
Patterns of Instability and Optimising Care  
 
Background 
Premature infants are prone to periods of hypoxia and hyperoxia. The causes are 
multifactorial.  An immature brain predisposes premature babies to central apnoea while 
the relative proportions of upper airway structures and low muscle tone make them 
susceptible to obstructive apnoea.27 Both poor peripheral chemoreceptor sensitivity to 
hypoxia and upregulated peripheral chemoreceptor responses appear to contribute to 
ventilatory instability.362-364 An underdeveloped lung structure and surfactant deficiency 
create ventilation-perfusion mismatch and chronic inflammation further compromises 
gas exchange.365  
Supplemental oxygen is frequently required to support respiration. However, oxygen 
therapy for premature infants is a delicate balancing act.  Cellular function requires an 
adequate oxygen supply and yet an excess can result in oxidative cell damage.76, 248, 267, 366 
Excess oxygen is also a key protagonist in the development of pulmonary vascular 
disease which further aggravates intermittent hypoxia due to pathological 
vasoreactivity.73, 74, 367, 368  The interaction between oxidative stress and inflammation 
appears to be a particularly toxic cocktail in the development of pulmonary morbidity in 
very preterm infants.  
Our evolving understanding of this narrow therapeutic window has led to the practice of 
oxygen saturation targeting for premature infants. Pulse oximetry allows clinicians to 
continuously monitor fluctuations in oxygen saturations and heart rate. Optimal targets 
have been the subject of intense research scrutiny in recent years.89, 272, 273, 276, 277, 369, 370 
However, despite oxygen saturation targeting, very premature infants in high level 
intensive care units often spend more than half of their time outside of their allocated 
range.280, 281 There are a number of factors which influence the amount of time infants 
spend within their target range. These include how narrow the set targets are, how close 
the alarm settings are to the targeted range, the nurse to patient ratio and the clinical 
risk profile of the population being studied.280, 281, 371, 372 Adherence to unit policies 
regarding oxygen saturation alarm limits is also variable. In a study by Clucas and 
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colleagues the lower alarm limit was set correctly 91% of the time but the upper alarm 
limit was only set correctly 23% of the time with only 22% of infants studied having both 
alarm limits set correctly.283.  Implementing new education programmes for nursing staff 
may not significantly increase the time spent in target.281, 369, 372. 
Software is now available that can process stored oxygen saturation and heart rate data. 
This facilitates the in-depth analysis of oxygen saturation instability. Clinicians can 
identify infants who may require more respiratory support or who are experiencing 
iatrogenic hyperoxia. Modern oximeters and cardiorespiratory monitors have multiple 
ways in which respiratory instability can be evaluated. These include histograms which 
can be set up to show time in target over a set period, mean oxygen saturation, 
coefficient of variation (CV) and desaturation event index (DSI).  
Gaps in current knowledge 
There has been little published on optimal measures of oxygen saturation instability that 
may be of use to the neonatologist.285 Further study of oxygen saturation instability 
patterns and the factors that contribute to this instability is needed in order develop 
strategies to improve stability and to understand what role, if any, oxygen saturation 
monitoring may have in identifying infants developing pulmonary vascular disease. More 
detailed analysis of oxygen saturations will also highlight iatrogenic hyperoxia, a known 
contributor to the development of late pulmonary hypertension in very premature 
infants. 
Hypotheses 
1. The pattern of oxygen saturation instability will vary over time in very preterm infants 
2. Infants who develop BPD or later pulmonary hypertension will have evidence of  
greater oxygen saturation instability  
3. Poor compliance with oxygen saturation alarm limits is a contributing factor to 
exposure to hypoxia and hyperoxia in neonatal units 
Aims 
1. To conduct detailed analysis of 72 hour recordings of oxygen saturation data using a 
variety of measures of instability at four time intervals from birth to 36 weeks PMA and 
to compare these measures in infants with and without BPD and/or pulmonary 
hypertension   
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2. To audit unit compliance with oxygen saturation alarm protocols and to survey nursing 
opinion of oxygen saturation targeting in the NICU 
Methods 
Participants 
Infants born at < 30 weeks gestation between March 2013 and April 2015 and cared for 
at Christchurch Women’s Hospital NICU were eligible for participation. Infants were 
excluded if they had known structural airway or lung anomalies, congenital anomalies of 
the pulmonary arteries or pulmonary veins, major systemic vessel-to-pulmonary artery 
collateral vessels, congenital heart disease (except those with patent ductus arteriosus, 
patent foramen ovale or secundum atrial septal defect < 5mm or tiny restrictive 
muscular ventricular septal defect), severe liver disease, or persistent pulmonary 
hypertension of the newborn on day 3 heart ultrasound (defined as severe hypoxia 
associated with estimated main pulmonary artery pressure >25mmHg). If infants had a 
grave prognosis such that they were not expected to survive to day 3 they were also 
excluded. 
Clinical data collection  
Clinical data was collected including gender, gestational age, birth weight, antenatal 
steroids, HsPDA day 3, inotropic support, maternal smoking in pregnancy, respiratory 
support and treatment for apnoea with the respiratory stimulants caffeine or doxapram. 
BPD was defined by either the definition used by the Australia and New Zealand 
Neonatal Network (ANZNN) at the time (persistent oxygen or respiratory support 
requirement at 36 weeks PMA) or graded using the National Institute of Child Health and 
Human Development (NICHD) grading system.287 Pulmonary hypertension was defined 
by conventional heart ultrasound as detailed in the methods chapter. 
 
Oxygen saturation monitoring and data collection 
72 hours of oxygen saturation and heart rate data recorded on day of life 0-3, 7-10, 25-
28 and at 36 weeks PMA using a Masimo Radical 7 pulse oximeter (Masimo Corporation, 
Irvine, California) with a two second averaging time. PROFOX analysis software (PROFOX 
Associates Inc, Escondido, California) provided numerical oxygen saturation and heart 
rate summary data which included: 
1. Percentage time spent below 88%, below 80% and above 95% 
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2. Percentage time spent in target range 
3. Mean oxygen saturation level and standard deviation (SD) 
4. Desaturation event index 4% (DSI4%) - defined as number of episodes per hour where 
oxygen saturation decreased by ≥4%  
5. Desaturation Index 4% >10s - defined as number of episodes per hour where oxygen 
saturation decreased by ≥4% lasting longer than 10 seconds 
6. Coefficient of variation (CV) of oxygen saturation was calculated using the formula: 
 CV= SD/mean 
These variables enabled us to compare relative instability during periods of assessment. 
Time spent in target range and in hyperoxia while on oxygen (defined in this case as 
oxygen saturations >95%), has only been assessed for the first 3 days of life as this is a 
critical period of transition for the preterm infant. Target ranges were as specified by unit 
protocol, which was revised in August 2013, after publication of the BOOST II trial and 
differed depending on whether infant was receiving oxygen therapy or not (Table 35).292 
Time receiving oxygen was assessed using nursing observation charts that recorded 
fraction of inspired oxygen hourly. It had to be assumed that this was the inspired 
fraction for the whole hour even though it is possible there may have been some 
adjustments made during this period that were not documented. 
Table 35: Oxygen saturation targets before and after revision of targets August 2013 




Old targets  
(air) 




88-92% 90-92% 88-100% 90-100% 
32-36 
weeks 
92-95% 92-95% 92-100% 92-100% 
≥36 
weeks 
95-98% 95-98% 95-100% 95-100% 
 
An example of the graphical oxygen saturation and heart rate data for a clinically stable 
infant (DSI4% 15, CV 0.015) and a comparatively unstable infant (DSI4% 104, CV 0.067) 
are shown in Figs. 41 and 42 respectively. A low signal IQ reading is also displayed. 
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Masimo state in their product information that this is assessed using “advanced signal 
algorithms” to generate a confidence interval with “low signal IQ” warning displayed 
when there is <30% signal quality. The processing algorithms are commercially 
protected, however, the company maintain that it is still likely to represent a true 
recording with any complete disruption of data recorded as a gap in the tracing. 
Comparative studies have shown Masimo monitors employing signal extraction 
technology have high specificity and sensitivity for SpO2 even in the setting of movement 
or low perfusion.373, 374  
Our data was also manually reviewed for aberrant data points which were excised from 
the recording prior to analysis. This included any region at the start of the trace where 
readings were missing or erratic and data acquisition had not yet stabilised and any 
regions where either heart rate or SpO2 data were completely missing. Finally the 
recording was automatically scanned for aberrant data (defined as a difference of >10% 
in SpO2 or >20 beats per minute for heart rate from the previous or subsequent data 
point) and each identified point reviewed manually to determine whether it was likely to 
represent a real or artefactual data point.  
 
Figure 41: Snapshot of oxygen saturation and heart rate data over time in a stable infant 
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Figure 42: Snapshot of oxygen saturation and heart rate data in an unstable infant 
Audit of oxygen saturation monitor alarm limits and nursing survey 
Audit 
Oxygen saturation monitor alarm settings were audited at Christchurch Women’s 
Hospital Neonatal Intensive Care Unit, New Zealand, on randomly selected days and 
nights between June and October 2015. Nursing staff were not made aware of the audit. 
Monitor alarm setting and the gestation of the infant were recorded and whether the 
infant was on oxygen. These limits were then compared to unit policy (Table 36). Minor 
breeches of protocol were arbitrarily defined as ± ≤ 2 saturation points. Major breeches 
were defined as ± ≥ 3 saturation points.  
Table 36: Oxygen saturation alarm limit policy during audit 
PMA Alarm limits in oxygen Alarm limits in air 
<32 weeks 88-94% 88-100% 
32-36 weeks 90-96% 90-100% 
>36 weeks 93-99% 93-100% 
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Survey 
After these data were collected, during December 2015 to January 2016, we conducted 
an anonymous survey of bedside neonatal nursing opinion of oxygen saturation targeting 
in the same NICU (Appendix E). This survey was designed for this study and has not been 
validated. All neonatal nurses were invited to participate anonymously using either an 
electronic survey on Survey Monkey (www.surveymonkey.com) or in written form. The 
survey consisted of questions on nursing experience of participants and nursing practice, 
knowledge, and opinion of oxygen saturation targeting. The unit had a change in oxygen 
saturation target ranges in October 2015 after our audit period, in line with new national 
guidelines.375  The survey includes questions regarding both protocols. Survey responses 
were collated and analysed using Microsoft Excel 
Statistical analysis 
Changes over time in quantitative measures are described using mean (SD) and/or 
median (IQR). Chi square or Fisher’s exact tests were used for comparison of percentages 
and t-test for independent samples for comparison of means. Mann-Whitney test was 
used to compare medians where distribution was non-Gaussian. If needed, some 
measures were log transformed to stabilise the variance. Repeated measure ANOVA was 
used to test significance of mean differences in measures of oxygen saturation instability 
over time. Repeated measures ANOVA analysis was used to assess effect of group and 
time interactions. Mean differences in oxygen saturation measures by BPD status over 
time adjusting for gender, gestation, birthweight z-score and presence of HsPDA on day 
3 were estimated from linear regression models fitted to the repeated measures data for 
each fitted within a Generalised Estimating Equation (GEE) framework.297 Contrasts on 
the marginal predicted mean scores from the fitted models were calculated to test 
significance of covariate adjusted mean differences on oxygen measures over time. Box 
and whisker plots or scatter plots were used to display results graphically. Data were 
analysed using Stata 15, SAS 9.4 or GraphPad InStat software. The data for the oxygen 
saturation audit were collated and analysed using Microsoft Excel and results displayed 
descriptively as percentages.  
Results 
Clinical characteristics 
51 infants had oxygen saturation monitoring on the first 3 time points and 47 at 36 
weeks PMA (2 deaths and 1 missed, 1 infant was missed and had monitoring at 47 weeks 
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PMA but was included in analysis). Table 12 (Chapter 3) documents the clinical 
characteristics of our cohort as a whole and by BPD status. Two thirds of our cohort had 
BPD with 15.7% discharged on home oxygen. None of our cohort was diagnosed with 
pulmonary hypertension by our predefined criteria meaning no further analysis could be 
conducted with respect to this outcome. All infants received caffeine therapy for the 
prevention and treatment of apnoea of prematurity. 
 
Oxygen saturation summary results 
The median (IQR) hours of oxygen saturation data analysed was 71.3 (66.8-72.2) for day 
0-3, 71.5 (67.7-73.6) for day 7-10, 71.6 (68.2-72.9) for day 25-28 and 70.5 (68.0-73.9) for 
36 weeks PMA.  
Mean (SD) maximum oxygen requirement in delivery suite was 70% (25) and this was the 
same for those who developed BPD and those who did not. Median (IQR) hours on 
oxygen during the 72 hour assessment period was 15 (3-44.7) on day 3, 14 (0-48.7) on 
day 10, 27 (2-67.3) on day 28 and 29 (0-70.1) at 36 weeks PMA.  
Table 37 shows summary statistics for pulse oximetry measures over time. There was a 
trend towards all parameters worsening initially, peaking at day 28, and then improving 
by 36 weeks PMA. There was a wide variation in the data at all time points. Oxygen 
saturation instability at 36 weeks PMA was similar to that seen in the first 72 hours of life 
across most parameters.  
Table 37: Summary statistics for pulse oximetry measures over time  
Measure Day 3 Day 10 Day 28 36 weeks P* 
Oxygen saturation      
Mean (SD) 94.0 (1.8) 93.7 (2.0) 93.6 (2.2) 95.9 (1.6) <0.001 
Median (IQR)  94.4 94.0  94.0  95.8   
IQR 92.9-95.1 91.8-95 92-95 95.2-96.9  
% Time with SpO2 
<88  





3.9 (3.4) 6.5 (6.1) 9.5 (7.5) 3.8 (2.7) <0.001 
2.6 3.9 7.3 2.8  
1.6 – 5.9 1.8 – 9.6 4.6 – 10.9 1.8 – 5.1  
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Measure Day 3 Day 10 Day 28 36 weeks P* 
% Time with SpO2 
<80  





0.52 (0.48) 0.82 (0.96) 1.68 (1.55) 0.85 (0.84) <0.001 
0.40 0.40 1.30 0.50  
0.20 – 0.74 0.10 – 1.20 0.70 – 2.20 0.30 – 1.20  
Coefficient of 
Variation 





0.033 (0.007) 0.036 (0.011) 0.045 (0.011) 0.036 (0.010) <0.001 
0.031 0.035 0.045 0.033  
0.026 – 0.038 0.029 – 0.043 0.039 – 0.050 0.028 – 0.042  
Desaturation Index 
4% 





20.8 (6.8) 36.0 (11.3) 56.9 (12.1) 51.3 (20.6) <0.001 
20.1 36.5 57.6 50.8  
15.5 – 25.8 28.3 – 41.8 47.9 – 66.0 39.9 – 62.2  
Desaturation Index 
4% >10s 




14.2 (4.9) 22.1 (6.0) 27.9 (6.9) 17.7 (6.0) <0.001 
14.3 22.1 27.1 17.5  
(10.1-17.1) (18.5-25.4) (24.2-33.4) (14.4-21.5)  
* Repeated measures ANOVA used to calculate significance 
 
Time spent with oxygen saturations <88% or <80% (Figs. 43, 44) 
Percentage time spent with oxygen saturations <88% or <80% rose over time peaking at 
day 28 before falling to similar levels to the first 3 days of life by 36 weeks PMA. The 
range was wide on days 10 and 28 with some infants spending up to one third of the 
time hypoxic. Across all data collection periods infants spent very little time with oxygen 
saturations <80%.  
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Figure 43: Percentage time spent with oxygen saturations <88% 
 
Figure 44: Percentage time spent with oxygen saturations <80% 
Coefficient of variation and desaturation event index (Figs. 45-51) 
Both the CV, DSI4% and the DSI4% >10 seconds increased over time to day 28 before 
falling (Figs. 47-49). Whereas the CV and DSI4%>10 seconds at 36 weeks PMA fell to 
levels similar to the first 3 days, the DSI4% remained higher than day 3 and day 10.  
There was considerable variation across the cohort for both of these parameters at all 
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time periods. If you follow the individual trajectories of CV (Fig. 50), it decreases for 
some infants between day 3 and day 10 and increases for others. Those infants who 
increased between day 3 and day 10 tended to have higher CV by day 28, however, there 
is considerable overlap. Only two infants in the whole cohort had a decrease in the CV 
between day 10 and day 28.  
Figs. 51-53 show the relationship between PMA and CV on days 3, 10 and 28. On day 3 
PMA appears to have little effect on CV but on day 10 and day 28 CV tended to be higher 
for infants with greater immaturity.   
The median (IQR) day 10 CV of infants with HsPDA on day 10 was significantly higher 
than those without (0.048 (0.040-0.049) compared to 0.032 (0.025-0.035), p <0.0001). 
The infants with the highest 10 CVs on day 10 all had HsPDA on day 10. None of the 
infants with the 15 lowest CVs on day 10 had HsPDA on day 10.  
 
Figure 45: Coefficient of variation for oxygen saturations over time 
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Figure 46: Desaturation event index 4% over time 
 
Figure 47: Desaturation Event Index 4% > 10 seconds over time 
 




Figure 48: Individual trajectories of oxygen saturation CV over time 
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Figure 50: Day 10 coefficient of variation of oxygen saturation by post-menstrual age 
 
 
Figure 51: Day 28 coefficient of variation of oxygen saturation by post-menstrual age 
Hyperoxia 
The median (IQR) hours in oxygen during the first 72 hours of life was 15 (3-45). Seven 
infants did not have any oxygen after admission to NICU during the first 72 hours of 
pulse oximetry recording. The median (IQR) percent time spent in target oxygen 
saturation range while on oxygen during the first 72 hours was 20.4% (10.1-35.6). The 
median (IQR) percent time spent hyperoxic (oxygen saturations >95%) while on oxygen 
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Bronchopulmonary dysplasia and time spent with oxygen saturations  
<88% or < 80%  
Percentage time spent with oxygen saturations <88% or <80% by BPD status (ANZNN 
definition) and BPD severity (NICHD definition) are shown in Tables 38-40 and Figs. 52 
and 55. Significant within group differences are seen as well as between group 
differences at each time period. Infants who went on to develop BPD developed greater 
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BPD or Death 
(n=33) 
P 




2.7 (2.1) 4.6 (3.8) 0.08 
2.0 2.9  
1.5 – 3.6 1.7 – 6.5  




3.4 (4.2) 8.2 (6.3) 0.01 
1.7 6.5  
0.7 – 4.0 2.9 – 12.6  




4.6 (2.4) 12.2 (8.0) <0.001 
4.6 9.3  
2.3 – 5.9 6.8 – 17.2  




2.5 (1.9) 4.5 (2.9) 0.02 
1.9 3.4  
1.4 – 2.8 2.2 – 7.4  
Repeated measures ANOVA: Effect of Group (BPD or Death) F(1,46)=12.2, p<0.01; Effect of Time 
F(3,138)=23.4, p<0.001; Group x Time interaction F(3,138)=4.9, p<0.005 
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Figure 52: Percentage time oxygen saturations <88% by BPD status  
 
Figure 53: Percentage time oxygen saturations <88% by BPD grade 
 
Repeated measures ANOVA: Effect of Group (NICHD BPD grade) F(2,45)=16.2, p<0.001; Effect of Time 

















0.43 (0.43) 0.57 (0.50) 0.36 
0.24 0.43  
0.16 – 0.56 0.22 – 0.80  




0.41 (0.85) 1.04 (0.96) 0.05 
0.10 0.80  
0.00 – 0.20 0.40 – 1.40  




0.84 (0.67) 2.14 (1.69) 0.008 
0.75 1.80  
0.30 – 1.20 1.00 – 2.60  




0.46 (0.50) 1.07 (0.91) 0.01 
0.30 0.80  
0.20 – 0.60 0.37 – 1.60  
Repeated measures ANOVA: Effect of Group (BPD or Death) F(1,46)=8.9, p<0.005; Effect of Time 
F(3,138)=18.6, p<0.001; Group x Time interaction F(3,138)=3.5, p=0.02 
 










Day 3     
Mean (SD) 
Median 
0.47 (0.47) 0.60 (0.48) 0.60 (0.53) 0.73 













IQR 0.20 – 0.67 0.16 – 0.80 0.35 – 0.81  




0.36 (0.44) 1.04 (1.05) 1.52 (1.25) <0.001 
0.20 0.60 1.30  
0.00 – 0.50 0.40 – 1.10 0.80 – 1.70  




1.07 (0.99) 1.72 (1.29) 2.81 (2.10) 0.004 
0.80 1.30 2.00  
0.37 – 1.30 1.00 – 2.00 1.70 – 3.10  




0.61 (0.68) 0.79 (0.91) 1.38 (0.91) 0.02 
0.30 0.40 1.20  
0.20 – 0.70 0.20 – 1.10 1.00 – 1.70  
Repeated measures ANOVA: Effect of Group (NICHD status) F(2,45)=8.6, p<0.001; Effect of Time 
F(3,135)=19.3, p<0.001; Group x Time interaction F(6,135)=3.3, p=0.005 
 
Bronchopulmonary dysplasia and coefficient of variation and desaturation index 
Tables 42-44 and Figs. 54-59 show summary statistics for CV, DSI (4%) and DSI (4%) 
>10seconds by BPD status.  
BPD and coefficient of variation 
Overall there was a significant difference in CV between those with BPD and those 
without and a significant difference in CV over time. The differences in CV between BPD 




weeks PMA. Although infants start out at a similar point for day 3 CV, for those who do 
not go on to develop BPD, the day 10 CV tends to remain stable or even fall where as it 
tends to rise for those who develop BPD (Fig. 54). The greatest rise tends to be seen in 
those who go on to develop severe BPD (Fig. 55). However, this does not hold true for all 
infants as there is some overlap in these parameters. Of note some infants without BPD 
still experience significant instability in oxygen saturations even at 36 weeks PMA.  












0.030 (0.007) 0.034 (0.007) 0.12 
0.029 0.033  
0.024 – 0.033 0.029 – 0.033  




0.029 (0.011) 0.039 (0.010) 0.007 
0.027 0.038  
0.021 – 0.033 0.034 – 0.045  




0.038 (0.008) 0.049 (0.010) 0.002 
0.039 0.048  
0.031 – 0.043 0.042 – 0.054  




0.031 (0.008) 0.038 (0.010) 0.01 
0.028 0.038  




Repeated measures ANOVA: Effect of Group (BPD or Death) F(1,45)=12.3, p<0.001; Effect of Time 
F(3,135)=27.3, p<0.001; Group x Time interaction F(3,135)=1.58, p=0.20 
 
 
Figure 54: Coefficient of variation of oxygen saturation over time by BPD status 
 
 
Figure 55: Coefficient of variation of oxygen saturation over time by BPD grade (NICHD definition) 
 
Repeated measures ANOVA: Effect of Group (NICHD status) F(2,44)=7.4, p=0.002; Effect of Time 





BPD and desaturation event index 
The DSI4% shows a clear and significant time trend with peak frequency around day 28 
followed by a decline. There was only modest evidence of differences by BPD status 
(ANZNN) around day 10 with higher DSI4% in those with a subsequent diagnosis of BPD 
(Fig. 56, Table 42). However, elaboration by BPD severity (NICHD grade) revealed 
stronger differences on days 10 and 28, but reflected a tendency for those with mild to 
moderate BPD to have a higher frequency of events than those with severe BPD (Fig. 57).  
These trends are echoed more strongly in the DSI4% >10sec data, with a clear peak at 
day 28 and the strongest differences by BPD status on days 10 and 28 with the mild to 
moderate BPD group peaking higher than the severe BPD group (Table 44)(Figs.58,59) 












19.9 (7.4) 21.2 (6.5) 0.39 
18.7 21.9  
15.5 – 23.4 16.6 – 26.0  




30.9 (9.5) 38.9 (11.3) 0.02 
31.3 38.4  
23.7 – 37.2 32.6 – 43.8  




58.1 (10.1) 56.2 (13.2) 0.59 
58.6 56.6  








50.2 (16.0) 51.8 (23.0) 0.79 
51.8 50.8  
42.3 – 60.5 39.0 – 64.9  
Repeated measures ANOVA: Effect of Group (BPD or Death) F(1,46)=0.85, p=0.36; Effect of Time 
F(3,138)=79.6, p<0.001; Group x Time interaction F(3,138)=1.19, p=0.31 
 
Figure 56: DSI4% over time by BPD status
 
Figure 57: DSI4% over time by BPD grade 
 
Repeated measures ANOVA: Effect of Group (NICHD BPD grade) F(2,45)=2.6, p=0.09; Effect of Time 









BPD or Death 
(N=33) 
P 




13.7 (5.3) 14.4 (4.8) 0.64 
12.5 14.8   
10.2-15.8 10.4-17.8  




18.9 (5.2) 23.9 (5.8)  0.004 
18.5 23.5   
14.3-23.2 21.4-27.5  




23.8 (4.9) 30.2 (6.9)  0.001 
24.2 30.4  
20.6-26.3 26.1-35.1  




16.7 (5.0) 18.3 (6.5) 0.39 
16.5 18.1  
13.1-19.9 14.8-22.4  
Repeated measures ANOVA: Effect of Group (BPD or Death) F(1,46)=8.2, p=0.006; Effect of Time 





Figure 58: Desaturation Event Index 4% > 10 seconds over time by BPD status  
 
 
Figure 59: Desaturation Event Index 4% >10 seconds by BPD grade 
 
Repeated measures ANOVA: Effect of Group (NICHD BPD grade) F(2,45)=5.9, p=0.005; Effect of Time 





Adjustment for covariates 
Table 44 demonstrates that when adjustments are made for the covariates of  gender, 
birth gestation, birthweight z score and day 3 HsPDA status there is very little difference 
in measures of oxygen saturation instability between those with and without BPD/death 
by 36 weeks PMA with the exception of CV. More significant differences are seen in 
parameters on days 10 and 28 with CV, time spent with oxygen saturations <88% and 
DSI4%>10 seconds appearing to offer more reliable discrimination. 
Table 44: Mean oxygen saturation parameters according to BPD status but adjusted for gender, birth 












36 weeks PMA 
0.032 0.033 0.54 
0.031 0.038 0.002 
0.040 0.048 0.001 
0.032 0.038 0.01 




36 weeks PMA 
3.7 4.0 0.77 
4.3 7.7 0.009 
5.5 11.7 0.001 
3.3 4.1 0.05 




36 weeks PMA 
0.60 0.48 0.66 
0.58 0.94 0.17 
1.01 2.05 0.001 















36 weeks PMA 
18.1 22.2 0.28 
29.1 39.9 0.005 
56.3 57.2 0.80 
48.4 52.7 0.28 




36 weeks PMA 
13.3 14.6 0.44 
18.6 24.1 0.001 
23.4 30.4 <0.001 
16.2 18.5 0.17 
 
Audit of alarm limit settings 
Summary 
The results of the audit of compliance with oxygen saturation alarm limit protocols are 
summarised in Tables 46, 47. In total 504 alarm settings were audited on a total of 91 
different infants on 49 different days. The median (range) number of data points for each 
infant was 3(1-44). Of the 504 alarm settings audited, on 245 occasions infants were in 
air and in the remaining 259 on oxygen. Of the alarm limits audited 54% were during a 
day shift and 46% an evening or night shift. Of all audited alarm settings 45% were 
incorrect, 54% for those on oxygen. Both upper and lower alarm settings were incorrect 
at a higher frequency in infants on oxygen across all groups, compared to infants in air. It 
was uncommon for both limits to be incorrect. 
Upper alarm limit 
The upper alarm setting was incorrect more frequently in those infants on oxygen who 
also had a higher rate of major breeches. Overall 20% of infants on oxygen had their 
upper alarm limit set at 100%. Of infants on oxygen who were <32weeks PMA, 20% had 
upper limit set incorrectly at 100% compared to 15% of those 32-36 weeks PMA and 24% 
of those >36weeks PMA. Of the 39 infants <28 weeks PMA on oxygen, 44% had their 




Lower alarm limit 
The lower alarm setting was incorrect more frequently in infants who were in air and, 
with the exception of the 32-36 week PMA group infants in air also had a higher rate of 
major breeches of lower alarm limit.  











227 (45) 123 (45.2) 61 (50.4) 43 (38.7) 
Both incorrect  23 (4.6) 5 (1.8) 14 (11.6) 4 (3.6) 
 
Upper incorrect  
only 












0  (0) 
Lower incorrect 
only 


















Table 46: Alarm limit compliance by post-menstrual age and oxygen status 
 All 
Oxygen n=259 
Air         n=245 
<32 Weeks 
Oxygen n=147 
Air         n=125 
32-36 Weeks 
Oxygen n=58 
Air          n=63 
>36 Weeks 
Oxygen n= 54 
Air         n=57 














































































































Survey of nursing opinion 
Of the 100 nurses employed in the neonatal unit 50 nurses responded to our survey 




Nursing experience of participants  
The majority of nurses worked rotating day and night shifts (72.5%) with 9.8% working 
only day shift and 17.6% working only night shift. Mean (SD) hours of work per week was 
33.4 (8.7). The mean (SD) years of neonatal nursing experience of respondents was 14.1 
(9.7) with 88.2% trained to work in the intensive care area of the neonatal unit. 
Nursing knowledge of oxygen saturation targeting 
Of respondents, 76.5% recalled being orientated to the unit policy on oxygen saturation 
targeting and alarm limit setting. Just over a quarter (26.9%) had attended an education 
session that included a discussion of oxygen saturation targeting within the last year, 
9.6% 1-2 years ago, 40.4% more than 2 years ago and 23.1% stated they had never 
attended an education session where this was discussed. 
Overall spontaneous recall of the old or new oxygen saturation targets was poor (Tables 
48, 49). Most nurses (92.3%) understood that the gestational age based targets should 
be based on post-menstrual age not birth gestation.  
Table 47: Recall of old oxygen saturation targets 
















56.3  34.4  43.8 21.9 14.7 11.8 
%Lower 
Correct 
65.6 65.6 50 50 14.7 23.5 
%Upper 
Correct 





Table 48: Recall of new oxygen saturation targets 
New oxygen saturation protocol 
 <36 wks air <36 wks oxygen  >36 wks air >36 wks oxygen 
%Both Correct 48.6 43.2 62.2 48.6 
%Lower Correct 48.6 56.8 62.2 62.2 
%Upper Correct 97.3 56.8 97.3 67.6 
 
Nursing practice and opinion on managing oxygen saturation targets 
The majority of nurses (76.9%) felt that both hypoxia and hyperoxia were potentially 
harmful to very preterm infants while 17.9% responded that hypoxia was more harmful 
and 5.1% responded that hyperoxia was more harmful. 70% of respondents cited the 
infant being too labile and desaturating too frequently as being the main reason why it 
was challenging to maintain infants within their targets.  One fifth of nurses (20%) felt 
the targets were too narrow, 2.5% felt the targets were too high, none felt they were too 
low and 7.5% cited other reasons.  
When asked what percentage of time they felt it was possible to keep infants < 30 weeks 
PMA within their targets nurses responses were variable (Fig. 60): 
 
 












































There was varying opinion on how what proportion of infants < 30 weeks PMA it is 
feasible to keep within their target range with only 17.1% stating this could be achieved 
in most infants (few infants= 29.3%, some infants = 31.7%, don’t know 22% ). 
When asked if they would alter alarm limits if faced with an unstable infant who was 
frequently alarming 85.4% said no, 14.6% said yes. However, if an infant was doing well 
22.2% said this would prompt them to be more lenient with their target range. 36.6% 
said gestational age influenced them being more lenient with targets. 
Survey results suggested a discussion of oxygen saturation targets or a review of alarm 
settings was not a routine part of nursing or medical handover (Figs. 61, 62). 
  
Figure 61: Nursing opinion on percentage of nursing handovers that oxygen saturation targets alarm settings 
are discussed 
 
Figure 62: Nursing opinion on percentage of medical ward rounds where oxygen saturation targets or alarm 

























Our study demonstrated that oxygen saturation instability tended to peak around day 28 
but that there was wide variability in all parameters measured. Most indices were worse 
in those that developed bronchopulmonary dysplasia but this difference was only 
significant in some parameters on day 10 and 28.  Despite an experienced nursing team 
and a clear unit protocol, compliance with oxygen saturation alarm limits was poor 
raising concern that premature infants may be exposed to iatrogenic hyperoxia. Staff find 
maintaining very premature infants in an optimal oxygen saturation range is challenging.  
Measures of oxygen saturation instability 
Oxygen saturation monitoring has become a fundamental part of the care of the preterm 
newborn. New technology now allows us to store and extract more detailed data and 
graph trends over time. In our cohort, measures of oxygen saturation instability all 
tended to worsen between the first 3 days of life and day 28 and then improve by 36 
weeks PMA to a level similar to that seen on day 3. This is consistent with a study by 
DiFiore.267  Our findings at 36 weeks PMA are similar to a measures of instability studied 
in another New Zealand cohort of preterm infants at discharge.376   
With the exception of DSI4%, all parameters (including DSI4%>10s) were worse in those 
babies who developed bronchopulmonary dysplasia with these differences becoming 
apparent by day 10. However, there was significant overlap between groups and over 
time. DSI4%>10 seconds, although reported by PROFOX reports may not be clinically 
meaningful in terms of neurodevelopmental outcomes as other groups only showed 
effects with oxygen saturations <80% for greater than 1 minute. 66The most reliable and 
discriminating indices of oxygen saturation instability were the coefficient of variation 
and time oxygen saturations <88%.  
Alarm limit compliance and nursing opinion of oxygen saturation targeting 
Neonatal intensive care nurses are highly skilled practitioners and play a vital role in 
oxygen saturation targeting. However, review of oxygen saturation alarm limit 
compliance in our unit revealed similar findings to a  study by Clucas et al.283 There was a 
high rate of incorrectly set alarm limits despite our nursing survey revealing an 
experienced nursing workforce.  This non-compliance was higher in babies on oxygen 
with a high rate of alarms being set at 100% in infants less than 28 weeks PMA who are 
particularly vulnerable to the harmful effects of hyperoxia.  Despite being displayed at 




quarters of nurses surveyed had either never attended an education session on oxygen 
saturation targeting or attended one greater than 2 years ago. It was clear that routine 
review of oxygen saturation targeting on nursing and medical handovers was not part of 
unit culture. Despite knowledge about risks of hypoxia/hyperoxia the majority of nursing 
staff responded that moderately preterm infants are inherently unstable and challenging 
to keep within current targets. This is a known difficulty in nursing very premature 
infants.280 A study by Nghiem et al also showed that 71% of nurses cited infant lability as 
the primary reason for infants not being maintained in target.284 More research is 
needed on the effect of human factors on oxygen saturation targeting and whether 
technology can be better utilised to improve this practice. 
Strengths and weaknesses 
Strengths of our study include a prospective well characterised cohort of at risk infants 
that had detailed analysis of a number of measures of oxygen saturation instability over 
four time points from birth to near term. We also attempted to review human factors 
that might contribute to infants being exposed to preventable hypoxia and hyperoxia. 
Weaknesses include the discontinuous oxygen saturation data that does not allow a 
comprehensive analysis of trends in instability over the whole time course of admission. 
During the period of monitoring we also did not have continuous inspired oxygen 
concentration data and instead had to rely on assumptions based on hourly nursing 
observations. We only reported time in target for the first three days and only in infants 
on oxygen. One of the difficulties in reporting time in target is the wide variation in 
targets used across units and the variable targets for when breathing oxygen compared 
to air and changing targets as infants mature. This leads to data that is difficult to 
interpret and fraught with potential inaccuracy and we felt it was best omitted. Although 
an attempt was made to exclude artefact from the oximetry data it is acknowledged that 
pulse oximeters do have a degree of error and different methods for scanning for 
aberrant data can affect results.376 We also acknowledge that other researchers have 
used different set points for defining hypoxia which will need to be considered when 
comparing studies.66  In addition our audit of alarm limits was performed on a different 
set of babies and our nursing survey conducted after data collection on our preterm 
cohort. We did not use a validated survey as we were unable to find one that met our 
needs and this highlights further work needed in this area.  Ultimately we are unable to 
distinguish whether periodic hypoxemia promotes the development of BPD or whether 




only and intended to address some of the knowledge gaps regarding the comparison of 
various currently available measures of oxygen saturation instability in the preterm 
population overtime. Going forward, further study is needed on continuous oxygen 
saturation data on larger cohorts to identify which measures best correlate with clinically 
important outcomes.  
Implications for practice 
Our data showed that while on oxygen during the first three days of life infants spend 
only one fifth of their time in the target oxygen saturation range and almost half of this 
time hyperoxic. This is concerning because excess oxygen exposure may be a 
preventable cause of subsequent pulmonary vascular maldevelopment. Conversely 
although all infants tended to have increasingly unstable oxygen saturations up to day 28 
some infants spent up to a third of their time with oxygen saturations below 88%. Not 
only might this increase the risk of poorer long term neurodevelopmental outcomes but 
in infants who have dysfunctional vasoactive pulmonary vessels hypoxia may precipitate 
a pulmonary hypertensive crisis. The common practice of hourly recordings of oxygen 
saturation and inspired oxygen concentration by nursing staff which informs clinical 
decision making does not capture detailed oxygen exposure and oxygen saturation 
instability data. We have demonstrated that pulse oximeters with downloadable memory 
offer the chance to use more discriminating data to further refine patient care. 
Our findings suggest steps that could be taken to improve oxygen saturation targeting 
and alarm compliance. Very narrow targets that are not evidenced based may be very 
challenging for nursing staff prompting frequent alarms and risking alarm fatigue. A 
review of alarm settings and oxygen saturation instability should be part of nursing and 
medical handovers. Preset alarms according to unit protocol should be programmed into 
the cardiorespiratory monitor with birth gestation inputted on admission to ensure 
correct initial settings. Monitors should include a feature whereby if alarms are altered 
outside unit protocol staff are asked to confirm they want to override this and document 
a reason. Histograms of oxygen saturation data with time in target highlighted and a 
review of the coefficient of variation over time could provide a much more sophisticated 






A number of research questions remain. Our cohort demonstrated, as others have, that 
the most unstable period for oxygen saturations for a preterm infant is not soon after 
delivery when the lungs are at their most immature and undergoing functional transition, 
but one month later.267 A similar pattern has been found in term infants.377 Oxygen 
saturation is a respiratory endpoint that has multiple contributing factors. The factors 
that lead one infant to be relatively stable while another has swinging saturations are still 
unclear and likely to be multifactorial.  However, it seems that this propensity for 
instability begins in the first ten days of life. Whether antenatal factors, such as maternal 
smoking, intrauterine and post-natal growth restriction and chorioamnionitis contribute, 
requires further study. Gestational age is clearly important and represents the degree to 
which normal foetal development has been disrupted. These factors combined with 
postnatal factors such as, persistent ductus arteriosus, infection, inflammation, oxygen 
exposure, positive pressure ventilation and nutrition contribute to this variation in 
respiratory stability. Infant care factors such as handling, pain and environmental light 
and noise are also important. The contribution of evolving pulmonary vascular disease to 
oxygen saturation instability is uncertain and difficult to differentiate from other causes 
of intermittent hypoxia but merits further investigation.   
It is clearly challenging to maintain infants with significant respiratory disease within 
recommended oxygen saturation targets. Automated oxygen delivery systems may offer 
greater refinement of oxygen saturation targeting. New algorithms for automated 
oxygen delivery to maintain oxygen saturation targets have shown promising results such 
that we are likely to see larger clinical trials soon. 378-380 Better utilisation of bedside 
technology may allow clinicians and nursing staff to further refine oxygen therapy and 
respiratory support in preterm infants and reduce iatrogenic harm. A comprehensive 
oxygen therapy stewardship programme from birth to discharge should be considered to 
improve current practice and reduce iatrogenic harm. As the causes of instability are 
complex, achieving this is likely to require a multifaceted approach. The advancement of 
technology that permits continuous high quality data acquisition and analysis holds 





Health and Neurodevelopmental Outcomes 
Beyond Hospital Discharge 
 
Introduction 
Globally the complications of premature birth are the second leading cause of death in 
children under the age of five with half of all babies born before 32 weeks in resource 
poor settings dying.381 However,  relatively simple measures can lead to significant 
survival gains in under-resourced settings.382 Reducing neonatal mortality globally has 
been at the heart of the Millennium Development Goals and the World Health 
Organisation  Every Newborn Action Plan.383 384 In contrast survival rates of even 
extremely preterm infants with access to neonatal intensive care are high. 385-388 
As survival rates after premature birth increase, the medical profession has an ethical 
responsibility to strive to ensure that the cost of survival is not severe 
neurodevelopmental disability or major medical morbidity. Children born prematurely 
are at risk of impaired lung function and increased risk of respiratory disease secondary 
to the effects of the lung underdevelopment and secondary damage caused by positive 
pressure ventilation, excess oxygen and inflammation.389-391 The brain is also particularly 
sensitive to the impact of prematurity due to the effects of intraventricular 
haemorrhage, hydrocephalus and diffuse white matter injury. This leads to a higher rate 
of cerebral palsy, intellectual impairment, hearing deficits as well as attentional and 
behavioural difficulties and educational underachievement. 11 The story of retinopathy of 
prematurity in which blindness is caused by the interaction between the developing 
retina and exposure to high levels of oxygen, has been one of the great tragedies of 
neonatal medicine.392 
Regional neonatal networks now work collaboratively to collect and analyse data on 
short and medium term neonatal outcomes in order to improve clinical care.393, 394 395 In 
addition, several large longitudinal cohort studies have been tracking long term 
outcomes for those born premature with some of those studies now providing data on 




There are a number of challenges in comparing outcome data for children born 
prematurely. Gestational age is the single greatest factor determining outcome. Accurate 
assessment of gestational age requires early pregnancy ultrasound or accurate last 
menstrual period date with a regular cycle. However, there is a margin of error even with 
early scans and not all pregnancies are dated by ultrasound and last menstrual period 
dates can be unreliable. There are significant differences in the lower gestational age 
limit at which life preserving treatment is offered and survival figures need to be explicit 
about whether those not offered resuscitation have been included. 401 Obstetric and 
neonatal care varies across centres and studies have shown outcomes can vary 
considerably even across intensive care units within the same country. 388, 402 
 
Cardiorespiratory morbidity after premature birth 
Beyond the neonatal unit premature-born children are prone to frequent readmissions 
secondary to respiratory illness, particularly in the first two years of life, and 
demonstrate impaired lung function that persists even into adolescence and early 
adulthood.25, 389, 390, 403, 404 405 406, 407 In the first year of life half of all children with BPD will 
be readmitted to hospital, more than double the rate seen in those without BPD and 
significantly higher than the rate in term born infants.408, 409 Because formal assessment 
of lung function is rarely possible below the age of six,410 assessment of respiratory 
function in the first 2 years beyond neonatal discharge is therefore inferred from clinical 
outcome data such as respiratory morbidity and readmission due to respiratory causes 
and/or need for respiratory support. Important sequelae, such as raised pulmonary 
artery pressure and subclinical ventricular dysfunction, have been demonstrated in 
survivors of bronchopulmonary dysplasia in early childhood.116, 411, 412 However,the 
contribution of pulmonary vascular disease to late respiratory morbidity is unclear.  
Morbidity from premature birth can be enduring with increasing evidence of poorer 
cardiorespiratory health in adulthood including pulmonary hypertension, cardiac 
dysfunction and an increased risk of metabolic syndrome which may shorten life 
expectancy. 17, 18, 45, 69, 71, 413, 414  Longitudinal studies are vital to fully understand the 
adverse effects of premature birth and to develop treatment strategies to mitigate these 
effects. Better prognostic markers are also needed to help identify premature infants 




Neurodevelopmental morbidity after premature birth 
Neurodevelopmental morbidity is an important adverse consequence of premature 
birth. A range of standardised tests have been validated and are now widely used to 
assess neurological outcomes for premature infants. Neurodevelopmental impairment 
rates can vary depending on the age at which the assessment is performed and the type 
of test administered.397 The Bayley Scale of Infant and Toddler Development (San 
Antonio, TX: PsychCorp) is a comprehensive neurodevelopmental assessment tool that 
has been widely validated for the evaluation of children born prematurely.415 The Bayley 
assessment is designed to screen children in order to identify those in need of more 
intensive developmental support and is often used to compare neonatal outcomes in 
research studies. The Bayley third edition generates scores for three composite 
parameters (cognitive, motor and language) within which there are subtests of receptive 
and expressive language and fine and gross motor ability.  Recently concern has been 
expressed that the revision of the tool from Bayley II to III has led to underdiagnosis of 
cognitive impairment and overdiagnosis of motor disability.416-420 Despite this debate, 
Bayley III remains widely used across Australasian neonatal units, with results being 
interpreted with caution and many recommending that impairment should be identified 
based on cut-points based on local reference data. 421  
Early markers to predict morbidity 
In the absence of reliable tools for accurate prediction of longer term cardiorespiratory 
and neurodevelopmental morbidity, there is increasing interest in identifying biomarkers 
that improve early detection and could guide preventive management for these 
conditions. BNP has been shown to be a powerful independent predictor of functional 
outcome after stroke in adults.422 Impaired cardiac function in the foetus and neonate 
has been linked to impaired brain development423 while BPD-associated pulmonary 
hypertension is an independent risk factor for poor neurodevelopmental outcomes.114, 
424 Prolonged hypoxic episodes in extremely premature infants are also associated with 
poorer neurodevelopmental outcomes.66 Biomarkers of cardiac function (NTproBNP) or 
echocardiographic indices of ventricular function (TAPSE, TAPSV) or clinical markers of 
respiratory instability (oxygen saturation coefficient of variation) may offer additional 





Gaps in knowledge 
Prematurely born infants are known to have greater respiratory morbidity in the first few 
years of life compared to term born peers, but clinical tools do not adequately identify 
those most at risk, and the contribution of pulmonary vascular disease is unknown. 
Studies of the utility of BNP and NTproBNP for predicting poor outcomes in premature 
infants have focused on BPD or death before hospital discharge. There have been no 
studies of early NTproBNP (a cardiac stress hormone) or TAPSE and TAPSV (ultrasound 
markers of right heart function) or oxygen saturation CV (a measure of oxygen saturation 
instability) as predictive markers of poor neurodevelopmental or health outcomes 
beyond neonatal discharge. We aimed to review the health outcomes of our cohort of 
preterm infants during the first two years of life and neurodevelopment at two years 
corrected age and to determine whether these early indices correlated with later 
outcomes. This study was not designed to inform mechanistic links but rather to be 
hypothesis generating for future research on larger prospective cohorts.  
Hypotheses 
1. Our very preterm cohort will experience high rates of respiratory morbidity in the first 
two years of life and morbidity will be greater in those with BPD 
2. Our cohort will experience similar rates of neurodevelopmental impairment to rates 
reported by ANZNN for the time period of the study 
3. Higher NTproBNP levels in the neonatal period will be associated with poorer 
cardiorespiratory health in the first two years of life and with higher rates of 
neurodevelopmental impairment at two years 
4. Poorer right heart function in the neonatal period will be associated with higher rates 
of cardiorespiratory morbidity in the first two years of life and higher rates of 
neurodevelopmental impairment at two years 
5. Greater oxygen saturation instability in the neonatal period will be associated with 
higher rates of cardiorespiratory morbidity in the first two years of life and higher rates 
of neurodevelopment impairment at two years 
Aims 
1. To describe the mortality, growth, health and neurodevelopmental outcomes in the 




2. To investigate whether early NTproBNP, TAPSE, TAPSV or oxygen saturation CV 
correlate with key outcomes, specifically: 
- duration of NICU stay 
- number of hospital readmissions in first 2 years 
- duration of hospital readmissions in first 2 years 
- neurodevelopmental impairment at 2 years 
Methods 
Participants 
Infants born at less than 30 weeks gestation between March 2013 and April 2015 and 
cared for at the Christchurch Neonatal Intensive Care Unit were eligible for inclusion. 
Infants were excluded if they had known structural airway or lung anomalies, congenital 
anomalies of the pulmonary arteries or pulmonary veins, major systemic vessel-to-
pulmonary artery collateral vessels, congenital heart disease (except those with patent 
ductus arteriosus, patent foramen ovale or secundum atrial septal defect < 5mm or tiny 
restrictive muscular ventriculoseptal defect), severe liver disease, or persistent 
pulmonary hypertension of the newborn on day 3 heart ultrasound (defined as severe 
hypoxia associated with estimated main pulmonary artery pressure >25mmHg). If infants 
had a grave prognosis such that they were not expected to survive to day 3 they were 
also excluded. 
Informed consent was obtained from parents of the participants and ethical approval 
was granted by the University of Otago Human Ethics Board (12/298). This consent 
included collecting data from clinical notes relevant to this trial, accessing follow-up data 
routinely collected for the Australian and New Zealand Neonatal Network (ANZNN) and a 
respiratory health questionnaire sent to parents/caregivers at the child’s first birthday. 
Testing and Data Collection 
NTproBNP, heart ultrasound, oxygen saturations 
Infants had NTproBNP levels and clinician-performed heart ultrasounds on days of life 3, 
10, 28 and at 36 weeks corrected age with oxygen saturation data collected for 
approximately 72 hours prior to these testing points. This testing is described in detail in 




Mortality and cardiorespiratory morbidity 
Mortality data in the first 2 years after neonatal discharge was collected from hospital 
records and the local ANZNN database. Electronic hospital databases were searched to 
identify all encounters with a hospital service in the first two years of life, all Emergency 
Department or Children’s Acute Assessment Unit presentations and all overnight 
admissions. This data was available for infants seen in Canterbury, South Canterbury, 
West Coast and Dunedin Hospitals but not for any presentations at other hospitals 
although we are only aware of two children who moved out of this region before two 
years of age and for one of these we were able to establish that they had no hospital 
admissions. When participants were 1 year of age a respiratory health questionnaire 
designed for this study and not previously validated was sent to parents (Appendix D). 
The aim of this questionnaire was to identify frequency of presentations to primary and 
secondary health care and respiratory morbidity in the first year of life. Consent was also 
sought to check responses against general practice and hospital health records. Two year 
growth outcomes were collected from local ANZNN database or hospital records. 
Neurodevelopment outcome 
Neurodevelopmental outcomes were reviewed at 2 years corrected age. Children in this 
cohort  qualified for formal neurodevelopmental testing if they met the ANZNN criteria 
for screening (born at <28 weeks gestation or < 1000g) or if their clinical course raised 
concern about the potential for adverse neurological outcome. Hospital records and/or 
the data submitted to the Australia and New Zealand Neonatal Network (ANZNN) were 
reviewed and the results of the closest neurodevelopmental assessment  to two years 
corrected age  (including paediatrician performed neurological examination and Bayley 
III or Carolina Curriculum assessment) were recorded.   
If Bayley’s III was performed, cognitive, language and motor delay was graded as mild, 
moderate or severe according to established criteria. Severe delay was defined as scores 
<-3 standard deviations (SD), moderate delay as scores -3 SD to <-2 SD, and mild delay as 
scores -2 SD to <-1 SD relative to the mean. The mean (SD) of these scales is 100 (15), 
giving cut-points are of: severe <55, moderate 55–69, and mild 70–84. Blindness was 
defined as vision < 6/60 in the best eye as assessed by an ophthalmologist. Significant 
hearing impairment was defined as requiring unilateral or bilateral hearing aids or 
cochlear implant. Cerebral palsy is a non-progressive motor disability present from birth. 




Functional Classification System (GMFCS).290  In this study cerebral palsy was identified 
based upon a diagnosis of cerebral palsy by a paediatrician or paediatric neurologist.  
Overall moderate to severe neurodisability was defined as either:298 
- moderate or severe cerebral palsy (GMFCS ≥3) or 
- visual acuity <6/60 in better eye or 
- sensorineural deafness with hearing aids or 
- developmental quotient less than –2 SD relative to reference standard. 
Any neurodevelopmental impairment defined as deficit in any domain requiring 
additional support or intervention. 
Comparative data 
Outcomes were compared to ANZNN data for that period, the Growing Up in New 
Zealand (GUINZ) study or population based data from the Ministry of Health or Statistics 
New Zealand. 298-300, 425, 426 Statistics New Zealand gathers population data for the New 
Zealand government. GUINZ is a longitudinal study tracking the health and development 
of approximately 7,000 New Zealand children, born 2009-2010, from before birth until 
they are young adults funded by the New Zealand government to inform future health 
and social policy. ANZNN is a collaborative network of neonatal units across Australia and 
New Zealand established in 1994 that monitors the care of high risk newborn infants by 
pooling data to ensure ongoing quality improvement in care. All level II and III neonatal 
units in New Zealand participate. Since its establishment the Network has developed a 
minimum data set and implemented a data collection that monitors the mortality and 
morbidity of infants admitted to neonatal intensive care units across Australia and New 
Zealand. Babies eligible for audit are those: 
1.  born at less than 32 weeks gestation, or 
2. weighing less than 1500 grams at birth, or 
3. received major surgery (surgery that involved opening a body cavity), or  
4. received therapeutic hypothermia. 
ANZNN recommend formal assessment for neurodevelopmental disability at 2 years 






Descriptive statistics of health outcomes are reported as means (SD) or medians (IQR or 
range). Z scores for the two year growth parameters were calculated according to the 
formula used by ANZNN. In the case of non-normal distributions Mann-Whitney test was 
used to evaluate for significant differences between those that did have BPD and those 
that did not. A p value of <0.05 was considered statistically significant.  
The analysis of neurodevelopmental outcomes is based on a sample of 48 infants: two 
infants died before discharge; and one child with a rare genetic syndrome was excluded 
on the basis of preliminary analysis identifying the infant as an extreme outlier on all 
measures of neurodevelopmental outcome.  
The strength of association between neurodevelopmental outcomes and measures of 
neonatal cardiorespiratory function was assessed using Spearman correlations. 
Statistically significant associations were adjusted using linear regression methods to 
control for gender, birthweight z-score, gestation, BPD status, antenatal steroids, 
maternal smoking and presence of HsPDA on day 3. Adjustments were conducted using 
multiple linear regression for duration of NICU stay; negative binomial regression for 
measures of hospital admission and duration of admission; logistic regression for 
neurodevelopmental delay. Spearman correlations assessed the strength of the 
association between measures of neonatal cardiorespiratory function (NTproBNP, TAPSE, 
TAPSV, oxygen saturation CV) and health and  neurodevelopmental outcomes (duration 
of NICU stay, readmissions, neurodevelopmental outcome). Because of the large number 
of statistical tests reported and the possibility that some associations would be 
statistically significant simply by chance a Bonferroni correction was applied to 
determine statistical significance. The Bonferroni corrected p-value, calculated to take 
into account the correlation between measures, was p<0.008. All analyses were 
conducted using SAS 9.4, Stata 15 or Graph Pad Instat software.    
Results 
Mortality in first two years of life 
Two children died between day 28 and 36 weeks PMA giving a survival to discharge 
home of 96%. One child died of a pulmonary haemorrhage secondary to Escherichia Coli 
sepsis and the other child of respiratory failure secondary to severe BPD. No child died 




Growth in first two years of life 
The mean (SD) z score at 2 years corrected for weight was -0.24 (1.3) (n=48), for height 
was -0.22 (1.3) (n=44) and for head circumference was -0.70 (1.2) (n=26). The duration 
of breastmilk feeding during the first year of life was available for 45 infants: 17.8% had 
breastmilk for less than 6 weeks, 11.1% for 6 weeks to 3 months, 6.7% for 4-6 months, 
35.5% for 7-12 months and 28.9% had breastmilk beyond 12 months. 
Health in first year of life 
After NICU discharge 98% of survivors had an encounter with some sort of hospital 
based service (inpatient or outpatient) in the first year of life. The median (range) of 
hospital service encounters (inpatient or outpatient) during the first year of life beyond 
neonatal discharge for the whole cohort was 8 (0-67). Two infants required intensive 
care admission, one for a respiratory arrest and another for severe apnoeas, both 
associated with a general anaesthetic. No children were diagnosed with pulmonary 
hypertension after discharge from neonatal unit. 
 Of the 49 surviving infants, 36 responded to the survey (73%). Table 49 summarises the 
social and demographic data of survey respondents while Table 50 details key survey 
results.  
Table 49:  Social and Demographic Data of survey respondents n=36 













Mean birth gestation  28.1 weeks  
Gender F: M 41.7% : 58.3% 
Bronchopulmonary dysplasia 64% 




Characteristic number or % 
Maternal smoking  25% 
Smoke-free homes† 66.7% 
Mean (range) NZ Deprivation Index Decile 305‡  5.3 (1-10) 
Attendance at daycare/early learning centre 16.7% 
Mean number of children living in the home (<16 years) 1.9 
Home heating 100% 
Single parent household 8.3%  
 
* Some infants identified as more than one ethnic group 
**Hallways, bathrooms, toilets and laundry excluded.  If living areas were open plan, the 
kitchen, dining area and lounge were counted separately.  
† Defined as no smokers living in the home 
‡Based on discharge address. 1 represents low deprivation and 10 high level of 
deprivation. 
Table 50: Health in first year of life 
Measure % (n=36) 
 required CPAP after NICU discharge 13.9 (5) 
 ventilated after NICU discharge (excluding for surgery) 2.8 (1) 
 no respiratory illness 50 (18) 




Measure % (n=36) 
 pneumonia 2.8 (1) 
 recurrent wheeze 11.1 (4) 
 inhaler prescribed   13.9 (5) 
 steroids prescribed 5.5 (2) 
 cough lasting > 4 weeks 13.9 (5) 
 discharged on apnoea monitor 63.9 (23) 
 apnoea requiring resuscitation post-NICU discharge 5.5 (2) 
 Eczema 41.7 (15) 
 Hayfever 2.8 (1) 
 ear infection 13.9 (5) 
 nasogastric tube feeds post-NICU discharge 22 (8) 
 treated for gastroesophageal reflux 50 (18) 
 immunisation up to date 100 (36)  
 influenza vaccine 33.3 (12)  





Hospital health outcomes in first two years of life 
Of the 49 surviving children, 57% presented to the hospital children’s acute assessment 
unit or the hospital emergency department in the first two years of life. The median 
(range) of presentations to the hospital children’s acute assessment unit or the hospital 
emergency department in the first two years of life was 1 (0-11).  Following index NICU 
discharge, 49% of our cohort were re-hospitalised for an overnight admission in the first 
2 years of life. The median number (range) of readmissions in first 2 years of life was 0 
(0-19). For those admitted there was a median 3.5 days of readmission (range1-148 
days). Cardiorespiratory causes accounted for 64% of readmissions. Of those without 
BPD (ANZNN definition) 55% were readmitted during the first 2 years (Median [range] of 
1 [0-2] admissions) with a median duration (range) of stay was 1(1-5) day. In comparison 
45% of those with BPD were readmitted during the first 2 years (Median 0 [0-19]).  
However, of those admitted the median stay was 5.5 (1-148) days. There was no 
significant difference in the number (p 0.813) or duration of readmissions (p 0.554) 
during first two years for those with or without BPD.  
Neurodevelopment at two years  
Neurodevelopmental information was available in all survivors between 1-3 years of age. 
28 of the 49 surviving children had a Bayley Scale of Infant Development (III) performed. 
A further 10 infants had formal neurodevelopmental assessment performed by a 
multidisciplinary early intervention team. For the remaining 11 infants who did not have 
formal neurodevelopmental assessment outpatient records were reviewed for any 
reference to impairment. 25/28 Bayley assessments were done at 24-27 months 
corrected age. The remaining 3 were assessed at 30, 31 and 34 months. The 10 infants 
who had an alternative form of validated developmental assessment (Carolina 
Curriculum and Neuro-Sensory Motor Development Assessment) by an Early 
Intervention team were assessed between 12 and 37 months corrected.427, 428 
No child in our study was blind or had significant hearing impairment. One child had a 
diagnosis of hemiplegic cerebral palsy (GMFCS level 2). One child had a diagnosis of 
global developmental delay thought to be secondary to a syndrome not yet identified. 
In our cohort of 49 survivors, moderate to severe neurodisability was identified in three 
children but in two of these children the area of impairment was language and it was 




scores. Any neurodevelopmental impairment was reported in 11 (22%) children. More 
detailed results of the Bayley assessment are shown in Table 51. 
Table 51: Bayley Scale of Infant Development (BSID) III Assessment (n=28) 
Measure Score or %  
(n=28) 
Median composite cognitive score  102.5 
Median composite language score  98.5 
Median composite motor score 97 
%(n) BSID  cognitive composite score <55 (3SD below mean) 0 (0) 
%(n) BSID  cognitive composite score 55-69 (2SD below mean) 3.6 (1) 
%(n) BSID cognitive composite score 70-84 (1SD below mean) 7.1 (2) 
%(n) BSID  language composite score <55 (3SD below mean) 0 (0) 
%(n) BSID language composite score 55-70 (2SD below mean)* 10.7 (3) 
%(n) BSID Language composite score 70-84 (1SD below mean)* 10.7 (3) 
%(n) BSID  motor composite score <55 (3SD below mean) 0 (0) 
%(n) BSID Motor composite score 55-69 (2SD below mean) 3.6 (1) 
%(n) BSID Motor composite score 70-84 (1SD below mean) 10.7 (3) 




NTproBNP, TAPSE, TAPSV, oxygen saturation CV and outcome 
Table 52 shows the Spearman correlations between our novel measures of neonatal 
cardiorespiratory function (NTproBNP, TAPSE, TAPSV, oxygen saturation CV) and  key 
health and  neurodevelopmental outcomes (duration of NICU stay, readmissions, 
neurodevelopmental outcome).  There were statistically significant associations 
between: 
1. Duration of NICU stay and: 
- NTproBNP on day 3 (r=.53) 
- day 10 TAPSE (r=-.41)  
- oxygen saturation CV on days 10 and 28 (r=.39, .38).  
Duration of NICU stay was higher amongst those with higher NTproBNP on day 3, those 
with smaller TAPSE on day 10, and those with higher oxygen saturation variability on day 
10 or 28.  
2. All measures of hospital readmission and: 
- day 28 NTproBNP (r= .41 to .51) 
All cause and cardiorespiratory readmissions and readmission days were higher amongst 
those with higher day 28 NTproBNP. Median (IQR) day 28 NTproBNP for those with no 
readmissions 40 pmol/L (31-87) compared to 83 pmol/L (60-166) for those who were 
readmitted in first 2 years. 
3. Neurodevelopmental impairment at age 2 years and: 
- day 28 TAPSE (r=-.40) 
Those with developmental impairment had smaller TAPSE on day 28. Mean (SD) day 28 
TAPSE for those without neurodevelopmental impairment at 2 years was 8.2mm (1.9) 





Table 52: Spearman correlations between health and neurodevelopmental outcomes (0-2 years) and 


























Day 3 .53* -.10 -.09 -.13 -.24 .23 
Day 10 .33 .08 .09 .14 .05 .22 
Day 28 .06 .41* .44* .51* .36 -.03 
TAPSE  
Day 3 -.13 .15 .12 .01 .04 -.16 
Day 10 -.41* .08 .06 .03 .11 -.14 
Day 28 -.20 -.05 -.08 .03 .03 -.40* 
TAPSV  
Day 3 -.01 .09 .08 .00 -.03 -.10 
Day 10 -.05 .22 .22 .39 .36 -.16 
Day 28 -.20 .05 .01 .02 -.11 -.10 
O2 Saturation CV 
Day 3 .14 .17 .19 .17 -.03 .33 
Day 10 .39* .03 .06 .13 .16 .18 
Day 28 .38* .11 .14 .13 .10 .10 




To identify whether our novel markers were independent predictors of key outcomes, 
the above associations were adjusted using linear regression methods to control for a 
range of established antenatal and perinatal factors including: gender, birthweight z-
score, gestation, BPD status, antenatal steroids, maternal smoking and presence of 
HsPDA on day 3. These analyses showed that for duration of NICU stay and all of the 
measures of hospital readmission/duration up to 2 years the observed associations were 
reduced and became statistically non-significant after covariate adjustment. However, 
for the measure of neurodevelopmental impairment at age 2 the strength of the 
observed association with day 28 TAPSE was unaffected by covariate adjustment. 
Table 53 illustrates the associations between day 28 TAPSE (by quartile) and 
neurodevelopmental impairment at age two. The table shows the rate of 
neurodevelopmental impairment before and after adjustment for covariates. The table 
also reports the regression coefficients and tests of significance from logistic regression 
models fitted to the data. The findings demonstrate a strong association between day 28 
TAPSE and rates of neurodevelopmental impairment, with very strong similarity between 
the unadjusted and adjusted results. The adjusted association is statistically non-
significant. However, this appears to be due to a slight inflation of the standard errors in 
the adjusted model rather than to a noticeable reduction in the adjusted model 
coefficient.   
Table 53: Rates (%) of neurodevelopmental impairment (0-2 years) by quartiles of Day 28 TAPSE; CV before 
and after covariate adjustment for gender, birthweight z-score, gestation, BPD status, antenatal steroids, 










Q1 (low) 10 40.0 41.4 
Q2 11 36.4 23.1 
Q3 12 8.3 10.9 
Q4 (high) 10 0.0 4.5 
  
B(SE) = -1.09 (0.46); 
p=0.02 
B(SE) = -1.07 (0.58); 
p=0.07 





We have presented growth, health and neurodevelopmental outcomes for our very 
preterm cohort out to two years corrected and demonstrated satisfactory growth and 
that respiratory symptoms are common but rates of significant neurodevelopmental 
impairment are low.  
Health outcomes 
Although most infants had only a few hospital service encounters during this period, a 
few children had high health needs and half of our cohort were readmitted to hospital 
during the first two years.  This is despite our cohort demonstrating low levels of 
overcrowding, high rates of home heating, high levels of immunisation and low 
attendance at early childhood education or daycare centres.429  Although rates of 
readmission were similar between infants with BPD and those without, those with BPD 
tended to have a longer admission and those children with the highest health needs also 
had BPD.  This is consistent with larger longitudinal preterm cohorts.408, 409, 430 A 
Norwegian cohort reported readmission rates of 49% at one year of while a local 
Christchurch cohort demonstrated a readmission rate of 55% in preterms in the first two 
years compared to 26% in term born controls.407, 431  The Growing Up in New Zealand 
(GUINZ) study reported only 20% of this predominantly term born cohort were admitted 
to hospital by age two.425  
One third of our survey respondents had bronchiolitis in the first year of life with more 
than one in ten having recurrent wheeze. No infant received prophylaxis against 
respiratory syncytial virus, the main pathogen implicated in bronchiolitis. Maternal 
smoking rates during pregnancy were 16.7% However, by one year of age 25% of 
mothers were smoking and one-third of households were not smoke-free. Antenatal 
smoke exposure has been linked to adverse foetal lung development and antenatal and 
postnatal smoke exposure is associated with poor respiratory health. 432-434 435-439 It is 
plausible that infants with premature lung disease are at even greater risk. Supporting 
women of childbearing age to quit smoking and maintain abstinence postnatally could 
have significant health benefits and reduced health costs for those children born 
prematurely.  
All of our survey respondents had received all scheduled immunisations by one year of 




months of age. The GUINZ cohort reported full immunisation rates of 92% at two years. 
Despite being a high risk population, only one third of our cohort received the influenza 
vaccination according to parental recall at one year. This vaccine is not part of the New 
Zealand schedule and is unfunded unless certain criteria a met. These criteria include 
children under the age of 5 years with significant respiratory disease which suggests 
more children could have been offered protection.  
In our cohort there were no late pulmonary hypertension diagnoses reported beyond 
neonatal discharge. However, pulmonary vascular disease is a spectrum of dysfunction 
and two children had significant respiratory events associated with general anaesthetic, 
necessitating admission to intensive care for respiratory support. It is possible this may 
reflect some pulmonary vasoreactivity. Studies have shown that children with pulmonary 
hypertension have a significantly greater risk of pulmonary hypertensive crisis, cardiac 
arrest or dying with anaesthesic induction.440 Without detailed follow-up of high risk 
children we risk missing occult cardiopulmonary dysfunction that could put children at 
significant risk.117, 441 
Neurodevelopmental outcomes 
Rates of cognitive, language and motor delay in our cohort were similar to that seen in 
contemporary extremely low birth weight cohorts born in Victoria Australia. 396, 442 
Neurological impairment rates reported by ANZNN in 2014 were higher, however, these 
data include infants born at less than 24 weeks and also term infants with hypoxic 
ischaemic encephalopathy making comparison difficult. ANZNN reported cerebral palsy 
in 7.4% in all children followed up. Any cognitive delay was reported in 15.1%, any 
language delay in 27% and any motor delay in 17.5%.298 One of the difficulties in 
assessing language and cognitive outcomes in our cohort was the assessment of children 
for who English is a second language where it was unclear how much this may have 
affected their performance. We also know that rates of neurodevelopmental impairment 
differ depending on the type of assessment tool, the quality of the assessment and the 
timing of assessment with motor impairments often decreasing over time while more 
subtle cognitive deficits reveal themselves. 
Growth outcomes 
All of our cohort received some breastmilk in the first year of life. This is similar to the 
GUINZ cohort which had 97% initiating breastfeeding at birth. 82% of our cohort 




of age compared to 37% in the GUINZ cohort. The high rates of initiating breastfeeding in 
our unit are likely the result of a supportive breastfeeding policy and culture, lactation 
consultant support and the establishment of a human milk bank. It is important to 
continue this support beyond hospital discharge in order to sustain breastfeeding. 
Growth rates were also good in our cohort which is important as postnatal growth can 
affect neurodevelopmental outcome.311, 313 
Early markers to predict morbidity 
We demonstrated strong univariate associations between our novel markers of 
cardiorespiratory status and adverse outcomes within the first two years. There was a 
strong positive association between day 3 NTproBNP and duration of NICU stay. There 
were equally significant positive associations between day 28 NTproBNP and subsequent 
hospital readmission rates.  As the presence of HsPDA is the primary factor driving high 
levels of NTproBNP on day 3 this supports early physiological instability having a 
significant impact on subsequent neonatal course. This is further evidence of the 
importance of supporting physiological stability from birth. Persistently high NTproBNP 
out to day 28, beyond the period of cardiac transition, is a marker of poorer 
cardiovascular adaptation. NTproBNP is an integrative marker of cardiorespiratory status 
that also reflects renal function and volume status. Early NTproBNP may help predict 
very preterm infants who are likely to have high needs during their NICU stay and a 
higher hospital readmission rate. 
TAPSE was negatively correlated with duration of NICU stay  on day 10 and with 
neurodevelopmental impairment on day 28. Oxygen saturation CV was positively 
correlated with duration of NICU stay on day 10 and 28.  No significant associations were 
found between TAPSV and health and neurodevelopmental outcomes. However, after 
adjusting for covariates these associations became non-significant apart from day 28 
TAPSE and neurodevelopmental outcome. There is biological plausibility that poorer 
cardiac function and greater oxygen saturation instability may affect brain development. 
These findings emphasise the importance of close evaluation of cardiorespiratory 
function and striving to maintain physiological stability from birth.   
Strengths and weaknesses 
A significant weakness of our study is the size of the cohorts and the impact on statistical 
analyses and the ability to demonstrate an independent ability of NTproBNP, TAPSE, 




(even after Bonferroni correction) seen in this cohort suggest there is a strong likelihood 
that markers such as NT-proBNP and TAPSE may provide independent predictive value in 
adequately powered cohorts.    Further studies of larger cohorts are therefore needed. 
Our findings may not be relevant to other cohorts and would need testing in that setting. 
Our cohort was well characterised and we provide comprehensive follow-up data to 2 
years. Despite our rigorous attempts, we cannot exclude that some follow-up data is 
missing, due to events occurring out of region.  We were unable to collect consistent 
data of family doctor visits and so have not reported this. The response rate to our 
survey was 73% and as we do not have data for the non-responders it is possible that 
there may be some selection bias in these results. The NZ social deprivation decile was 
also lower for survey respondents than the whole cohort suggesting some of the non-
responders had greater levels of social deprivation which may adversely affect health 
outcomes. In addition the social deprivation index is a crude tool for estimating social 
deprivation.  
Implications for practice 
In summary, our cohort is similar to regional cohorts and demonstrated high health 
utilisation in the first two years of life but low levels of significant neurodevelopmental 
impairment. Gestational age, birthweight and BPD are likely be the strongest 
determinants or poor health and neurodevelopmental outcomes. We have shown some 
significant univariate associations for novel markers of cardiorespiratory function but 
acknowledge a much larger cohort is needed to demonstrate independent predictive 
value. However, these data suggest that there would be value in exploring novel 
prognostic markers further.  NTproBNP and TAPSE in particular may be useful as part of a 











To be born prematurely is to experience an interruption of development, triggering a 
range of adaptive responses that may offer a short term survival benefit but have long 
term consequences. Infants born very prematurely are at risk of lung maldevelopment 
including pulmonary vascular maldevelopment which can have lasting effects.57, 114, 391, 443 
The pulmonary vascular disease-pulmonary hypertension spectrum is an adaptive path 
of pulmonary development that is influenced by baseline genetic risk, currently poorly 
understood, interacting with a multitude of in-utero and postnatal factors.57, 443 
Identifying this pathological pattern of development, and the factors that contribute to 
its development, is critical to the timely implementation of management that could 
prevent the significant associated morbidity and mortality.  The complex aetiology of late 
pulmonary hypertension in very premature infants means that prevention and treatment 
will require a multifaceted approach. Due to the insidious development of pulmonary 
hypertension, screening and surveillance is needed to improve outcomes.86, 87, 221 Clinical 
information, heart ultrasound evaluation, pulse oximetry data and biomarkers may all 
have a role to play. This thesis describes a coordinated series of studies that evaluated 
modern markers of cardiac function and their ability to detect abnormality in in a real 
world population of preterm infants. We sought to evaluate tools that could improve 
detection of pulmonary hypertension and could be used for screening. Careful 
characterisation of clinical, biomarker and novel ultrasound indices has provided 
important novel findings in regard to the temporal profile of these markers, the 
feasibility of their acquisition and their value in detecting cardiopulmonary abnormality 
and predicting outcomes. 
Summary of findings 
NTproBNP 
This study investigated whether the cardiac stress hormone NTproBNP could be used as 
a biomarker to detect rising pulmonary artery pressure in very prematurely born infants. 
Prior to commencing this study, estimates of the incidence of pulmonary hypertension 




37% in those with BPD and prolonged ventilation.64, 80, 81  However, none of our cohort 
born at less than 30 weeks gestation had pulmonary hypertension at 36 weeks PMA 
according to our definition using conventional  ultrasound criteria.120, 444 Nor did any 
infant have a subsequent diagnosis of pulmonary hypertension by two years of age. This 
precluded testing of our primary hypothesis. This low incidence of pulmonary 
hypertension in very preterm infants was replicated in a recent Australian study and 
suggests that the overall prevalence of pulmonary hypertension in a modern setting may 
be lower than rates from highly specialised quaternary centres.354 However, it is possible 
that we have missed pulmonary hypertensive disease by using criteria that were too 
stringent. In the absence of cardiac catheterisation data we also cannot exclude lesser 
degrees of pulmonary vascular disease. We only used one quantitative measure (TR jet 
peak velocity) which is often not detectable in late pulmonary hypertension in preterm 
infants.199, 207 Our alternative criteria were subjective and so may have been affected by 
the experience or bias of the assessor. Due to the low sensitivity of any one heart 
ultrasound parameter for detecting pulmonary hypertension it is likely that a wide range 
of indices will need to be evaluated.207  However, our cohort also had low rates of 
intrauterine growth retardation, good post-natal growth and predominantly non-invasive 
respiratory support with few infants at the extremes of prematurity.  All of these factors 
are likely to have contributed to a lower than expected rate of pulmonary hypertension. 
We cannot exclude lesser degrees of pulmonary vascular disease which may cause 
increased morbidity during challenges such as respiratory illness or general anaesthesia.  
This is, to the best of our knowledge, the first study to investigate temporal changes in 
NTproBNP, paired with heart ultrasound and oxygen saturation data, in a general cohort 
of infants born at <30weeks gestation at multiple time points from day 3 to 36 weeks 
PMA – a time point at which many recommend screening for pulmonary hypertension. 
We demonstrated that NTproBNP levels are high on day 3 and tend to fall over time. We 
showed that levels in very premature infants are considerably higher than those seen in 
adults and are highly variable on day 3 and day 10 of life, primarily due to the effects of 
transitional circulation. NTproBNP proved to be a highly sensitive and specific predictor of 
HsPDA. 
BPD is characterised by both a paucity of alveoli and a paucity of pulmonary vessels and 
is often complicated by pulmonary hypertension.56 Bronchopulmonary dysplasia did not 




HsPDA. This is in contrast to other studies.185 NTproBNP is clearly very sensitive to acute 
ventricular pressure and volume overload as demonstrated by the effect of HsPDA. 
However, the more slowly evolving chronic stress that chronic lung disease, such as BPD, 
may confer predominantly on upon the right ventricle may not be such a strong stimulus 
to BNP release. In the very preterm infant the development of pulmonary vascular 
collateral pathways may mitigate some of the potential cardiac effects of BPD. In the 
similar adult setting of chronic obstructive pulmonary disease in the absence of heart 
failure, NTproBNP levels are also not very high.445  Acute exacerbations of chronic 
obstructive pulmonary disease do cause a rise in NTproBNP although its performance is 
better for negative predictive value than positive.445 Therefore NTproBNP may still be a 
useful biomarker of acute decompensation due to pulmonary hypertension either due to 
an acute crisis or because compensatory cardiac mechanisms fail.   
We investigated other factors affecting NTproBNP levels in this population. Although 
impaired renal function increased levels, haemoglobin levels, recent exposure to 
intermittent hypoxia and mechanical ventilation did not. Chronological age but not 
gestational age influenced levels. Unexpectedly, levels at 36 weeks PMA were higher in 
those without a history of HsPDA and without a diagnosis of BPD. We explored whether 
high levels post-partum were in part due to processing of the peptide and performed 
additional analyses to identify circulating isoforms of BNP. Findings from this analysis 
demonstrated that NT proBNP1-76 was the dominant circulating form and there was no 
evidence of significant glycosylation or of circulating fragments. Hence the difference 
seen at 36 weeks PMA could not be explained by glycosylation differences. Our findings 
also support a high degree of biological variability in NTproBNP as has been shown in the 
adult population with levels being driven predominantly by factors stimulating secretion 
rather than by altered post processing or clearance.196  
Heart ultrasound 
In the absence of invasive cardiac catheterisation, estimating main pulmonary artery 
pressure and assessing RV function using heart ultrasound is critical to detecting 
pulmonary hypertension. However, conventional ultrasound criteria for diagnosing 
pulmonary hypertension may not be sufficiently sensitive to identify late pulmonary 
hypertension in premature infants that evolves slowly and beyond the period of 




Clinician performed heart ultrasound in the NICU is currently primarily being used to 
monitor transitional circulation. Our study demonstrated that it is feasible for more 
advanced quantitative measures of right ventricular function to be incorporated into 
clinician performed heart ultrasound. This  may be of value to a pulmonary hypertension 
screening programme as utilising clinician scanners is likely to increase the availability of 
scanning, reduce costs and allow infants to be scanned in the NICU.  
We also investigated the effects of time, growth and BPD on these heart ultrasound 
measures which had not previously been reported. Our study revealed some important 
results and demonstrated that some parameters performed better than others in terms 
of ease of acquisition, reproducibility and discriminating qualities with TAPSE performing 
particularly well. Our study also highlighted the importance of incorporating 
developmental changes in these indices over time into reference ranges. Our results 
need to be further validated in larger preterm cohorts and developmental changes 
compared to term born infants. 
With very to extremely premature birth the immature heart has to adapt to post-natal 
circulatory changes and compensate for an underdeveloped pulmonary vascular system. 
Initially this is likely to be through increased contractility, which may explain the 
unexpected increases in TAPSE seen in our cohort. Eventually, if RV preload or afterload 
stress persists, systolic and diastolic dysfunction will occur with structural changes in the 
RV seen as hypertrophy and/or dilatation.343 This persisting chronic stress on the 
developing heart may be the reason adults born very prematurely have evidence of RV 
hypertrophy, RV dysfunction and sub-clinical pulmonary vascular disease.45, 69, 347 The 
absence of overt pulmonary hypertension in the neonatal period does not exclude the 
presence of cardiac adaptations that may have consequences to cardiovascular health in 
adulthood. 
Oxygen saturation monitoring 
Supporting developmentally immature lungs often requires oxygen to overcome the 
effects of an underdeveloped gas-exchange interface which contributes to chronic 
intermittent hypoxemia in very premature babies. However, hyperoxia can have a toxic 
effect on the developing lung and in particular interfere with pulmonary vascular 
development.  A great deal has been published on the importance of oxygen saturation 




saturation instability changes over time and the utility of various measures of instability 
now available to the clinician with modern oximeters.285  
Our study demonstrated that babies born at less than 30 weeks are most unstable on 
days 25-28 of life compared to the other time points we studied. Oxygen saturation CV 
and percentage time spent with oxygen saturation less than 88% appeared to offer the 
most consistent discriminating value when comparing infants with and without BPD. 
Babies who went on to be diagnosed with BPD became more unstable than those who 
did not from about day 7-10 highlighting the critical importance of early care. Time in 
target during the first 72 hours, a critical period of physiological transition, was low and 
the incidence of exposure to hyperoxia unacceptably high.  In our neonatal intensive care 
unit there was a high rate of incorrect alarm settings identified putting particularly 
extremely preterm infants on oxygen therapy at risk of undetected and potentially 
harmful hyperoxia.  
Health and neurodevelopmental outcomes 
Rates of respiratory disease in the first two years of life were high in our very preterm 
cohort. Half required readmission to hospital during this period predominantly due to 
respiratory illness. In contrast, rates of moderate to severe neurodevelopmental 
impairment were low. This is consistent with other studies and regional network  
data.7, 407 406, 430 
Early life NTproBNP predicted duration of NICU stay and hospital readmission while 
TAPSE strongly predicted any neurodevelopmental impairment by two years. These 
findings further emphasise the impact of early cardiorespiratory stability on later 
outcomes. 
Implications for practice 
Use of NTproBNP in premature infants 
We showed that NTproBNP is a highly sensitive and specific marker of HsPDA by our 
definition. This is consistent with a recent systematic review.180  However, incorporation 
into clinical practice has been impeded by the lack of consensus definition of HsPDA  in 
relation to clinically meaningful outcomes and the ever shifting opinion on whether to 
treat PDA or not. These issues will need to be resolved before NTproBNP can be used 
routinely, however, NTproBNP should be considered during the design of in any future 




There is insufficient evidence to recommend NTproBNP as a standalone biomarker for 
pulmonary hypertension screening in very premature infants. However, it may be useful 
as an adjunct to heart ultrasound particularly to monitor response to treatment. A 
baseline level should therefore be considered in at risk infants at 36 weeks PMA as part 
of a pulmonary hypertension surveillance programme.  
Optimal heart ultrasound parameters for diagnosing late pulmonary hypertension  
There is currently no consensus on optimal heart ultrasound criteria for the diagnosis of 
late pulmonary hypertension in very premature infants.  Our findings support further 
training for neonatologists in quantitative measures of right heart function that could be 
incorporated into clinician performed heart ultrasound under the oversight of a 
paediatric cardiology service. This would enable better study of the changes in right 
heart function over time in response to preterm birth. On the basis of our review of 
current literature and our study findings we recommend the inclusion of TAPSE, tissue 
Doppler indices and evaluation of the LV eccentricity index.205, 206, 209, 214, 446, 447  
Oxygen saturation targeting 
Our study highlights the challenge of managing oxygen saturation instability in very 
premature infants. We also demonstrated that an increase in instability is usual for all 
infants but that some infants are particularly unstable and that this often becomes 
apparent in the first 7-10 days. While this may suggest some in-utero programming this 
emphasises the importance of striving to maintain physiological stability form birth. We 
propose that more attention needs to be paid to the human factors contributing to poor 
time in target and suggest an oxygen saturation stewardship programme should be 
evaluated to reduce iatrogenic harm.    
Optimising health and neurodevelopmental outcomes 
The high level of health utilisation of our cohort in the first two years of life and the 
significant burden of respiratory disease emphasise the importance of preventative care. 
Supporting mothers to stop smoking in pregnancy and not return to smoking in the post-
partum period and homes to be smoke free in addition to supporting breastfeeding may 
help to reduce the burden of respiratory illness in infants born prematurely.  
Two infants in our cohort had life threatening respiratory events requiring intensive care 
associated with a general anaesthetic after discharge from NICU. Other studies have 




hypertension.440, 448  This highlights the importance of identifying infants with a 
propensity to respiratory instability prior to discharge to allow careful pre-operative 
work-up for occult pulmonary hypertension and judicious anaesthetic planning to reduce 
this risk.  
In the absence of a vaccine against respiratory syncytial virus which is responsible for a 
great deal of the respiratory morbidity, prophylaxis with a virus-specific neutralising 
antibody is the only available option to reduce morbidity. This is recommended by the 
American Academy of Pediatrics for use in infants born at <29 weeks gestation.449  
Unfortunately the cost of this therapy is high and it is not subsidised by the government 
in New Zealand. Clinicians should consider applying for exceptional circumstances 
funding for high risk infants.  
Screening for pulmonary hypertension  
No screening programme for late pulmonary hypertension in premature infants currently 
exists in New Zealand. International practice is also highly variable.121 Many international 
guidelines and pulmonary hypertension research groups now recommend screening.86-88  
Currently published recommendations for screening show a lack of consensus although 
some common ground does exist. We have reviewed these recommendations and 
recommend a national surveillance programme should be developed to better identify 
the incidence and reduce the associated morbidity/mortality of this condition. A 
suggested protocol for screening in the New Zealand setting, based on published 
recommendations, is included in Appendix F.  In order to be cost-effective this 
programme should be based upon relative risk and embedded within existing national 
and Australasian neonatal networks. This would inform prevalence of this condition in 
our population and identify any locally relevant ethnic differences, allow audit of the 
programme design and monitoring of any adverse events. Studies to establish reference 
ranges for heart ultrasound parameters and NTproBNP should be conducted alongside 
this surveillance programme with a view to refining this protocol informed by these data. 
International collaboration and networking should be encouraged. 
Who to screen 
Our review of recommendations and screening algorithms published by a variety of 
experts shows some variability as to which infants should be screened but all bar one 
protocol included those with a diagnosis of BPD.62, 84, 86-88, 111-113, 119, 120, 207 Some groups 




pulmonary hypertension may occur in infants  with mild BPD or without BPD and expand 
criteria to include all infants with BPD, infants below a specified birthweight or 
gestational age or any infant displaying symptoms suspicious for pulmonary 
hypertension. A recent systematic review by Nagiub and metanalysis by Al-Ghanem 
provide valuable information on odds ratios for a variety of risk factors that should be 
considered when developing a screening programme.115, 450 
When to screen 
Early detection of pulmonary hypertension has been shown to improve survival in adults 
and children.108, 451-453 Screening for pulmonary hypertension in premature infants needs 
to be planned at a time when most infants will be detected and yet early enough that 
detection can still improve outcomes. There is consensus across most groups that 
screening should be conducted around 36 weeks PMA.  Studies that have looked at 
screening earlier, such as that done by Mourani et al on day 7, have shown that the 
presence of pulmonary hypertension on day 7 ultrasound is associated with a 
significantly increased risk of BPD and late pulmonary hypertension but also that some 
cases of early pulmonary hypertension resolve by 36 weeks PMA.84 Further support for 
screening at 36 weeks PMA is provided by Bhat et al who showed that assessment at 4 
weeks diagnoses only one third of affected infants.64 We also know that a percentage of 
infants will present after 36 weeks PMA necessitating the inclusion in the guidelines of 
indications for reassessment if initial assessment is negative.62, 112 The optimum timing 
for reassessment is uncertain although most agree that serial monitoring while oxygen 
dependent is advisable. 
What tests to use 
All protocols we reviewed recommended an echocardiogram for screening with cardiac 
catheterisation reserved for those with severe disease or prior to considering long term 
pulmonary vasodilator therapy.  It is important to note that although an echocardiogram 
is reasonably good at detecting pulmonary hypertension it is not reliable for classifying 
severity when compared to cardiac catheterisation.199There is some variation regarding 
which ultrasound parameters to include in echocardiographic assessment. All would 
agree that a full evaluation for any structural heart disease is essential. The most 
commonly included parameters are TR jet and MPA flow Doppler interrogation, RV 
dilatation/hypertrophy and septal flattening either assessed qualitatively or quantitatively 




defect, if present, to estimate RV pressures is recommended by some as a useful 
adjunct.  Some algorithms suggest use of more advanced techniques such as TAPSE and 
tissue Doppler indices (for example RIMP, E’, E’/A’, S’) for assessing RV function, however, 
many of these indices need further validation in the preterm population. 
The Pediatric Pulmonary Hypertension Network recommend at a minimum: 
1. A complete evaluation of cardiac anatomy including interrogation of shunts and the 
identification of pulmonary veins 
2. An assessment of RV and LV size, hypertrophy and function 
3. Evaluation of intraventricular septal position 
4. Interrogation, if present, of tricuspid/pulmonary regurgitation jet 
5. Simultaneous measurement of blood pressure 
Echocardiogram findings must therefore be interpreted in the context of the clinical 
situation. A diagnosis of pulmonary hypertension is therefore based on cumulative risk 
factors combined with clinical suspicion and supported by the cumulative weight of 
echocardiographic evidence.  
Although most NICUs in New Zealand have ready access to an ultrasound machine that 
can be used at the bedside, and many neonatologists have some training in heart 
ultrasound, the experience and capability is variable. Clinician performed heart 
ultrasound is not equivalent to an echocardiogram performed by a cardiac 
ultrasonographer or cardiologist and has traditionally been used to evaluate basic 
structure and function in the period of transitional circulation.  Any proposed change to 
this scope would need to be discussed with paediatric cardiology and the Australasian 
Society of Ultrasound Medicine. If neonatologists were to conduct the heart ultrasound 
at 36 weeks PMA then further training specialising in the assessment of late pulmonary 
hypertension would be needed. 
Some, but not all guidelines, recommend serum BNP or NTproBNP to be used at baseline 
and follow-up to help monitor response to treatment. As BNP or NTproBNP levels can be 
highly variable with no clear diagnostic cut-off point, serial assessment is recommended. 
Pulse oximetry is not included in any screening protocol but is highlighted in some as a 





Strengths and Weaknesses 
Strengths of this study are that it is a well described cohort representative of a 
population at risk of pulmonary hypertension. Paired biomarker, heart ultrasound and 
pulse oximetry data were evaluated over four clinically relevant time points. Subjects 
were followed up to two years of age with health and neurodevelopmental data. 
Interpretation of heart ultrasound and pulse oximetry data was performed blinded to 
NTproBNP results. The paediatric cardiologist completing the evaluation for pulmonary 
hypertension at 36 weeks PMA was blinded to clinical condition of the infant and test 
results. An extensive review of literature in this field was conducted and current 
evidence was incorporated in discussions of this study’s findings, recommendations 
made and to highlight gaps in knowledge.  
A key weakness of our study was a cohort size that, in hindsight, was inadequate to test 
our primary hypothesis. Although we recruited the minimum number recommended by 
our initial power calculations the incidence of pulmonary hypertension was less than 
expected and we were unable to extend our recruitment due to limited funding and 
personnel. We also recognise that infection may affect BNP secretion and thereby affect 
NTproBNP levels. As 58% of our cohort had histological evidence of chorioamnionitis it is 
possible that this may have influenced our day 3 NTproBNP levels. However, we think 
this is unlikely to have been a major confounder in the absence of any clinical evidence 
of significant sepsis and in the absence of a raised CRP.  With regards to BNP isoform 
testing we also had to pool samples across clinical groups and time due to small sample 
volumes. Taking a larger sample volume for NTproBNP testing would have allowed 
analysis of individual differences in isoforms and glycosylation patterns over time. 
However, we were able to demonstrate the predominant circulating isoform in the very 
preterm population and that glycosylation is low. We demonstrated some novel data on 
more advanced quantitative ultrasound measures of right heart function. However, 
there is a need for larger cohort studies to establish reference ranges for the heart 
ultrasound parameters discussed. It would have been valuable to have been able to 
compare the changes in these parameters over time, and those for oxygen saturation, to 
a control group of term-born infants. Continuous oxygen saturation data combined with 
contemporaneous continuous inspired oxygen concentration data would give a more 
accurate picture of time in target. Ideally ultrasound estimates of pulmonary artery 
pressure should be compared contemporaneously with cardiac catheterisation data but 




have had a more detailed ultrasound evaluation of the left ventricle due to the 
interdependence of RV and LV. Renal function was not evaluated at all NTproBNP testing 
time points and as such we cannot exclude the possibility that renal dysfunction may 
have contributed to higher levels of NTproBNP. Agitation, hypoxia, hypercarbia, and 
changes in airway pressure can cause transient changes in pulmonary vascular pressures 
so snapshot assessments may not accurately reflect pulmonary vascular function. BPD 
rates differ by ethnicity so risk of pulmonary hypertension is also likely to differ and our 
findings may not be generalizable to populations with a different ethnic make-up.  
Future Directions 
There are a number of important questions that demand further research.  
In order to better compare the incidence of pulmonary hypertension in very premature 
infants, an ultrasound based consensus definition using advanced quantitative techniques 
is needed. National and international collaboration should be encouraged to develop and 
refine surveillance/screening recommendations. National registries, especially if 
embedded within already existing neonatal data collection networks, would help our 
understanding of the natural history of this disease. Furthermore these data could better 
identify risk factors that may inform trials of preventative strategies and treatments.  
There is currently insufficient evidence to recommend NTproBNP in isolation for 
screening for pulmonary in very premature infants. However ,it  may be a useful adjunct 
to heart ultrasound evaluation for diagnosis and serial monitoring to evaluate the effect 
of treatment strategies. Evaluation of NTproBNP at 36 weeks PMA as part of a national 
pulmonary hypertension surveillance programme would better inform us of the potential 
predictive value of this cardiac marker. 
Exposure of a developmentally immature lung to hyperoxia is a potentially preventable 
contributor to pulmonary vascular disease. Aspiring to optimal target saturations is not 
enough. We need to examine the human factors that may contribute to sub-optimal 
time in target and harness technology to assist us in better delivering this goal. An 
oxygen saturation stewardship programme aiming to reduce exposure to excess oxygen 
from the birthing suite to discharge should be developed within neonatal units. This 
programme should examine both human and technological aspects of oxygen delivery 




There is also an urgent need for better early markers of pulmonary vascular disease if we 
are to reduce morbidity and mortality from this condition. We know from adult studies 
that more than 50% of the pulmonary circulation has to be obstructed before we see an 
elevation in resting pulmonary artery pressure.454 Current ultrasound markers are not 
sensitive enough to detect early disease. B-type natriuretic peptide rise appears to be a 
late phenomenon related to failure of cardiac adaptive mechanisms. Advanced 
cardiorespiratory imaging techniques such as three dimensional echocardiography and 
cardiac magnetic resonance imaging may help fill this void. A number of other potential 
biomarkers have been investigated in other settings but are yet to be tested in the 
preterm population.455 These include endothelial cell markers, inflammatory markers, 
markers of oxidative stress, micro-RNA, heart function-related markers, extracellular 
matrix related proteins and metabolic biomarkers.  
More work is needed to further our understanding of the mechanisms of pulmonary 
vascular development and in particular the interaction between antenatal factors such as 
intrauterine growth restriction, preeclampsia, chorioamnionitis and maternal smoking 
and postnatal factors such as mechanical ventilation, hyperoxia, poor growth and 
infection. Genetic and epigenetic factors are also poorly understood. Unravelling these 
mechanisms will help the development of novel therapies which are likely to impact not 
only on pulmonary hypertension but also bronchopulmonary dysplasia. There is also a 
need for further study of the developmental changes and adaptive mechanisms of the 
preterm heart with particular attention paid to the long term effects of premature birth 
on cardiovascular function. To advance this field cross-disciplinary collaboration is 
essential.456 
Finally it is imperative that we use what is currently known to improve care. To this end 
we need to optimise respiratory care to minimise invasive ventilation, avoid hyperoxia, 
minimise hypoxic episodes and utilise all available data to deliver precision management. 
It is also vital that we consider the global impact of this disease. As low and middle 
income countries upscale neonatal care more children born very prematurely will 
survive. Given the high rates of intrauterine and post-natal infection and antenatal and 
post-natal growth restriction in under-resourced populations, these surviving infants and 
are at significant risk of pulmonary hypertension if exposed to unregulated oxygen. It is 
vital that these countries are supported to develop strategies to mitigate this risk. The 




criteria, data validated specifically for premature infants and collaboration to address an 
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Table 54: Summary of recommendations for screening preterm born infants for pulmonary hypertension (PH) 
Study Patient selection Timing Initial screening test Follow-up screening 
(even if initial screen 
negative) 
Indication for cardiac 
catheterisation 
Krishnan 201786 
Expert consensus from 
Pediatric Pulmonary 
Hypertension Network 
1. Persistent ventilator support at 
day 7 
2. Moderate to severe BPD or 
no/mild BPD who have worsening 
respiratory course/prolonged 
oxygen requirement 
3. Sustained need for respiratory 
support with recurrent hypoxemia 
 Day 7 if meet criteria 1 
 36 weeks PCA if meet 
criteria 2 





BNP/NTproBNP if echo 
positive for PH 
Echocardiogram 4-6 
monthly if oxygen 
requirement persists or any 
time there is worsening of 
oxygen requirement or need 
for increased respiratory 
support. 
2-4 monthly if PH confirmed 
Echocardiogram suggests 
>2/3 systemic arterial 
pressure with severe septal 
flattening OR 
Echocardiographic 
measures of PH and 





American Heart Association 
and American Thoracic 
Society guidelines 
1. Severe respiratory distress 
syndrome especially in context of 
oligohydramnios or IUGR 
2.BPD requiring ventilator support 
or not weaning from oxygen or 
oxygen requirement out of 
proportion to respiratory disease  
3.Any infant with slow clinical 
improvement requiring high levels 
of respiratory support and oxygen 
or recurrent hypoxemia or 
unexplained poor growth or 
persistently high PaCO2 
 Early if meet criteria 1 
 At 36 weeks PCA if 
meet criteria 2 




diagnosis and follow-up 
4-6 monthly 
echocardiogram 
Persistent signs of severe 
cardiorespiratory disease or 
Before commencement of 






Study Patient selection Timing Initial screening test Follow-up screening 
(even if initial screen 
negative) 




Infants with BPD – particularly 
those with moderate to severe 
BPD 
 Not stated Echocardiogram Not stated Not stated 
Weismann 2017113 
Single centre, prospective 
1. BPD OR  
2. Birthweight ≤ 750g OR 
3.  Clinical suspicion of PH  
 36-38 weeks PCA Echocardiogram 
Consider NTproBNP 




prior to pulmonary 
vasodilator drugs 
Mehler 2018112 
Single centre, prospective 
 
Birth weight <1000g 
AND 
1. BPD or 
2. No BPD or 
3. Clinical signs of pulmonary 
hypertension 
 36 weeks PCA if meet 
criteria 1 
 At discharge for 
criteria 2 
 Any time for criteria 3 
Echocardiogram 3-6 months post discharge 





Single centre, expert 
consensus 
1. < 28 weeks GA at birth or 
2. Birthweight  ≤1250g 




Every 2 months if persistent 
oxygen requirement 
 
On a case by case basis after 
consultation with 
cardiology, anaesthesiology 
and respiratory specialist 
Hilgendorff 2016 
88 
Report of European 
Pulmonary Vascular Disease 
Network 
1. Severe BPD or  
2. <28 GA at birth or  
3. Consider if prolonged oxygen 
requirement, frequent 
desaturations or poor growth 
 Once or twice a month 




NTproBNP if pulmonary 
hypertension confirmed 
Beyond discharge 3 monthly 
if BPD and need for oxygen. 
3-6 monthly if growth 
retardation/failure to thrive,  
VLBW, BPD without ongoing 
oxygen, ventilation or CPAP 
beyond 28 days of age 
Persistent pulmonary 
hypertension despite 
adequate treatment of lung 





Study Patient selection Timing Initial screening test Follow-up screening 
(even if initial screen 
negative) 




1. Moderate or severe BPD 
or 
2. Severe respiratory 
disease and/or suspicion 
of pulmonary 
hypertension 
 36 weeks if criteria 1 




4 monthly while on oxygen 
or  
Echocardiography and serial 
BNP more frequently 
according to severity of PH 
Severe PH (RV systolic 
pressure >35mmHg and RV 
systolic pressure/systemic 
systolic blood pressure >2/3 
or severe septal flattening 
Mourani 2009120 
Expert opinion  
1. Infants with severe RDS who 
require high levels of oxygen and 
ventilator support, especially if 
IUGR or oligohydramnios or 
2. Infants with slow rate of clinical 
improvement with persistent or 
progressive needs for respiratory 
support or 
3. Infants with BPD who require 
positive pressure ventilation or are 
oxygen dependent at 36 weeks 
CGA or have recurrent cyanotic 
episodes  
 Early if criteria 1 or 
 Any time pulmonary 
hypertension is 
suspected such as 
criteria 2 or 







echocardiogram while on 
oxygen then 2 months after 
weaning from oxygen  
Echo confirmed pulmonary 
hypertension AND 
1.Persistent signs of severe 
cardiorespiratory disease or 
clinical deterioration not 
directly related to airways 
disease or  




3. Prior to starting chronic 
vasodilator therapy or 





Study Patient selection Timing Initial screening test Follow-up screening 
(even if initial screen 
negative) 




recommendations based on 
retrospective review 
BPD AND 
1. Birth GA ≤ 25 weeks or 
2. Birthweight <600g or 
3. Small for gestational age or 
4. Prolonged mechanical 
ventilation or 
5. Increased oxygen 
requirements that cannot be 
explained by lung pathology 
or 
6. Poor growth despite 
adequate caloric intake 
Not specified Echocardiogram Not specified Severe respiratory disease 
and severe pulmonary 





Birth GA <33 weeks and BPD  
 
 3 months of age  
 
Echocardiogram If not on oxygen 6 months, 
12 months and then every 2 
years 
If on oxygen assess at 8-10 
days  after cessation of 
oxygen, 3,6 and 12 months 
then every 2 years 







Table 55: Proposed heart ultrasound criteria for diagnosis (bold) or suggested measures for evaluation of 
pulmonary hypertension in reviewed studies 
Study Criteria/measure 
Krishnan 201786 Elevated TR jet velocity if present  
Septal flattening 
RV dilation/hypertrophy  
TAPSE 
RV fractional area change  
Tissue Doppler E/E’, S’, E’/A’, RIMP 
Abman 201587 Elevated TR jet peak velocity  
Raised systolic pulmonary pressure: systemic systolic blood pressure  
Septal flattening qualitatively or by  LVEI 
Evidence of right to left shunting 
RV dilatation 
TAPSE 
Evaluation of LV function and for pulmonary vein stenosis 
Naguib 2015207 If TR jet present: 
- estimated pulmonary  artery systolic pressure >40 mmHg 
- ratio of systolic time to diastolic time (SD/DD) >1.15 
-ratio of TR velocity to tissue velocity time integral of pulmonary valve Doppler  
(TVR/VTI) >0.14 
If no TR and no PDA: 
- RIMP >0.38 
- LPA flow analysis (inflection time <4.3 msec, AT/RVET <0.31, deceleration index 
>0.4) 
If no TR but PDA present with left to right shunt: 
- LPA flow analysis (inflection time <4.3 msec, AT/RVET <0.31, deceleration index 
>0.4) 
- eccentricity index <0.81 
- TAPSE<0.5cm 
If no TR but PDA present with right to left shunt: 
- mean pulmonary artery pressure>systolic pulmonary artery pressure  




TR jet gradient of >36 mmHg or presence of septal flattening in systole 
Mehler 2018112 TR jet peak velocity of ≥2.8m/s or systolic pulmonary pressure*:systemic systolic 
blood pressure ≥0.5 
Altit 2017111 TR jet velocity gradient 
Pulmonary regurgitation gradient 
Direction of PFO/ASD/PDA/VSD shunts 
End-systolic septal position qualitatively or by LVEI 
AT/RVET ratio 
Tricuspid systolic to diastolic time ratio 
RIMP 
TAPSE  
E/A and E’/A’  of tricuspid valve by conventional and tissue Doppler 
TAPSV (S’) 
Pulmonary veins Doppler: rule out pulmonary vein stenosis  
Right-sided structural measurements and pulmonary valve size 







Refer to echocardiographic recommendations by European Paediatric Pulmonary 
Vascular Disease 
Network457 




TV S’, E’,A’ 
LVEI 
Pulmonary artery acceleration time 
Evaluation of left ventricle 
Mourani 2015221 Estimated RV systolic pressure >35mmHg by interrogation of TR jet* or  
septal flattening 
Mourani 2009120 Elevated systolic pulmonary artery pressure by interrogation of TR jet* 











Estimated pulmonary artery pressure >25mmHg by interrogation of TR jet* or 
pulmonary regurgitation jet 
Septal flattening 
Dilatation of the right atrium or main pulmonary artery 
RV hypertrophy or dysfunction 





   
  
Participant Information Sheet: Neonatal BNP Study  
Study title: Investigating  BNP levels in extremely preterm babies:   
Can BNP help to identify babies at high risk of the complications 
of premature lung disease? 
 
Locality: Christchurch Women’s 
Hospital 







Dr Sarah Harris Contact phone number: 0211544835 
 
Your child is invited to take part in a study on BNP (B-type natriuretic peptide) 
levels in preterm babies born at less than 30 weeks gestation.  Whether or not 
your child takes part is your choice.  If you don’t want them to take part, you don’t 
have to give a reason, and it won’t affect the care your baby receives.  If you do 
want them to take part now, but change your mind later, you can pull out of the 
study at any time.   
 
This Participant Information Sheet will help you decide if you’d like your child to 
take part.  It sets out why we are doing the study, what your participation would 
involve, what the benefits and risks to you might be, and what would happen after 
the study ends.  We will go through this information with you and answer any 
questions you may have.  We expect this will take about 20 minutes.  You may 
also want to talk about the study with other people, such as family, whānau, 





If you agree to take part in this study, you will be asked to sign the Consent Form 
on the last page of this document.  You will be given a copy of both the Participant 
Information Sheet and the Consent Form to keep. 
 
This document is 7 pages long, including the Consent Form.  Please make sure 
you have all the pages. 
Why are we doing the study? 
 
Babies who are born very prematurely have very immature cardiovascular (heart 
and blood vessels) and respiratory (lung) systems. Neonatal intensive care aims 
to support these systems until they mature over time such that the baby can cope 
on their own. Some infants do remarkably well while others struggle with 
complications related to the immaturity of their heart and lungs. A few infants may 
develop a potentially life threatening complication called pulmonary hypertension 
where the blood vessels do not develop normally in the lungs and place strain on 
the heart. This complication can lead babies to have repeated sudden drops in the 
level of oxygen in the blood and require prolonged breathing support. Doctors do 
not know exactly how many babies are susceptible to the complication because it 
is not routinely looked for. Current estimates in the medical literature suggest up 
to one in three babies who develop chronic lung disease due to their prematurity 
may have pulmonary hypertension. 
 
This study aims to test the level of a protein in the blood over the first few weeks 
of life to see if it can help us to predict which babies are more likely to develop 
pulmonary hypertension. The protein occurs naturally in the body and is called N-
terminal pro B type natriuretic peptide (NTpBNP for short). This protein has been 
extensively studied in the adult population and there are many studies in older 
children but comparatively little study has been done in the neonatal age group. It 
has already been shown that NTpBNP levels increase with increasing severity of 
neonatal lung disease and that levels are high in term babies born with pulmonary 
hypertension. We would like to compare levels in babies born very prematurely to 
see whether they are higher in babies who develop complications of premature 
lung disease, in particular, pulmonary hypertension. If this protein proves to be 
useful in this setting it may open up further studies to address how we can prevent 





This study aims to recruit 80 patients over 2 years. 
This study is being conducted as part of a Masters of Medical Science, University 
of Otago. It has been reviewed and approved by the University of Otago Human 
Ethics Committee. 
 
My supervisors are: 
Associate Professor Nicola Austin, Neonatologist, Christchurch Women’s 
Hospital. 
Associate Professor Richard Troughton, Cardiologist, Christchurch Hospital 
 
This study is funded through a Masonic Paediatric Fellowship with assistance from 
the Maurice and Phyllis Paykel Trust. 
A Maori Health Consultation has been conducted and the study will be conducted 
in a manner that honours the principles of the Treaty of Waitangi. 
What would participation involve? 
Babies who take part in this study will have the following blood tests, 
echocardiograms (heart ultrasound) and oxygen saturation monitoring performed: 
1. Blood tests:  
 On days 3, 10, 28 and when infants reach the equivalent of 36 
weeks gestation (ie. 4  weeks before their original due date).  
 This test will be for the NTpBNP protein level in their blood.  
 Babies born prematurely routinely need blood tests to monitor their 
health and we would aim to do the study test at the same time as 
routine blood tests so your child would not be exposed to any 
additional discomfort. 
 The amount of blood needed for this test is very small (0.6ml) so 
that the whole amount for the study would total half a teaspoon of 
blood.   
 A C-reactive protein test is done at the same time to check for any 
signs of infection as this can falsely elevate the NTpBNP level. This 
test is often part of the routine tests premature babies have as part 
of their care. The amount of blood needed for this test is 0.1-0.2ml. 
If you child is unwell with an infection at the time the NTpBNP level 
may have to be deferred or repeated at another time. 
 If there is sample left over after testing we seek separate consent 
to store this for future testing for some of the new bio-markers that 




pulmonary hypertension.  
(This does NOT involve genetic testing). 
 
2. Echocardiograms (heart ultrasound): 
 On days 3,10, 28 and when they reach the equivalent of 36 weeks 
gestation (ie. 4  weeks before their original due date).  
 The ultrasound is similar to a pregnancy scan except that a small 
ultrasound probe will be moved over the infant’s chest to obtain a 
picture of the structure and function of the heart and major blood 
vessels. 
 Ultrasound involves sound waves and is used routinely in neonatal 
care and considered safe for premature babies. 
 The heart ultrasound will take approximately 30 minutes. 
 
3. Oxygen saturation monitoring: 
 It is routine for premature babies to have the oxygen levels 
monitored continuously via a band that is placed around a hand or 
foot. 
 For this study we will use a more sophisticated monitor that has the 
ability to detect changes in oxygen levels every 2 seconds and 
store that information so that we can download it later for analysis. 
 This will be performed for 72 hours around days 3, 10, 28 and when 
they reach the equivalent of 36 weeks gestation (ie. 4  weeks before 
their original due date).  
 
We will also be collecting background data about your infant’s health from the 
clinical notes that are relevant to the interpretation of the results of the study. 
Your baby’s health and well-being are paramount to the research team and we will 
always put their needs above that of our research. As the principal investigator I 
will make myself available throughout the study to answer any questions or 
address any concerns you may have.  
What are the possible benefits and risks to you of participating? 
There are no clear benefits to your baby in participating in this study. However, it 
is hoped this study will help us provide better care for premature babies in the 
future just as our care of your child today is guided by the results of past research. 
There is no financial payment for participation. We do not anticipate that this study 
will put your child at any additional risk. If at any point during the blood testing or 
heart ultrasounds your infant does not appear to be coping with the handling we 






What would happen if you were injured in the study?  
In the unlikely event of a physical injury as a result of your child’s participation in 
this study, they may be covered by ACC under the Injury Prevention, 
Rehabilitation, and Compensation Act 2001.  ACC cover is not automatic, and 
your child’s case would need to be assessed by ACC according to the provisions 
of the Injury Prevention, Rehabilitation, and Compensation Act 2001.  If your 
child’s claim is accepted by ACC, you still might not get any compensation.  This 
depends on a number of factors, such as whether you are an earner or non-earner.  
ACC usually provides only partial reimbursement of costs and expenses, and 
there may be no lump sum compensation payable.  There is no cover for mental 
injury unless it is a result of physical injury.  If you have ACC cover, generally this 
will affect your right to sue the investigators. 
If you have any questions about ACC, contact the nearest ACC office or the 
investigator. 
What are the rights of participants in the study? 
Your child’s participation in this study is entirely voluntary. It is up to you to decide 
whether or not to take part. If you decide to take part you are still free to withdraw 
at any time and without giving a reason. This will not affect the standard of care 
your child receives. 
This is a cohort study, which means we study a selected group of patients over 
time. To avoid bias in the study the investigators and clinical team will not know 
the results of the NTpBNP level until the analysis phase. The oxygen saturation 
data will be downloaded at a later time and so we recommend you discuss any 
concerns you have regarding your baby’s oxygen saturation levels with the clinical 
team caring for your baby. We will be able to discuss the results of the heart 
ultrasound with you.  
Patient confidentiality will be protected. Documents will be stored securely and 
patient data de-identified (your baby will be known in the study by a study number 
rather than by their name or NHI number). 
We would normally inform your baby’s General Practitioner of their participation in 






What will happen after the study ends, or if you pull out? 
Once the study is complete we plan to submit the results for presentation at a 
medical conference and for publication in a medical journal. As in the study no 
individual patient will be identified during either presentation or publication. 
If you would like to receive a copy of the results of the research when it is complete 
you can request this on the consent form. It may take 3 years for the final study 
results to become available to you. 
The study records will be kept in a secure hospital location for 15 years. The 
secure storage of these records is the responsibility of the neonatal research team. 
After this time the study records will be destroyed. 
Where can you go for more information about the study, or to raise concerns or 
complaints? 
 
If you have any questions, concerns or complaints about the study at any stage, 
you can contact:  
Principal Investigator 
Dr Sarah Harris 
Neonatal Pediatrician 
Christchurch Women’s Hospital  
If you have any complaints about the study you are entitled to take these to the 
Health and Disability Commissioner or voice them through the hospital complaints 
process. 
If you want to talk to someone who isn’t involved with the study, you can contact 
an independent health and disability advocate on: 
 
Phone:  0800555050 
Fax:   08002SUPPORT(080027877678) 
Email:   advocacy@hdc.org.nz 
 
You can also contact the University of Otago Human Ethics Committee that 






     
 
Consent Form: Neonatal BNP Study 
 
Declaration by participant:(signed by parent/legal guardian as participant is a child) 
I have read, or have had read to me in my first language, and I understand the Participant 
Information Sheet.   
I understand that this study involves my child having blood tests, heart ultrasounds and 
oxygen saturation monitoring. 
I have had the opportunity to ask questions and I am satisfied with the answers I have 
received. 
I have been given a copy of the Participant Information Sheet and Consent Form to keep. 
I understand that my child’s participation is voluntary and that I am free to withdraw my 
child from the study at any time, without giving any reason, without my medical care or 
legal rights being affected. 
I understand the results of the project may be published and will be available in the 
University of Otago Library (Dunedin, New Zealand) and that no personal or identifying 
information about my child will be included. 
 
I freely agree for my child ……………………………………………………......... to 
participate in this study.   
I  agree / do not agree (delete one) for any blood left over after testing to be stored 
for up to 5 years  for future testing for cardioendocrine biomarkers.  
 
I consent to any remaining samples being disposed of using:  
 





   Disposed with appropriate karakia 
 
 
I agree / do not agree (delete one) for my child’s GP to be informed of participation 
in this study. 
I would / would not (delete one) like to receive a copy of the results of the study 
upon completion. 





Declaration by member of research team: 
I have given a verbal explanation of the research project to the participant, and have 
answered the participant’s questions about it.   






This study has been approved by the University of Otago Human Ethics Committee. If you 
have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (ph 03 479 8256). Any 



























Respiratory Health Questionnaire1 
Name of Child: …………………………………………………………… 
     
Study Number: BOPP………… 
 
How to complete the questionnaire:  
 
These questions refer to your child’s health AFTER discharge from the neonatal unit 
until NOW.  
 
  
Please tick the appropriate box  
 
 




If you are unsure of an answer, tick or write “UNSURE”.  
  
There are 48 questions.  
It should be completed by a parent/caregiver who lives with the child. 
 
If you have difficulty understanding this questionnaire contact: 
Sarah (phone) 0211544835 or email sarah.harris@otago.ac.nz  






                                                          








Date questionnaire completed:  
 
day ____ month ______ year ________ (please fill in today’s date)  
 
Person completing questionnaire: 
 




Other      
 
If you ticked “other” please state your relationship to the child ……………………… 
 






If you ticked “other”, please tell us which language: 
…………………………………….. 
 
CONSENT TO ACCESS MEDICAL RECORDS: 
 
I give consent for the BOPP Study research team to access the General 
Practitioner and hospital medical records of my 
child……………………………………………………… 
for the purposes of cross-checking the information given in this 
questionnaire.               
 







1.  Since discharge from the neonatal unit, how many times has your child seen a 
GP or family doctor? (if unsure give an estimate) 
Never 





2. Since discharge from the neonatal unit, has your child been seen in the hospital 
emergency department, CAA (Children’s Acute Assessment) or been admitted to 




 If YES: How many times? …………… (please write number) 
What was the reason your child was seen in the emergency 





















5. After discharge from neonatal unit has your child ever been admitted to the 








6.  Since discharge from the neonatal unit has your child had any of the following 


















8. Since discharge from the neonatal unit has your child used an inhaler to treat 




If NO skip to question 10. 
 
9.  How often would your child usually need to take this inhaler?  
Every day 
 1- 6 times a week 
1-3 times every month 
Less than once a month  
Only with a cold/respiratory infection 
 
10. Since discharge from the neonatal unit, has your child used an inhaler to 








11. Since discharge from the neonatal unit, has your child required treatment with 




If NO, skip to question 13. 
 
12. Since discharge from the neonatal unit, how many times has your child 
required treatment with steroids?  
………………………………………(write number) 
 













15. Since discharge from the neonatal unit, has your child required tube feeds 







If NO, skip to question 17. 
 
16. How old were they when they no longer required tube feeds? 
Stopped tube feeds at ……………………………………(please state in months) 
Still requiring tube feeds  now 
 
17. Does your child snore when they sleep? 
No, never. 
Yes, occasionally 
Yes, most of the time 
 
18. When your child went home from the neonatal unit did they use an apnoea 






19. Since discharge from the neonatal unit, has you child has any episodes where 















21. Since discharge from the neonatal unit, has your child been diagnosed (by a 






22. Since discharge from the neonatal unit, has your child been diagnosed (by a 
















24. How many ear infections has your child had since discharge from the neonatal 
unit? 
…………………………(please fill in number of infections) 
 









If NO, skip to question 28. 
 
27. Which immunisations have they had so far? 
6 week vaccines 
3 month vaccines 
5 month vaccines 
15 month vaccines 
 








29. Has your child been given palivizumab (this is an injection to prevent the RSV 








If NO skip to question 32. 
 
31. How long did your child have breast milk?  
 <6weeks  




Continues to have breast milk 
 










33. What treatment have they needed for this? (tick as many as apply) 
Gaviscon    
Ranitidine 
Omeprazole 
Surgery (“Nissen fundoplication”) 










35. How many adults (16 years or older) live in your home?  
……………………………………………(please write number) 
 
36. How many children (< 16 yrs) live in your home?   
…………………………………………….(please write number) 
If ZERO skip to question 38. 
 
37. How many of the children are under 5 years? 
………………………………………….(please write number) 
 
38. How many rooms are there in your house? 
(If your living areas are open plan, count kitchen, dining area and lounge separately. Do 
not count  hallways/bathrooms/toilets/laundry)     





39. How do you heat your home? (tick as many as apply)  
 




gas heaters in rooms  
 
coal or wood fire  
 







40. Do you keep any household pets?  
 







If NO skip to question 42. 
 
 








































43. How many cigarettes per day does the child’s mother smoke?  
 
1 to 10  
 
11 to 20  
 



























46. How many cigarettes per day does the child’s father smoke?  
 
1 to 10  
 
11 to 20  
 
























47. Of the other people living at your house, how many are smokers? 
 
…………………………………….(please write number) 
 
 






Please write any comments you have about your child’s health or about the 










         
Oxygen Saturation Targeting Questionnaire 
 
With the change in saturation alarm limits recently we conducting a survey of 
nursing opinion on oxygen saturation targeting. Please note that these surveys 
are completely confidential and anonymous and are designed to reflect unit rather 
than individual practice. Please answer all questions. 
 
Thank you very much for taking the time to do this survey. Please circle (or write) 
your answer: 
1. Do you work primarily: 
a. Day shift 
b. Evening/night 
c. Rotating  
 
2. How many hours on average do you work a week? 
 
3. Are you level three trained?  
a. Yes 
b. No  
 





5. Do you recall being orientated our unit protocol regarding oxygen 




6. When did you last attend an education session that included 
discussion of oxygen saturation targeting? 
a. < 1 year ago 
b. 1-2 years ago 
c. > 2 years ago 
d. Never 
 
 For these questions please use your own recall and do not confer with colleagues 
or look up protocol  
7. The oxygen saturation targets in the unit changed at the end of 
October this year. What were the OLD oxygen saturation alarm limit 
settings?  
a. <32 weeks in air 
b. < 32 weeks in oxygen 
c. 32-36 weeks in air 
d. 32-36 weeks in oxygen 
e. >36 weeks in air 
f. >36 weeks in oxygen 
 
8. B. What are the NEW oxygen saturation alarm limit settings?  
a. <36 weeks in air 
b. <36 weeks in oxygen 
c. 36 weeks in air 





9. On each monitor in the unit there is a sign with gestational age and 
target ranges on it. With regards to the OLD guidelines, did you use 
the infant’s birth gestational age or their corrected gestational age to 
set alarm limits?  
a. Birth gestational age 
b. Corrected gestational age 
 
10. What % of time do you think infants< 30 weeks spend in their target 
saturation ranges on our unit? 




11. In your opinion, how feasible was it to maintain infants born at <30 
weeks gestation within the OLD oxygen saturation range? 
a. The policy range was feasible for MOST of these infants 
b. The policy range was feasible for SOME of these infants 
c. The policy range was feasible for FEW of these infants 
d. Don’t know 
 
12. In your opinion, what is the MAIN reason why infants born <30 weeks 
gestation CANNOT be maintained within the oxygen saturation range 
as specified by your NICU's written Unit Policy/Guideline? Choose one 
of the following answers. 
a. Oxygen saturation range TOO LOW 
b. Oxygen saturation range TOO HIGH 
c. Oxygen saturation range TOO NARROW 






13. If a baby tends to fluctuate in their oxygen saturation level, frequently 
activating the alarms, do you change the alarm setting?  
a. Yes  
b. No  
14. If a baby is doing well does this prompt you to be more lenient with 
their target range?  
a. Yes  
b. No  
15. Does the gestational age of an infant prompt you to be more lenient 
on their target range?  
a. Yes 
b. No  
16. Are oxygen saturation targets and alarm limits discussed as part of 
bedside nursing handover? 
a. All the time 




17.  Are oxygen saturation targets and alarm limits discussed as part of 
medical ward round? 
a. All the time 




18.  In your opinion what is potentially more harmful for an infant born at 
< 28 weeks gestation? 
a. Hypoxia 
b. Hyperoxia 





19. In your opinion what is potentially more harmful for an infant born at 
34 weeks gestation? 
a. Hypoxia 
b. Hyperoxia 
c. Hypoxia and hyperoxia both equally important 
 
This concludes your survey. Please encourage other nurses in your unit to 
complete this survey without discussing the questions or your answers. Thank 





Proposal for the Surveillance of  
Pulmonary Hypertension in Premature infants 
 
There are currently no national screening recommendations for late pulmonary 
hypertension in preterm born infants in New Zealand. There is currently no international 
consensus on screening for late pulmonary hypertension in premature infants. In the 
absence of international consensus this proposal is based on a review of recently 
published proposed guidelines for the screening/surveillance of later pulmonary 
hypertension in infants born very prematurely.62, 84, 86-88, 111, 112, 119, 120, 207 These 
recommendations are American Heart Association class of recommendation level 1 and 
level of evidence B or C meaning the benefit of screening is considered greater than the 
risk but the recommendation is based upon evidence from a single randomised 
controlled trial or non-randomised studies or consensus expert opinion. This proposal  is 
designed to be practical in the New Zealand setting and to be a starting point for a 
national discussion on surveillance for this condition. Interpretation of echocardiographic 
indices should be based upon published reference data. 
 
Who should undergo screening/surveillance: 
Criteria A Criteria B 
 All infants born at < 28 weeks 
gestation 
 Any very preterm infant who has 
persistent need for mechanical 
ventilation or non-invasive respiratory 
support and oxygen(excluding low 
flow nasal prong oxygen) at 36 weeks 
PMA 
 
 Any infant in whom pulmonary 
hypertension is suspected eg. Oxygen 
requirement out of keeping with the 
degree of lung disease, slow clinical 
improvement with persisting high 






Criteria A Criteria B 
 Any infant with IUGR/SGA who has 
persistent oxygen requirement or 
recurrent hypoxemia at 36 weeks 
PMA 
 Any infant who on any earlier 
scanning (at or after day 7) had signs 
of raised pulmonary pressures 
 
Timing of screening tests: 
1. Initial screen 
Criteria A - 36 weeks PMA 
Criteria B - Any time pulmonary hypertension suspected 
2. Follow-up scans 
1. If signs of pulmonary hypertension on initial scan 
 Repeat scans according to level of clinical concern to guide management 
2. If no signs of pulmonary hypertension on initial scan 
 Repeat 3 months after 36 week PMA scan 
 If persistent oxygen requirement at this second scan then repeat scans 3 
monthly while on oxygen 
 If signs of pulmonary hypertension at this second scan then repeat scans 3 






 Echocardiography  
Components considered essential are marked with *. Other parameters should be done 
if scanner expertise allows.  
1. A complete evaluation of cardiac anatomy including evaluation for tricuspid 
regurgitation, pulmonary regurgitation, interrogation of shunts and the identification of 
pulmonary veins* 
2. If significant tricuspid regurgitation present then calculate estimated pulmonary artery 
pressure using Bernoulli equation and compared to systolic systemic pressure*  
3. Qualitative evaluation of RV and LV for dilatation and hypertrophy* 
4. Left ventricular eccentricity index* 
5. Evaluation of right ventricular function (TAPSE, tricuspid valve E’/A’ and S’, right index 
of myocardial performance) 
6. Evaluation of left ventricular function (consider calculating LV output by interrogation 
of aortic outflow or  LV ejection fraction by Biplane Simpson’s method, mitral annular 
plane of systolic excursion, mitral valve E’/A’ and S’ and left index of myocardial 
performance) 
N-Terminal -proBNP  
 If pulmonary hypertension confirmed do baseline NTproBNP and repeat at 
follow-up 
3. Blood pressure 
 Measured at the same time as heart scan 
